Novel diazepines targeting non-structural 4B (NS4B) protein of yellow fever virus and methods of use thereof
By targeting the non-structural 4B protein of yellow fever virus, it interferes with its interaction with other viral non-structural proteins and host cell proteins, the problem of yellow fever virus infection treatment in the prior art has been solved and achieved Effective prevention and treatment of yellow fever, dengue fever and Japanese encephalitis virus.
Patent Information
- Application Number
- CN202380035734.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-10
- Filing Date
- 2023-03-10
- Publication Date
- 2024-12-03
AI Technical Summary
Existing antiviral therapies are not effective in treating yellow fever virus infection, especially in areas with low vaccination rates, where specific drugs are lacking for yellow fever virus replication.
A diazepamide compound targeting the non-structural 4B (NS4B) protein of the yellow fever virus was developed to block viral replication by interfering or blocking the interaction of the NS4B protein with other viral non-structural proteins and host cell proteins.
The compound is able to effectively prevent and treat yellow fever virus infections, including yellow fever, dengue virus and Japanese encephalitis virus infections, providing a new antiviral therapy strategy.
Smart Images

Figure BDA0005096868860000021 
Figure BDA0005096868860000031 
Figure BDA0005096868860000032
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 318,538, filed on March 10, 2022, the entire contents of which are incorporated herein by reference.
[0003] Statement Regarding Federally Funded Research
[0004] This invention was made with government support under Grant No. R01AI134732 from the National Institutes of Health. The government has certain rights in this invention. Technical Field
[0005] The present invention describes compounds that target the nonstructural 4B (NS4B) protein of yellow fever virus (YFV) and are useful for treating viral infections and related diseases. The present invention further describes a novel chemotype that can be used to prevent yellow fever virus infection. Background Art
[0006] Yellow fever is an acute viral hemorrhagic disease that threatens approximately one billion people in tropical regions of Africa, Central America, and South America. Despite the availability of a highly effective yellow fever vaccine for over seven decades, low vaccination rates have failed to prevent outbreaks in high-risk areas. An estimated 1.7 million people in Africa are infected with the yellow fever virus annually, resulting in 29,000 to 60,000 deaths, a figure that exceeds the estimated global death toll from dengue virus infection. Once an outbreak occurs, the effectiveness of vaccination decreases, necessitating the use of other intervention strategies, such as antiviral therapies. However, there is currently no specific antiviral therapy to treat this life-threatening disease, and the development of antiviral drugs that inhibit yellow fever virus replication is a major medical need.
[0007] The viral nonstructural 4B (NS4B) protein is a non-enzymatic integral membrane protein. The flavivirus NS4B protein is involved in viral RNA replication and evasion of the host innate immune response. The fact that many cell culture and animal adaptive mutations map to NS4B strongly suggests the key role of this protein in viral replication and pathogenesis. The exact functional involvement of flavivirus NS4B in the viral replication cycle and the molecular mechanisms of evasion of host innate immunity remain to be determined. Previous studies have demonstrated that NS4B dimerization and interaction with other viral nonstructural proteins (including NS1, NS2A, NS3 and NS4A) and many host cellular proteins are required for its function in forming the viral RNA replication organelle (RO) and antagonizing the immune response. In addition, compounds that can interfere with or block the interaction of viral NSB4 with other viral nonstructural proteins (including NS1, NS2A, NS3 and NS4A) and many host cellular proteins may be used to treat and prevent flavivirus infections. Flavivirus infections can be treated with compounds that target NSB4 to block or interfere with the interaction of viral NSB4 with other viral nonstructural proteins (including NS1, NS2A, NS3, and NS4A) and host cell proteins (including yellow fever virus, dengue virus, and Japanese encephalitis virus). Summary of the Invention
[0008] The present invention relates to novel diazepine compounds of formula (I),
[0009]
[0010] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, isotope analogs, prodrugs and complexes thereof, wherein:
[0011] A choose freedom the group formed;
[0012] When A is When m is 0;
[0013] When A is When , n is selected from 0 and 1;
[0014] R 1 Selected from the group consisting of C3-C7 cycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
[0015] When A is When , m is selected from 0 and 1;
[0016] When A is When , n is selected from 0 and 1;
[0017] R2 Selected from the group consisting of C3-C8 cycloalkyl, C4-C10 bicycloalkyl, C3-C7 branched alkyl, C1-C6 haloalkyl, C3-C8 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
[0018] When A is When , m is selected from 0 and 1;
[0019] When A is When , n is selected from 0 and 1;
[0020] R 3 Selected from C3-C8 cycloalkyl; C3-C7 branched alkyl, C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
[0021] R 4 Selected from the group consisting of:
[0022]
[0023] as well as p is 1, 2, 3, 4, or 5;
[0024] X 1 is 0, 1, 2, or 3;
[0025] Y is 0, 1, 2, 3, or 4;
[0026] When R 4 yes When , p is not 1;
[0027] When R 4 yes When , p is not 1;
[0028] X chooses freedom the group formed;
[0029] R a Selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and haloalkyl;
[0030] R b Selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and halogen;
[0031] R c Selected from C1-C12 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH2, CHF2, CF3, C2-C9 haloalkyl, C3-C9 branched haloalkyl, NR dR e , an optionally substituted benzyl, an optionally substituted CH2 heteroaryl, an optionally substituted aryl, an optionally substituted heteroaryl, and a C3-C6 cycloalkyl ring optionally containing oxygen,
[0032] R a and R b Together they may form a C3-C6 cycloalkyl ring optionally containing oxygen;
[0033] R d is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloacyl, an optional aromatic ring, and an optionally substituted heteroaromatic ring;
[0034] R e is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloacyl, an optional aromatic ring, and an optionally substituted heteroaromatic ring;
[0035] R f Selected from the group consisting of hydrogen, C1-C12 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl CH2F, CHF2, CF3, C2-C9 haloalkyl, C3-C9 branched haloalkyl, optionally substituted benzyl, optionally substituted CH2 heteroaryl, optionally substituted aryl, optionally substituted heteroaryl, and a C3-C6 cycloalkyl ring optionally containing oxygen;
[0036] R 5 Selected from C2-C8 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH2F, CHF2, CF3, C2-C9 haloalkyl, C3-C9 branched haloalkyl, optionally substituted benzyl, optionally substituted CH2 heteroaryl, CH2OR 5a 、CH(CH3)OR 5a 、C(R 5e )2OR 5a 、C(R 5e )2OR 5a 、CH2SR 5a , CH2CH2SCH3, CH2CH2SO2CH3, CH2CH2CH2NR 5c R 5d 、CH2COR 5b 、CH2CH2COR 5b 、(CH2) z (C3-C7 cycloalkyl) and a C3-C6 cycloalkyl ring optionally containing oxygen;
[0037] Z is 1, 2, 3, 4, 5, or 6;
[0038] R 5aSelected from the group consisting of hydrogen, C1-C6 alkyl, C3-C7 branched alkyl, optionally substituted phenyl, optionally substituted benzyl and optionally substituted CH2CH2Ar;
[0039] R 5b selected from the group consisting of OH, C1-C6 alkoxy and NH2;
[0040] R 5c and R 5d are each independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;
[0041] R 5e is a C1-C4 alkyl group;
[0042] R 6 and R 7 It is hydrogen;
[0043] or
[0044] R 6 and R 7 Together with the atoms to which they are attached, they form a 6-membered aromatic ring selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted;
[0045] or
[0046] R 6 and R 7 Together with the atoms to which they are attached, they form a substituted 5-6 membered heteroaromatic ring containing 1-2 nitrogen atoms, the heteroaromatic ring being selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted;
[0047] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0048] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0049] q is 0, 1, 2, 3, 4, 5, or 6;
[0050] The compounds of the present invention include compounds having formula (II):
[0051]
[0052] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0053] The compounds of the present invention include compounds having formula (III):
[0054]
[0055] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0056] Compounds of the present invention include compounds having formula (IV):
[0057]
[0058] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0059] R 8a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0060] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0061] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0062] q is 0, 1, 2, 3, 4, 5, or 6;
[0063] R 8b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0064] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0065] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0066] q is 0, 1, 2, 3, 4, 5, or 6;
[0067] R 8c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0068] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0069] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0070] q is 0, 1, 2, 3, 4, 5, or 6;
[0071] R 8d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0072] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0073] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0074] q is 0, 1, 2, 3, 4, 5, or 6;
[0075] R 8a 、R 8b and R 8d At least two of them are hydrogen;
[0076] The compounds of the present invention include compounds having formula (V):
[0077]
[0078] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0079] The compounds of the present invention include compounds having formula (VI):
[0080]
[0081] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0082] R 9a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0083] R13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0084] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0085] q is 0, 1, 2, 3, 4, 5, or 6;
[0086] R 9b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0087] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0088] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0089] q is 0, 1, 2, 3, 4, 5, or 6;
[0090] R 9c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0091] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0092] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0093] q is 0, 1, 2, 3, 4, 5, or 6;
[0094] R 9d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0095] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0096] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0097] q is 0, 1, 2, 3, 4, 5, or 6;
[0098] R 9a 、R 9band R 9d At least two of them are hydrogen;
[0099] The compounds of the present invention include compounds having formula (VII):
[0100]
[0101] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0102] Compounds of the present invention include compounds having formula (VIII):
[0103]
[0104] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0105] Compounds of the present invention include compounds having formula (IX):
[0106]
[0107] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein
[0108] R 10a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0109] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0110] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0111] q is 0, 1, 2, 3, 4, 5, or 6;
[0112] R 10b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0113] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0114] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0115] q is 0, 1, 2, 3, 4, 5, or 6;
[0116] R 10c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0117] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0118] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0119] q is 0, 1, 2, 3, 4, 5, or 6;
[0120] R 10d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0121] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0122] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0123] q is 0, 1, 2, 3, 4, 5, or 6;
[0124] R 10a 、R 10b and R 10d At least two of them are hydrogen;
[0125] The compounds of the present invention include compounds having formula (X):
[0126]
[0127] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0128] Compounds of the present invention include compounds having formula (XI):
[0129]
[0130] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0131] R 11aSelected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0132] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0133] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0134] q is 0, 1, 2, 3, 4, 5, or 6;
[0135] R 11b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0136] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0137] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0138] q is 0, 1, 2, 3, 4, 5, or 6;
[0139] R 11c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0140] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0141] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0142] q is 0, 1, 2, 3, 4, 5, or 6;
[0143] R 11d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0144] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0145] R 14selected from the group consisting of hydrogen and C1-C6 alkyl;
[0146] q is 0, 1, 2, 3, 4, 5, or 6;
[0147] R 11a 、R 11b and R 11d At least two of them are hydrogen;
[0148] The compounds of the present invention include compounds having formula (XII):
[0149]
[0150] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0151] The compounds of the present invention include compounds having formula (XIII):
[0152]
[0153] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0154] R 12a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0155] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0156] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0157] q is 0, 1, 2, 3, 4, 5, or 6;
[0158] R 12b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0159] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0160] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0161] q is 0, 1, 2, 3, 4, 5, or 6;
[0162] R 12c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0163] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0164] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0165] q is 0, 1, 2, 3, 4, 5, or 6;
[0166] R 12d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0167] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0168] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0169] q is 0, 1, 2, 3, 4, 5, or 6;
[0170] R 12a 、R 12b and R 12d At least two of them are hydrogen;
[0171] Compounds of the present invention include compounds having formula (XIV):
[0172]
[0173] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0174] Compounds of the present invention include compounds having formula (XV):
[0175]
[0176] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0177] Compounds of the present invention include compounds having formula (XVI):
[0178]
[0179] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0180] Compounds of the present invention include compounds having formula (XVII):
[0181]
[0182] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0183] Compounds of the present invention include compounds having formula (XVIII):
[0184]
[0185] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0186] R 15 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0187] R 16 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0188] Compounds of the present invention include compounds having formula (XIX):
[0189]
[0190] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0191] R 17 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0192] The compounds of the present invention include compounds having the formula (XX):
[0193]
[0194] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0195] R 18Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0196] Compounds of the present invention include compounds having formula (XXI):
[0197]
[0198] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0199] R 19 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0200] The following compounds are expressly excluded from the scope of the present invention:
[0201]
[0202] The present invention also relates to compositions comprising an effective amount of one or more compounds of the present invention and an excipient.
[0203] The present invention also relates to a method for treating or preventing yellow fever virus infection, which comprises administering to a subject an effective amount of the compound or composition of the present invention.
[0204] The present invention further relates to a method for treating or preventing yellow fever virus infection, wherein the method comprises administering to a subject a composition comprising an effective amount of one or more compounds of the present invention and an excipient.
[0205] The present invention also relates to a method for treating or preventing a disease or condition associated with yellow fever virus infection, comprising administering to a subject an effective amount of a compound or composition of the present invention.
[0206] The present invention further relates to a method for treating or preventing a disease or condition associated with yellow fever virus infection, wherein the method comprises administering to a subject a composition comprising an effective amount of one or more compounds of the present invention and an excipient.
[0207] The present invention also relates to a method for treating or preventing dengue virus infection, which comprises administering to a subject an effective amount of the compound or composition of the present invention.
[0208] The present invention further relates to a method for treating or preventing dengue virus infection, wherein the method comprises administering to a subject a composition comprising an effective amount of one or more compounds of the present invention and an excipient.
[0209] The present invention also relates to a method for treating or preventing diseases or conditions associated with dengue virus infection, comprising administering an effective amount of a compound or composition of the present invention to a subject.
[0210] The present invention further relates to a method for treating or preventing a disease or condition associated with dengue virus infection, wherein the method comprises administering to a subject a composition comprising an effective amount of one or more compounds of the present invention and an excipient.
[0211] The present invention also relates to a method for treating or preventing Japanese encephalitis virus infection, which comprises administering an effective amount of the compound or composition of the present invention to a subject.
[0212] The present invention further relates to a method for treating or preventing Japanese encephalitis virus infection, wherein the method comprises administering to a subject a composition comprising an effective amount of one or more compounds of the present invention and an excipient.
[0213] The present invention also relates to a method for treating or preventing a disease or condition associated with Japanese encephalitis virus infection, comprising administering an effective amount of a compound or composition of the present invention to a subject.
[0214] The present invention further relates to a method for treating or preventing a disease or condition associated with Japanese encephalitis virus infection, wherein the method comprises administering to a subject a composition comprising an effective amount of one or more compounds of the present invention and an excipient.
[0215] The present invention also relates to a process for preparing the diazepine compounds of the present invention.
[0216] These and other objects, features and advantages will become apparent to those skilled in the art from a reading of the following detailed description and the appended claims. Unless otherwise indicated, all percentages, ratios and proportions herein are by weight. Unless otherwise indicated, all temperatures are in degrees Celsius (° C.). All references cited are, in relevant part, incorporated herein by reference; the citation of any reference should not be construed as an admission that it is prior art with respect to the present invention. DETAILED DESCRIPTION
[0217] The diazepine compounds of the present invention can treat and prevent YFV infection by targeting viral NS4B and its interactions with other viral nonstructural proteins (including NS1, NS2A, NS3, NS4A, and host cell proteins). It has been found that blocking the interaction of NS4B protein with other viruses (including NS1, NS2A, NS3, NS4A, and host cell proteins) is a viable method to limit viral replication. In addition, compounds that can interfere with or block the interaction of viral NS4B with other viral nonstructural proteins (including NS1, NS2A, NS3, and NS4A) and host cell proteins can be used to treat and prevent flavivirus infections. Flavivirus infections that can be treated with compounds that target NS4B to block or interfere with the interaction of viral NS4B with other viral nonstructural proteins (including NS1, NS2A, NS3, and NS4A) and host cell proteins (including yellow fever virus, dengue virus, and Japanese encephalitis virus) can be treated.
[0218] Throughout this specification, when compositions are described as having, including, or comprising particular components, or when processes are described as having, including, or comprising particular process steps, it is contemplated that the compositions taught herein also consist essentially of, or consist of, those components, and that the processes taught herein also consist essentially of, or consist of, those process steps.
[0219] In the present invention, when an element or component is included in a list of elements or components and / or selected from a list of elements or components, it should be understood that the element or component may be any one of the elements or components and may be selected from a group consisting of two or more of the elements or components.
[0220] Unless otherwise specifically stated, the singular used in the present invention includes the plural (and vice versa). In addition, when the term "about" is used before a quantitative value, the present teachings also include the specific quantitative value itself unless otherwise specifically stated.
[0221] Should be understood that, as long as the present invention remains operable, the order of steps or the order in which certain actions are performed is not important.In addition, two or more steps or actions can be performed simultaneously.
[0222] The term "halogen" as used herein refers to chlorine, bromine, fluorine and iodine.
[0223] Unless otherwise indicated, "alkyl" and / or "aliphatic" as used herein, whether used alone or as part of a substituent group, refers to straight and branched carbon chains having 1 to 20 carbon atoms or any number within this range (e.g., 1 to 6 carbon atoms or 1 to 4 carbon atoms). 1-6) shall independently refer to the number of carbon atoms in the alkyl portion or the larger alkyl portion containing the alkyl substituent. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, etc. The alkyl group may be optionally substituted. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3-carboxypropyl, etc. In substituents with multiple alkyl groups such as (C 1-6 In the amino group (alkyl)2, the alkyl groups may be the same or different.
[0224] As used herein, the terms "alkenyl" and "alkynyl," whether used alone or as part of a substituent, refer to straight and branched carbon chains having 2 or more carbon atoms, preferably 2-20 carbon atoms, wherein the alkenyl chain has at least one double bond in the chain and the alkynyl chain has at least one triple bond in the chain. Alkenyl and alkynyl groups may be optionally substituted. Non-limiting examples of alkenyl groups include vinyl, 3-propenyl, 1-propenyl (also known as 2-methylvinyl), isopropenyl (also known as 2-methylvinyl-2-yl), buten-4-yl, and the like. Non-limiting examples of substituted alkenyl groups include 2-chlorovinyl (also known as 2-chloroethylene), 4-hydroxybuten-1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, 7-hydroxy-7-methyloct-3,5-dien-2-yl, and the like. Non-limiting examples of alkynyl groups include ethynyl, prop-2-ynyl (also known as propargyl), propyn-1-yl, and 2-methylhex-4-yn-1-yl. Non-limiting examples of substituted alkynyl groups include 5-hydroxy-5-methylhex-3-ynyl, 6-hydroxy-6-methylhept-3-yn-2-yl, 5-hydroxy-5-ethylhept-3-ynyl, and the like.
[0225] " cycloalkyl " used in the present invention, whether used alone or as part of another group, refers to a non-aromatic carbon-containing ring including cyclized alkyl, alkenyl and alkynyl, for example, having 3 to 14 ring carbon atoms, preferably 3 to 7 or 3 to 6 ring carbon atoms, or even 3 to 4 ring carbon atoms, and optionally containing one or more (e.g., 1, 2 or 3) double bonds or triple bonds. Cycloalkyl can be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridged and / or spirocyclic ring systems), wherein carbon atoms are located inside or outside the ring system. Any suitable ring position of cycloalkyl can be covalently linked to the defined chemical structure. The cycloalkyl ring can be optionally substituted. Non-limiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydrosulfonyl; bicyclo[6.2.0]decyl, decahydronaphthyl, and dodecahydro-1H-fluorenyl. The term "cycloalkyl" also includes carbocycles that are bicyclic hydrocarbon rings, non-limiting examples of which include bicyclo-[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octyl, and bicyclo[3.3.3]undecenyl.
[0226] "Haloalkyl" includes side-chain and straight-chain saturated aliphatic hydrocarbon groups with a specific number of carbon atoms that are substituted with one or more halogens.Haloalkyl includes perhaloalkyl, in which all hydrogens of the alkyl group are replaced with halogens (e.g., -CF3, -CF2CF3). In addition to halogens, haloalkyl can optionally be substituted with one or more substituents. Examples of haloalkyl include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
[0227] The term "alkoxy" refers to a group -O-alkyl, wherein alkyl is as defined above. Alkoxy may be optionally substituted. The term C3-C6 cyclic alkoxy refers to a ring containing 3 to 6 carbon atoms and at least one oxygen atom (e.g., tetrahydrofuran, tetrahydro-2H-pyran). C3-C6 cyclic alkoxy may be optionally substituted.
[0228] The term "aryl", when used alone or as part of another group, is defined as an unsaturated aromatic monocyclic ring of 6 carbon members or an unsaturated aromatic polycyclic ring of 10-14 carbon members in the present invention. The aryl ring can be, for example, a phenyl or naphthyl ring, each ring optionally being substituted with one or more moieties capable of replacing one or more hydrogen atoms. The non-limiting examples of aryl include: phenyl, naphthalene-1-yl, naphthalene-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl, 3-methoxyphenyl, 8-hydroxynaphthalene-2-yl, 4,5-dimethoxynaphthalene-1-yl and 6-cyano-naphthalene-1-yl. Aryl also includes, for example, a phenyl or naphthyl ring fused to one or more saturated or partially saturated carbocyclic rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl, indenyl), which may be substituted on one or more carbon atoms of the aromatic and / or saturated or partially saturated rings.
[0229] The term "arylalkyl" or "aralkyl" refers to the group -alkyl-aryl, where alkyl and aryl are as defined herein. The aralkyl groups of the present invention are optionally substituted. Examples of arylalkyl groups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl, and the like.
[0230] The terms "heterocyclic" and / or "heterocycle" and / or "heterocylyl", whether used alone or as part of another group, are defined herein as one or more rings having 3 to 20 atoms, wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O) or sulfur (S), and wherein the ring further comprising the heteroatom is non-aromatic. In heterocyclic groups comprising 2 or more fused rings, the ring with the non-heteroatom can be an aryl group (e.g., indolinyl, tetrahydroquinolinyl, chromanyl). Exemplary heterocyclic groups have 3 to 14 ring atoms, wherein 1 to 5 are heteroatoms independently selected from nitrogen (N), oxygen (O) or sulfur (S). One or more N or S atoms in the heterocyclic group can be oxidized. The heterocyclic group can be optionally substituted.
[0231] Non-limiting examples of heterocyclic units having a single ring include: diazirinyl, aziridinyl, urazolyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyl, oxathiazolidinyl, oxazolidinyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-one (valerolactone), 2,3,4,5-tetrahydro-1H-azacyclopentyl, 2,3-dihydro-1H-indole, and 1,2,3,4-tetrahydroquinoline. Non-limiting examples of heterocyclic units having 2 or more rings include hexahydro-1H-pyrrolazinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl, chromanyl, isochromanyl, indolyl, isoindolyl, and decahydro-1H-cycloocta[b]pyrrolyl.
[0232] No matter used alone or as part of another group, the term "heteroaryl" is defined in the present invention as one or more rings with 5 to 20 atoms, wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O) or sulfur (S), and wherein at least one additional ring comprising heteroatoms is aromatic. In heteroaryls comprising 2 or more fused rings, the ring with non-heteroatoms can be a carbocycle (e.g., 6,7-dihydro-5H-cyclopentanepyrimidine) or an aryl (e.g., benzofuranyl, benzothienyl, indolyl). Exemplary heteroaryls have 5 to 14 ring atoms and contain 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O) or sulfur (S). One or more N or S atoms in heteroaryls can be oxidized. Heteroaryls can be substituted. Non-limiting examples of heteroaryl rings containing a monocyclic ring include 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, furanyl, thienyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing two or more fused rings include benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxyquinolinyl, and isoquinolinyl.
[0233] A non-limiting example of the above heteroaryl groups is a C1-C5 heteroaryl group having 1-5 carbon ring atoms and at least one additional ring atom that is a heteroatom (preferably 1-4 additional ring atoms that are heteroatoms) independently selected from nitrogen (N), oxygen (O), or sulfur (S). Examples of C1-C5 heteroaryl groups include, but are not limited to, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.
[0234] Unless otherwise stated, when two substituents are taken together to form a ring having the specified number of ring atoms (e.g., R 2 and R 3 When taken together with the nitrogen (N) to which they are attached to form a ring having 3 to 7 ring members, the ring may have carbon atoms and optionally one or more (e.g., 1-3) other heteroatoms independently selected from nitrogen (N), oxygen (O) or sulfur (S). The ring may be saturated or partially saturated and may be optionally substituted.
[0235] For the purposes of this invention, fused ring units containing a single heteroatom, as well as spirocycles, bicyclic rings, etc., will be considered to belong to the ring family corresponding to the heteroatom-containing ring. For example, 1,2,3,4-tetrahydroquinoline has the following formula:
[0236]
[0237] For the purposes of the present invention, it is considered to be a heterocyclic unit. 6,7-dihydro-5H-cyclopentylpyrimidine having the following formula:
[0238]
[0239] For the purposes of this invention, it is considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both the saturated and aromatic rings, the aromatic ring will predominate and determine the type of ring to which it belongs. For example, 1,2,3,4-tetrahydro-[1,8]naphthyridine has the following formula:
[0240]
[0241] For the purposes of the present invention, these are regarded as heteroaryl units.
[0242] Whenever a term or any of its prefix roots appears in the name of a substituent, the name should be interpreted as including those limitations provided by the present invention. For example, whenever the term "alkyl" or "aryl" or any of their prefix roots appears in the name of a substituent (e.g., arylalkyl, alkylamino), the name should be interpreted as including those limitations given above for "alkyl" and "aryl".
[0243] The term "substituted" is used throughout the specification. The term "substituted" is defined in the present invention as a portion having one or more hydrogen atoms replaced by a substituent or several (e.g., 1 to 10) substituents, whether acyclic or cyclic, as defined below. A substituent can replace one or two hydrogen atoms of a single portion at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form a substituent, a new portion or unit. For example, a substitution unit requiring a single hydrogen atom to replace includes halogen, hydroxyl, etc. Two hydrogen atom substitutions include carbonyl, oxime, etc. Replacing two hydrogen atoms of adjacent carbon atoms includes epoxy, etc. In this specification, the term "substituted" is used to indicate that a portion may have one or more hydrogen atoms replaced by a substituent. When a portion is described as "substituted," any number of hydrogen atoms may be substituted. For example, difluoromethyl is a substituted C1 alkyl; trifluoromethyl is a substituted C1 alkyl; 4-hydroxyphenyl is a substituted aromatic ring; (N,N-dimethyl-5-amino)octanyl is a substituted C8 alkyl; 3-guanidinopropyl is a substituted C3 alkyl; and 2-carboxypyridinyl is a substituted heteroaryl.
[0244] Variable groups as defined herein, such as alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocyclyl, and heteroaryl as defined herein, whether used alone or as part of another group, may be optionally substituted. Optionally substituted groups will be represented as such.
[0245] The following are non-limiting examples of substituents that can replace a hydrogen atom on a moiety: halogen (chlorine (Cl), bromine (Br), fluorine (F), and iodine (I)), -CN, -NO2, oxo (=O), -OR x 、-SR x 、-N(R x )2、-NR x C(O)R x 、-SO2R x 、-SO2OR x 、-SO2N(R x )2, –C(O)R x 、C(O)OR x 、–C(O)N(R x )2、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C1-6 Alkoxy, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-14 Cycloalkyl, aryl, heterocycle or heteroaryl, wherein alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocycle and heteroaryl are each optionally substituted by 1-10 (e.g., 1-6 or 1-4) independently selected from halogen, -CN, -NO2, oxo and R x substituted by a group; wherein R x is independently hydrogen, -OR x+1 、-SR x+1 ,–C(O)R x+1 、–C(O)OR x+1 、–C(O)N(R x+1 )2. –SO2R x+1 、-S(O)2OR x+1 ,–N(R x+1 )2. –NR x+1 C(O)R x+11 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, cycloalkyl (e.g., C 3-6 cycloalkyl), aryl, heterocyclic or heteroaryl, or two R x The units, together with the atoms to which they are attached, form an optionally substituted carbocyclic or heterocyclic ring having 3 to 7 ring atoms; wherein R x+1 is independently hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, cycloalkyl (e.g., C 3-6 cycloalkyl), aryl, heterocyclic or heteroaryl, or two R x+1 The units, together with the atoms to which they are attached, form an optionally substituted carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring preferably has 3 to 7 ring atoms.
[0246] In some embodiments, the substituents are selected from
[0247] i)–OR x+2 ; For example, -OH, -OCH3, -OCH2CH3, -OCH2CH2CH3;
[0248] ii)–C(O)R x+2 ; For example, –COCH3, –COCH2CH3, –COCH2CH2CH3;
[0249] iii) – C(O) orx+2 ; For example, –CO2CH3, –CO2CH2CH3, –CO2CH2CH2CH3;
[0250] iv)–C(O)N(R x+2 )2; for example, –CONH2, –CONHCH3, –CON(CH3)2;
[0251] v)–N(R x+2 )2; for example, –NH2, –NHCH3, –N(CH3)2, –NH(CH2CH3);
[0252] vi) Halogens: –F, –Cl, –Br and –I;
[0253] vii)-CH e X g ; wherein X is a halogen, m is 0-2, e+g=3; for example, –CH2F, –CHF2, –CF3, –CCl3 or –CBr3;
[0254] viii)-SO2R x+2 ; For example, –SO2H; -SO2CH3; -SO2C6H5;
[0255] ix) a C1-C6 linear, branched or cyclic alkyl group;
[0256] x) cyano
[0257] xi) nitro;
[0258] xii)N(R x+2 )C(O)R x+2 ;;
[0259] xiii) oxo (=O);
[0260] xiv) heterocyclic ring; and
[0261] xv) heteroaryl.
[0262] Among them, each R x+2 are independently hydrogen, optionally substituted C1-C6 straight or branched chain alkyl (e.g., optionally substituted C1-C4 straight or branched chain alkyl), or optionally substituted C3-C6 cycloalkyl (e.g., optionally substituted C3-C4 cycloalkyl); or two R x+2 The units can be taken together to form a ring containing 3-7 ring atoms. In certain aspects, each R x+2 are independently hydrogen, C1-C6 linear or branched alkyl optionally substituted by halogen or C3-C6 cycloalkyl, or C3-C6 cycloalkyl.
[0263] Throughout the specification, substituents of compounds are disclosed in groups or ranges. Specifically, this specification includes each individual subcombination of the members of these groups and ranges. For example, the term "C 1-6 The term “alkyl” is specifically used to disclose individually C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl.
[0264] For the purposes of the present invention, the terms "compound," "analog," and "composition of matter" are also applicable to the biological effector agents described in the present invention, including all enantiomeric forms, diastereomeric forms, salts, etc., and the terms "compound," "analog," and "composition of matter" are used interchangeably in this specification.
[0265] The compounds described herein may contain asymmetric atoms (also referred to as chiral centers), and some compounds may contain one or more asymmetric atoms or centers, which may therefore produce optical isomers (enantiomers) and diastereomers. The teachings of the present invention and the compounds disclosed herein include such enantiomers and diastereomers, as well as racemic and resolved enantiomerically pure R and S stereoisomers, and other mixtures of R and S stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers can be obtained in pure form by standard methods known to those skilled in the art, including but not limited to diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. The present invention also includes cis and trans isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It should also be understood that the teachings of the present invention include all possible regioisomers and mixtures thereof, which can be obtained in pure form by standard separation methods known to those skilled in the art, including but not limited to column chromatography, thin layer chromatography, and high performance liquid chromatography.
[0266] Pharmaceutically acceptable salts of the compounds of the present invention can be formed using organic and inorganic bases, and the salts may have an acidic moiety. Depending on the amount of acidic hydrogen available for deprotonation, both monoanionic and polyanionic salts may be considered. Suitable salts formed with bases include metal salts such as alkali metal or alkaline earth metal salts, such as sodium salts, potassium salts, or magnesium salts; ammonium salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine, pyrrolidine, mono-, di-, or tri-lower alkylamines (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl-, or dimethylpropylamine), or mono-, di-, or trihydroxy lower alkylamines (e.g., mono-ethanolamine, diethanolamine, or triethanolamine). Specific non-limiting examples of inorganic bases include NaHCO , Na CO , KHCO , K CO , Cs CO , LiOH, NaOH, KOH, NaH PO , Na HPO , and Na PO . Internal salts can also be formed. Similarly, when the compounds disclosed herein contain a basic moiety, organic and inorganic acids can be used to form salts. For example, salts can be formed from the following acids: acetic acid, propionic acid, lactic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, tartaric acid, succinic acid, dichloroacetic acid, vinylsulfonic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalenesulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phosphoric acid, phthalic acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, toluenesulfonic acid and camphorsulfonic acid, as well as other known pharmaceutically acceptable acids.
[0267] When any variable occurs more than one time in any constituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence (e.g., in N(R x+1 )2, each R x+1 Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0268] The term "treating" as used herein refers to partially or completely alleviating, inhibiting, improving and / or relieving a condition that a patient is suspected of suffering from.
[0269] As used herein, "therapeutically effective" and "effective dose" refer to a substance or amount that elicits a desired biological activity or effect.
[0270] Unless otherwise indicated, the terms "subject" or "patient" are used interchangeably to refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats and mice, and other animals. Therefore, the terms "subject" or "patient" used in the present invention refer to any mammalian patient or subject to which the compounds of the present invention can be administered. In an exemplary embodiment of the present invention, in order to identify a subject patient for treatment according to the methods of the present invention, recognized screening methods are used to determine risk factors associated with the target or suspected disease or condition, or to determine the status of an existing disease or condition in the subject. These screening methods include, for example, routine examinations to determine risk factors that may be associated with the target or suspected disease or condition. These and other conventional methods allow clinicians to select patients who need to be treated using the methods and compounds of the present invention.
[0271] Diazepine compounds of the present invention
[0272] The compounds of the present invention are diazepine compounds and include all enantiomeric and diastereomeric forms having formula (I) and pharmaceutically acceptable salts thereof:
[0273]
[0274] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, isotopic analogs, prodrugs and complexes thereof, wherein:
[0275] A choose freedom as well as the group formed;
[0276] When A is When m is 0;
[0277] When A is When , n is selected from 0 and 1;
[0278] R 1 Selected from C3-7 cycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
[0279] When A is When , m is selected from 0 and 1;
[0280] When A is When n, n is selected from 0 and 1;
[0281] R 2 Selected from C3-C8 cycloalkyl, C4-C10 bicycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
[0282] When A is When , m is selected from 0 and 1;
[0283] When A is When , n is selected from 0 and 1;
[0284] R 3 Selected from the group consisting of C3-C8 cycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
[0285] R 4 Choose Free
[0286]
[0287] as well as the group formed;
[0288] p is 1, 2, 3, 4, or 5;
[0289] When R 4 for When , p is not 1;
[0290] When R 4 for When , p is not 1;
[0291] X 1 is 0, 1, 2, or 3;
[0292] Y is 0, 1, 2, 3, or 4;
[0293] X chooses freedom the group formed;
[0294] R a Selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and halide;
[0295] R b Selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and halide;
[0296] R c Selected from C1-C12 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH2F, CHF2, CF3, C2-C9 haloalkyl, C3-C9 branched haloalkyl, NR d R e, optionally substituted benzyl, optionally substituted CH2 heteroaryl, optionally substituted aryl and optionally substituted heteroaryl, and the group consisting of a C3-C6 cycloalkyl ring optionally containing oxygen;
[0297] R a and R b Together they may form a C3-C6 cycloalkyl ring optionally containing oxygen;
[0298] R d is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, an optional aromatic ring, and an optionally substituted heteroaromatic ring;
[0299] R e is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, an optional aromatic ring, and an optionally substituted heteroaromatic ring;
[0300] R f Selected from the group consisting of hydrogen, C1-C12 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH2F, CHF2, CF3, C2-C9 haloalkyl, C3-C9 branched haloalkyl, optionally substituted benzyl, optionally substituted CH2 heteroaryl, optionally substituted aryl, optionally substituted heteroaryl, and a C3-C6 cycloalkyl ring optionally containing oxygen;
[0301] R 5 Selected from C2-C8 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH2F, CHF2, CF3, C2-C9 haloalkyl, C3-C9 branched haloalkyl, optionally substituted benzyl, optionally substituted CH2 heteroaryl, CH2OR 5a 、CH(CH3)OR 5a 、C(R 5e )2OR 5a 、C(R 5e )2OR 5a 、CH2SR 5a , CH2CH2SCH3, CH2CH2SO2CH3, CH2CH2CH2NR 5c R 5d 、CH2COR 5b 、CH2CH2COR 5b 、(CH2) z (C3-C7 cycloalkyl) and a C3-C6 cycloalkyl ring optionally containing oxygen;
[0302] z is 1, 2, 3, 4, 5, or 6;
[0303] R 5aSelected from the group consisting of hydrogen, C1-C6 alkyl, C3-C7 branched alkyl, optionally substituted phenyl, optionally substituted benzyl and optionally substituted CH2CH2Ar;
[0304] R 5b selected from the group consisting of OH, C1-C6 alkoxy and NH2;
[0305] R 5c and R 5d are each independently selected from hydrogen and optionally substituted C1-C6 alkyl;
[0306] R 5e is a C1-C4 alkyl group;
[0307] R 6 and R 7 It is hydrogen;
[0308] or
[0309] R 6 and R 7 Together with the atoms to which they are attached, they form a 6-membered aromatic ring selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted;
[0310] or
[0311] R 6 and R 7 Together with the atoms to which they are attached, they form a substituted 5-6 membered heteroaromatic ring containing 1-2 nitrogen atoms, the heteroaromatic ring being selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted;
[0312] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0313] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0314] q is 0, 1, 2, 3, 4, 5, or 6;
[0315] The compounds of the present invention include compounds having formula (II):
[0316]
[0317] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0318] The compounds of the present invention include compounds having formula (III):
[0319]
[0320] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0321] Compounds of the present invention include compounds having formula (IV):
[0322]
[0323] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0324] R 8a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0325] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0326] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0327] q is 0, 1, 2, 3, 4, 5, or 6;
[0328] R 8b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0329] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0330] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0331] q is 0, 1, 2, 3, 4, 5, or 6;
[0332] R 8c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0333] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0334] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0335] q is 0, 1, 2, 3, 4, 5, or 6;
[0336] R 8d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0337] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0338] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0339] q is 0, 1, 2, 3, 4, 5, or 6;
[0340] R 8a 、R 8b and R 8d At least two of them are hydrogen.
[0341] The compounds of the present invention include compounds having formula (V):
[0342]
[0343] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0344] The compounds of the present invention include compounds having formula (VI):
[0345]
[0346] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0347] R 9a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0348] R13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0349] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0350] q is 0, 1, 2, 3, 4, 5, or 6;
[0351] R 9b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0352] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0353] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0354] q is 0, 1, 2, 3, 4, 5, or 6;
[0355] R 9c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0356] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0357] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0358] q is 0, 1, 2, 3, 4, 5, or 6;
[0359] R 9d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0360] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0361] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0362] q is 0, 1, 2, 3, 4, 5, or 6;
[0363] R 9a 、R9b and R 9d At least two of them are hydrogen;
[0364] The compounds of the present invention include compounds having formula (VII):
[0365]
[0366] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0367] Compounds of the present invention include compounds having formula (VIII):
[0368]
[0369] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0370] Compounds of the present invention include compounds having formula (IX):
[0371]
[0372] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein
[0373] R 10a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0374] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0375] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0376] q is 0, 1, 2, 3, 4, 5, or 6;
[0377] R 10b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0378] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0379] R 14selected from the group consisting of hydrogen and C1-C6 alkyl;
[0380] q is 0, 1, 2, 3, 4, 5, or 6;
[0381] R 10c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0382] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0383] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0384] q is 0, 1, 2, 3, 4, 5, or 6;
[0385] R 10d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0386] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0387] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0388] q is 0, 1, 2, 3, 4, 5, or 6;
[0389] R 10a 、R 10b and R 10d At least two of them are hydrogen;
[0390] The compounds of the present invention include compounds having formula (X):
[0391]
[0392] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0393] Compounds of the present invention include compounds having formula (XI):
[0394]
[0395] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0396] R 11a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0397] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0398] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0399] q is 0, 1, 2, 3, 4, 5, or 6;
[0400] R 11b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0401] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0402] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0403] q is 0, 1, 2, 3, 4, 5, or 6;
[0404] R 11c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0405] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0406] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0407] q is 0, 1, 2, 3, 4, 5, or 6;
[0408] R 11d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl, and heteroaromatic ring;
[0409] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0410] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0411] q is 0, 1, 2, 3, 4, 5, or 6;
[0412] R 11a 、R 11b and R 11d At least two of them are hydrogen;
[0413] The compounds of the present invention include compounds having formula (XII):
[0414]
[0415] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0416] The compounds of the present invention include compounds having formula (XIII):
[0417]
[0418] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein
[0419] R 12a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0420] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0421] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0422] q is 0, 1, 2, 3, 4, 5, or 6;
[0423] R 12b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0424] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0425] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0426] q is 0, 1, 2, 3, 4, 5, or 6;
[0427] R 12c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0428] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0429] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0430] q is 0, 1, 2, 3, 4, 5, or 6;
[0431] R 12d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl;
[0432] R 13 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0433] R 14 selected from the group consisting of hydrogen and C1-C6 alkyl;
[0434] q is 0, 1, 2, 3, 4, 5, or 6;
[0435] R 12a 、R 12b and R 12d At least two of them are hydrogen;
[0436] Compounds of the present invention include compounds having formula (XIV):
[0437]
[0438] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0439] Compounds of the present invention include compounds having formula (XV):
[0440]
[0441] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0442] Compounds of the present invention include compounds having formula (XVI):
[0443]
[0444] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0445] Compounds of the present invention include compounds having formula (XVII):
[0446]
[0447] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
[0448] Compounds of the present invention include compounds having formula (XVIII):
[0449]
[0450] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0451] R 15 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0452] R 16 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0453] Compounds of the present invention include compounds having formula (XIX):
[0454]
[0455] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0456] R 17 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0457] The compounds of the present invention include compounds having the formula (XX):
[0458]
[0459] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0460] R 18 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0461] Compounds of the present invention include compounds having formula (XXI):
[0462]
[0463] including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
[0464] R 19 Selected from C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl;
[0465] The following compounds are expressly excluded from the scope of the present invention:
[0466]
[0467] In some embodiments, A is In some embodiments, A is In some embodiments, A is In some embodiments, m is 0.
[0468] In some embodiments, m is 1.
[0469] In some embodiments, n is 0.
[0470] In some embodiments, n is 1.
[0471] In some embodiments, R 1 It is a C3-7 cycloalkyl group.
[0472] In some embodiments, R 1 It is a C3-C7 branched chain alkyl group.
[0473] In some embodiments, R 1 It is a C1-C6 haloalkyl group.
[0474] In some embodiments, R 1 It is a C3-C7 branched haloalkyl group.
[0475] In some embodiments, R 1 is an optionally substituted aryl group.
[0476] In some embodiments, R 1 is an optionally substituted heteroaryl group.
[0477] In some embodiments, R 2 It is a C3-C8 cycloalkyl group.
[0478] In some embodiments, R 2 is a C4-C10 bicycloalkyl group. In some embodiments, R 2 It is a C3-C7 branched chain alkyl group.
[0479] In some embodiments, R 2 It is a C1-C6 haloalkyl group.
[0480] In some embodiments, R 2 is a C3-C7 branched haloalkyl group. In some embodiments, R 2 is an optionally substituted aryl group.
[0481] In some embodiments, R 2 is an optionally substituted heteroaryl group.
[0482] In some embodiments, R 3 It is a C3-C8 cycloalkyl group.
[0483] In some embodiments, R 3 It is a C3-C7 branched chain alkyl group.
[0484] In some embodiments, R 3 It is a C1-C6 haloalkyl group.
[0485] In some embodiments, R 3 It is a C3-C7 branched haloalkyl group.
[0486] In some embodiments, R 3 is an optionally substituted aryl group.
[0487] In some embodiments, R 3 is an optionally substituted heteroaryl group.
[0488] In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes
[0489] In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, R 4 yes In some embodiments, X 1 is 0.
[0490] In some embodiments, X 1 is 1.
[0491] In some embodiments, X 1 It's 2.
[0492] In some embodiments, X 1 It's 3.
[0493] In some embodiments, p is 1.
[0494] In some embodiments, p is 2.
[0495] In some embodiments, p is 3.
[0496] In some embodiments, p is 4.
[0497] In some embodiments, p is 5.
[0498] In some embodiments, y is 0.
[0499] In some embodiments, y is 1.
[0500] In some embodiments, y is 2.
[0501] In some embodiments, y is 3.
[0502] In some embodiments, y is 4.
[0503] In some embodiments, X is In some embodiments, X is In some embodiments, R a It’s H.
[0504] In some embodiments, R a It is a C1-C6 alkyl group.
[0505] In some embodiments, R a is C3-C6 cycloalkyl. In some embodiments, R a It's a halogen.
[0506] In some embodiments, R b It’s H.
[0507] In some embodiments, R b It is a C1-C6 alkyl group.
[0508] In some embodiments, R b is C3-C6 cycloalkyl. In some embodiments, R b It's a halogen.
[0509] In some embodiments, R c It is a C1-C12 alkyl group.
[0510] In some embodiments, R c It is a C3-C11 branched alkyl group.
[0511] In some embodiments, R c It is a C3-C8 cycloalkyl group.
[0512] In some embodiments, R c It is a C5-C15 bicycloalkyl group.
[0513] In some embodiments, R c It is CH2F.
[0514] In some embodiments, R c It is CHF2.
[0515] In some embodiments, R c It's CF3.
[0516] In some embodiments, R c It is a C2-C9 haloalkyl group.
[0517] In some embodiments, R c It is a C3-C9 branched haloalkyl group.
[0518] In some embodiments, R c is an optionally substituted benzyl group.
[0519] In some embodiments, R c is optionally substituted CH2 heteroaryl.
[0520] In some embodiments, R c is an optionally substituted aryl group.
[0521] In some embodiments, R c is an optionally substituted heteroaryl group.
[0522] In some embodiments, R c It is a 3-membered cycloalkyl ring.
[0523] In some embodiments, R c It is a 4-membered cycloalkyl ring.
[0524] In some embodiments, R c It is a 5-membered cycloalkyl ring.
[0525] In some embodiments, R c It is a 6-membered cycloalkyl ring.
[0526] In some embodiments, R c It is a 3-membered cycloalkyl ring containing oxygen.
[0527] In some embodiments, R c It is a 4-membered cycloalkyl ring containing oxygen.
[0528] In some embodiments, R c It is a 5-membered cycloalkyl ring containing oxygen.
[0529] In some embodiments, R c It is a 6-membered cycloalkyl ring containing oxygen.
[0530] In some embodiments, R a and R b Together they form a 3-membered cycloalkyl ring.
[0531] In some embodiments, R a and R b Together they form a 4-membered cycloalkyl ring.
[0532] In some embodiments, R a and R b Together they form a 5-membered cycloalkyl ring.
[0533] In some embodiments, R a and R b Together they form a 6-membered cycloalkyl ring.
[0534] In some embodiments, R a and R b Together they form a 3-membered cycloalkyl ring containing oxygen.
[0535] In some embodiments, R a and R b Together they form a 4-membered cycloalkyl ring containing oxygen.
[0536] In some embodiments, R a and R b Together they form a 5-membered cycloalkyl ring containing oxygen.
[0537] In some embodiments, R a and R b Together they form a 6-membered cycloalkyl ring containing oxygen.
[0538] In some embodiments, R d It's hydrogen.
[0539] In some embodiments, R d It is a C1-C6 alkyl group.
[0540] In some embodiments, R d It is a C3-C6 cyclic acyl group.
[0541] In some embodiments, R d Optionally, it is an aromatic ring.
[0542] In some embodiments, R d is an optionally substituted heteroaryl ring.
[0543] In some embodiments, R e It's hydrogen.
[0544] In some embodiments, R e It is a C1-C6 alkyl group.
[0545] In some embodiments, R e It is a C3-C6 cycloalkyl group.
[0546] In some embodiments, R e Optionally, it is an aromatic ring.
[0547] In some embodiments, R e is an optionally substituted heteroaryl ring.
[0548] In some embodiments, R f It's hydrogen.
[0549] In some embodiments, R f It is a C1-C12 alkyl group.
[0550] In some embodiments, R f It is a C3-C11 branched alkyl group.
[0551] In some embodiments, R f It is a C3-C8 cycloalkyl group.
[0552] In some embodiments, R f It is a C5-C15 bicycloalkyl group.
[0553] In some embodiments, R f It is CH2F.
[0554] In some embodiments, R f It is CHF2.
[0555] In some embodiments, R f It's CF3.
[0556] In some embodiments, R f It is a C2-C9 haloalkyl group.
[0557] In some embodiments, R f It is a C3-C9 branched haloalkyl group.
[0558] In some embodiments, R f is an optionally substituted benzyl group, in some embodiments, R f is an optionally substituted CH2 heteroaryl. In some embodiments, R f is an optionally substituted aryl group.
[0559] In some embodiments, R f is an optionally substituted heteroaryl group.
[0560] In some embodiments, R f It is a C3 cycloalkyl ring.
[0561] In some embodiments, R f It is a C4 cycloalkyl ring.
[0562] In some embodiments, R f It is a C5 cycloalkyl ring.
[0563] In some embodiments, R f It is a C6 cycloalkyl ring.
[0564] In some embodiments, R f It is a C3 cycloalkyl ring containing oxygen.
[0565] In some embodiments, R f It is a C4 cycloalkyl ring containing oxygen.
[0566] In some embodiments, Rf It is a C5 cycloalkyl ring containing oxygen.
[0567] In some embodiments, R f It is a C6 cycloalkyl ring containing oxygen.
[0568] In some embodiments, R 5 It is a C2-C8 alkyl group.
[0569] In some embodiments, R 5 It is a C3-C11 branched alkyl group.
[0570] In some embodiments, R 5 It is a C3-C8 cycloalkyl group.
[0571] In some embodiments, R 5 It is a C5-C15 bicycloalkyl group.
[0572] In some embodiments, R 5 It is CH2F.
[0573] In some embodiments, R 5 It is CHF2.
[0574] In some embodiments, R 5 It's CF3.
[0575] In some embodiments, R 5 It is a C2-C9 haloalkyl group.
[0576] In some embodiments, R 5 is a C3-C9 branched haloalkyl group. In some embodiments, R 5 is an optionally substituted benzyl group.
[0577] In some embodiments, R 5 is optionally substituted CH2 heteroaryl.
[0578] In some embodiments, R 5 It is CH2OR 5a .
[0579] In some embodiments, R 5 is CH(CH3)OR 5a .
[0580] In some embodiments, R 5 It is C(R 5e )2OR 5a. .
[0581] In some embodiments, R 5 It is C(R 5e )2OR 5a .
[0582] In some embodiments, R 5 It is CH2SR 5a .
[0583] In some embodiments, R 5 It is CH2CH2SCH3.
[0584] In some embodiments, R 5 It is CH2CH2SO2CH 3. .
[0585] In some embodiments, R 5 I is CH2CH2CH2NR 5c R 5d .
[0586] In some embodiments, R 5 It is CH2COR 5b .
[0587] In some embodiments, R 5 It is CH2CH2COR 5b .
[0588] In some embodiments, R 5 Yes (CH2) z (C3-C7 cycloalkyl).
[0589] In some embodiments, z is 0.
[0590] In some embodiments, z is 1.
[0591] In some embodiments, z is 2.
[0592] In some embodiments, z is 3.
[0593] In some embodiments, z is 4.
[0594] In some embodiments, z is 5.
[0595] In some embodiments, z is 6.
[0596] In some embodiments, R 5 It is a C3-C6 cycloalkyl ring optionally containing oxygen.
[0597] In some embodiments, R 5a It's hydrogen.
[0598] In some embodiments, R 5a It is a C1-C6 alkyl group.
[0599] In some embodiments, R 5ais a C3-C7 branched alkyl group. In some embodiments, R 5a is optionally substituted phenyl.
[0600] In some embodiments, R 5a is an optionally substituted benzyl group.
[0601] In some embodiments, R 5a is optionally substituted CH2CH2Ar.
[0602] In some embodiments, R 5b It's OH.
[0603] In some embodiments, R 5b It is a C1-C6 alkoxy group.
[0604] In some embodiments, R 5b It's NH2.
[0605] In some embodiments, R 5c It's hydrogen.
[0606] In some embodiments, R 5c is an optionally substituted C1-C6 alkyl group.
[0607] In some embodiments, R 5d It's hydrogen.
[0608] In some embodiments, R 5d is an optionally substituted C1-C6 alkyl group.
[0609] In some embodiments, R 5e It is a C1-C4 alkyl group.
[0610] In some embodiments, R 7 It's hydrogen.
[0611] In some embodiments, R 7 It's hydrogen.
[0612] In some embodiments, R 6 and R 7 Together with the atoms to which they are attached, they form a 6-membered aromatic ring selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, At least one of the C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl groups is partially substituted.
[0613] In some embodiments, R 6 and R 7 Together with the atoms to which they are attached, they form a substituted heteroaromatic ring containing a nitrogen atom selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted.
[0614] In some embodiments, R 6 and R 7 Together with the atoms to which they are attached, they form a 5-membered heteroaromatic ring containing two nitrogen atoms, the heteroaromatic ring being selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted.
[0615] In some embodiments, R 6 and R 7 Together with the atoms to which they are attached, they form a substituted 6-membered heteroaromatic ring containing 1 nitrogen, the heteroaromatic ring being selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy,
[0616] At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted.
[0617] In some embodiments, R 6 and R 7 Together with the atoms to which they are attached, they form a substituted 6-membered heteroaromatic ring containing 2 nitrogen atoms, the heteroaromatic ring being selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy,
[0618] At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted.
[0619] In some embodiments, R 8a It's hydrogen.
[0620] In some embodiments, R 8a It's a halogen.
[0621] In some embodiments, R 8a It is a C1-C6 haloalkyl group.
[0622] In some embodiments, R 8a It's cyano.
[0623] In some embodiments, R 8a It is a C1-C6 alkyl group.
[0624] In some embodiments, R 8a It is a C1-C6 alkoxy group.
[0625] In some embodiments, R 8a yes In some embodiments, R 8a It is a C3-C8 cycloalkyl group.
[0626] In some embodiments, R 8a is a C3-C8 heterocycle, an aryl group. In some embodiments, R 8a It is a heteroaryl group.
[0627] In some embodiments, R 8b It's hydrogen.
[0628] In some embodiments, R 8b It's a halogen.
[0629] In some embodiments, R 8b It is a C1-C6 haloalkyl group.
[0630] In some embodiments, R 8b It's cyano.
[0631] In some embodiments, R 8b It is a C1-C6 alkyl group.
[0632] In some embodiments, R 8b It is a C1-C6 alkoxy group.
[0633] In some embodiments, R 8b yes In some embodiments, R 8b It is a C3-C8 cycloalkyl group.
[0634] In some embodiments, R 8b It is a C3-C8 heterocycle.
[0635] In some embodiments, R 8b It is an aryl group.
[0636] In some embodiments, R 8b It is a heteroaryl group.
[0637] In some embodiments, R 8c It's a halogen.
[0638] In some embodiments, R 8c It is a C1-C6 haloalkyl group.
[0639] In some embodiments, R 8c It's cyano.
[0640] In some embodiments, R 8c It is a C1-C6 alkyl group.
[0641] In some embodiments, R 8c It is a C1-C6 alkoxy group.
[0642] In some embodiments, R 8c yes In some embodiments, R 8c It is a C3-C8 cycloalkyl group.
[0643] In some embodiments, R 8c It is a C3-C8 heterocycle.
[0644] In some embodiments, R 8c It is an aryl group.
[0645] In some embodiments, R 8c It is a heteroaryl group.
[0646] In some embodiments, R 8d It's hydrogen.
[0647] In some embodiments, R 8d It's a halogen.
[0648] In some embodiments, R 8d It is a C1-C6 haloalkyl group.
[0649] In some embodiments, R 8d It's cyano.
[0650] In some embodiments, R 8d It is a C1-C6 alkyl group.
[0651] In some embodiments, R 8d It is a C1-C6 alkoxy group.
[0652] In some embodiments, R 8d yes In some embodiments, R 8d It is a C3-C8 cycloalkyl group.
[0653] In some embodiments, R 8d It is a C3-C8 heterocycle.
[0654] In some embodiments, R 8d It is an aryl group.
[0655] In some embodiments, R 8d It is a heteroaryl group.
[0656] In some embodiments, R 9a It's hydrogen.
[0657] In some embodiments, R 9a It's a halogen.
[0658] In some embodiments, R 9a It is a C1-C6 haloalkyl group.
[0659] In some embodiments, R 9a It's cyano.
[0660] In some embodiments, R 9a It is a C1-C6 alkyl group.
[0661] In some embodiments, R 9a It is a C1-C6 alkoxy group.
[0662] In some embodiments, R 9a yes In some embodiments, R 9a It is a C3-C8 cycloalkyl group.
[0663] In some embodiments, R 9a It is a C3-C8 heterocycle.
[0664] In some embodiments, R 9a It is an aryl group.
[0665] In some embodiments, R 9a It is a heteroaryl group.
[0666] In some embodiments, R 9b It's hydrogen.
[0667] In some embodiments, R 9b It's a halogen.
[0668] In some embodiments, R 9b It is a C1-C6 haloalkyl group.
[0669] In some embodiments, R 9b It's cyano.
[0670] In some embodiments, R 9b It is a C1-C6 alkyl group.
[0671] In some embodiments, R 9b It is a C1-C6 alkoxy group.
[0672] In some embodiments, R 9b yes In some embodiments, R 9b It is a C3-C8 cycloalkyl group.
[0673] In some embodiments, R 9b It is a C3-C8 heterocycle.
[0674] In some embodiments, R 9b It is a heteroaryl group.
[0675] In some embodiments, R 9b It's hydrogen.
[0676] In some embodiments, R 9b It's a halogen.
[0677] In some embodiments, R 9b It is a C1-C6 haloalkyl group.
[0678] In some embodiments, R 9b It's cyano.
[0679] In some embodiments, R 9b It is a C1-C6 alkyl group.
[0680] In some embodiments, R 9b It is a C1-C6 alkoxy group.
[0681] In some embodiments, R 9b yes In some embodiments, R 9b It is a C3-C8 cycloalkyl group.
[0682] In some embodiments, R 9b It is a C3-C8 heterocycle.
[0683] In some embodiments, R 9b It is an aryl group.
[0684] In some embodiments, R 9b It is a heteroaryl group.
[0685] In some embodiments, R 9c It's a halogen.
[0686] In some embodiments, R 9c It is a C1-C6 haloalkyl group.
[0687] In some embodiments, R 9c It's cyano.
[0688] In some embodiments, R 9c It is a C1-C6 alkyl group.
[0689] In some embodiments, R 9c It is a C1-C6 alkoxy group.
[0690] In some embodiments, R 9c yes In some embodiments, R 9c It is a C3-C8 cycloalkyl group.
[0691] In some embodiments, R 9c It is a C3-C8 heterocycle.
[0692] In some embodiments, R9c It is an aryl group.
[0693] In some embodiments, R 9c It is a heteroaryl group.
[0694] In some embodiments, R 9d It's hydrogen.
[0695] In some embodiments, R 9d It's a halogen.
[0696] In some embodiments, R 9d It is a C1-C6 haloalkyl group.
[0697] In some embodiments, R 9d It's cyano.
[0698] In some embodiments, R 9d It is a C1-C6 alkyl group.
[0699] In some embodiments, R 9d It is a C1-C6 alkoxy group.
[0700] In some embodiments, R 9d yes In some embodiments, R 9d It is a C3-C8 cycloalkyl group.
[0701] In some embodiments, R 9d It is a C3-C8 heterocycle.
[0702] In some embodiments, R 9d It is an aryl group.
[0703] In some embodiments, R 9d It is a heteroaryl group.
[0704] In some embodiments, R 10a It's hydrogen.
[0705] In some embodiments, R 10a It's a halogen.
[0706] In some embodiments, R 10a It is a C1-C6 haloalkyl group.
[0707] In some embodiments, R 10a It's cyano.
[0708] In some embodiments, R 10a It is a C1-C6 alkyl group.
[0709] In some embodiments, R 10a It is a C1-C6 alkoxy group.
[0710] In some embodiments, R 10a yes In some embodiments, R 10a It is a C3-C8 cycloalkyl group.
[0711] In some embodiments, R 10a It is a C3-C8 heterocycle.
[0712] In some embodiments, R 10a It is an aryl group.
[0713] In some embodiments, R 10a It is a heteroaryl group.
[0714] In some embodiments, R 10b It's hydrogen.
[0715] In some embodiments, R 10b It's a halogen.
[0716] In some embodiments, R 10b It is a C1-C6 haloalkyl group.
[0717] In some embodiments, R 10b It's cyano.
[0718] In some embodiments, R 10b It is a C1-C6 alkyl group.
[0719] In some embodiments, R 10b It is a C1-C6 alkoxy group.
[0720] In some embodiments, R 10b yes In some embodiments, R 10b It is a C3-C8 cycloalkyl group.
[0721] In some embodiments, R 10b It is a C3-C8 heterocycle.
[0722] In some embodiments, R 10b It is an aryl group.
[0723] In some embodiments, R 10b It is a heteroaryl group.
[0724] In some embodiments, R 10c It's a halogen.
[0725] In some embodiments, R 10c It is a C1-C6 haloalkyl group.
[0726] In some embodiments, R 10c It's cyano.
[0727] In some embodiments, R 10c It is a C1-C6 alkyl group.
[0728] In some embodiments, R 10c It is a C1-C6 alkoxy group.
[0729] In some embodiments, R 10c yes In some embodiments, R 10c It is a C3-C8 cycloalkyl group.
[0730] In some embodiments, R 10c It is a C3-C8 heterocycle.
[0731] In some embodiments, R 10c It is an aryl group.
[0732] In some embodiments, R 10c It is a heteroaryl group.
[0733] In some embodiments, R 10d It's hydrogen.
[0734] In some embodiments, R 10d It's a halogen.
[0735] In some embodiments, R 10d It is a C1-C6 haloalkyl group.
[0736] In some embodiments, R 10d It's cyano.
[0737] In some embodiments, R 10d It is a C1-C6 alkyl group.
[0738] In some embodiments, R 10d It is a C1-C6 alkoxy group.
[0739] In some embodiments, R 10d yes In some embodiments, R 10d It is a C3-C8 cycloalkyl group.
[0740] In some embodiments, R 10d It is a C3-C8 heterocycle.
[0741] In some embodiments, R 10d It is an aryl group.
[0742] In some embodiments, R 10d It is a heteroaryl group.
[0743] In some embodiments, R 11a It's hydrogen.
[0744] In some embodiments, R 11a It's a halogen.
[0745] In some embodiments, R 11a It is a C1-C6 haloalkyl group.
[0746] In some embodiments, R 11a It's cyano.
[0747] In some embodiments, R 11a It is a C1-C6 alkyl group.
[0748] In some embodiments, R 11a It is a C1-C6 alkoxy group.
[0749] In some embodiments, R 11a yes In some embodiments, R 11a It is a C3-C8 cycloalkyl group.
[0750] In some embodiments, R 11a It is a C3-C8 heterocycle.
[0751] In some embodiments, R 11a It is an aryl group.
[0752] In some embodiments, R 11a It is a heteroaromatic ring.
[0753] In some embodiments, R 11b It's hydrogen.
[0754] In some embodiments, R 11b It's a halogen.
[0755] In some embodiments, R 11b It is a C1-C6 haloalkyl group.
[0756] In some embodiments, R 11b It's cyano.
[0757] In some embodiments, R 11b It is a C1-C6 alkyl group.
[0758] In some embodiments, R 11b It is a C1-C6 alkoxy group.
[0759] In some embodiments, R 11b yes In some embodiments, R 11b It is a C3-C8 cycloalkyl group.
[0760] In some embodiments, R 11bIt is a C3-C8 heterocycle.
[0761] In some embodiments, R 11b It is an aryl group.
[0762] In some embodiments, R 11b It is a heteroaromatic ring.
[0763] In some embodiments, R 11c It's a halogen.
[0764] In some embodiments, R 11c It is a C1-C6 haloalkyl group.
[0765] In some embodiments, R 11c It's cyano.
[0766] In some embodiments, R 11c It is a C1-C6 alkyl group.
[0767] In some embodiments, R 11c It is a C1-C6 alkoxy group.
[0768] In some embodiments, R 11c yes In some embodiments, R 11c It is a C3-C8 cycloalkyl group.
[0769] In some embodiments, R 11c It is a C3-C8 heterocycle.
[0770] In some embodiments, R 11c It is an aryl group.
[0771] In some embodiments, R 11c It is a heteroaromatic ring.
[0772] In some embodiments, R 11d It's hydrogen.
[0773] In some embodiments, R 11d is halogen. In some embodiments, R 11d is a C1-C6 haloalkyl group. In some embodiments, R 11d It's cyano.
[0774] In some embodiments, R 11d It is a C1-C6 alkyl group.
[0775] In some embodiments, R 11d It is a C1-C6 alkoxy group.
[0776] In some embodiments, R 11d yes In some embodiments, R11d It is a C3-C8 cycloalkyl group.
[0777] In some embodiments, R 11d It is a C3-C8 heterocycle.
[0778] In some embodiments, R 11d It is an aryl group.
[0779] In some embodiments, R 11d It is a heteroaromatic ring.
[0780] In some embodiments, R 12a It's hydrogen.
[0781] In some embodiments, R 12a It's a halogen.
[0782] In some embodiments, R 12a It is a C1-C6 haloalkyl group.
[0783] In some embodiments, R 12a It's cyano.
[0784] In some embodiments, R 12a It is a C1-C6 alkyl group.
[0785] In some embodiments, R 12a It is a C1-C6 alkoxy group.
[0786] In some embodiments, R 12a yes In some embodiments, R 12a It is a C3-C8 cycloalkyl group.
[0787] In some embodiments, R 12a It is a C3-C8 heterocycle.
[0788] In some embodiments, R 12a It is an aryl group.
[0789] In some embodiments, R 12a It is a heteroaryl group.
[0790] In some embodiments, R 12b It's hydrogen.
[0791] In some embodiments, R 12b It's a halogen.
[0792] In some embodiments, R 12b It is a C1-C6 haloalkyl group.
[0793] In some embodiments, R 12b It's cyano.
[0794] In some embodiments, R 12b It is a C1-C6 alkyl group.
[0795] In some embodiments, R 12b It is a C1-C6 alkoxy group.
[0796] In some embodiments, R 12b yes In some embodiments, R 12b It is a C3-C8 cycloalkyl group.
[0797] In some embodiments, R 12b It is a C3-C8 heterocycle.
[0798] In some embodiments, R 12b It is an aryl group.
[0799] In some embodiments, R 12b It is a heteroaryl group.
[0800] In some embodiments, R 12c It's a halogen.
[0801] In some embodiments, R 12c It is a C1-C6 haloalkyl group.
[0802] In some embodiments, R 12c It's cyano.
[0803] In some embodiments, R 12c It is a C1-C6 alkyl group.
[0804] In some embodiments, R 12c It is a C1-C6 alkoxy group.
[0805] In some embodiments, R 12c yes In some embodiments, R 12c It is a C3-C8 cycloalkyl group.
[0806] In some embodiments, R 12c It is a C3-C8 heterocycle.
[0807] In some embodiments, R 12c It is an aryl group.
[0808] In some embodiments, R 12c It is a heteroaryl group.
[0809] In some embodiments, R 12d It's hydrogen.
[0810] In some embodiments, R 12d It's a halogen.
[0811] In some embodiments, R 12d It is a C1-C6 haloalkyl group.
[0812] In some embodiments, R 12d It's cyano.
[0813] In some embodiments, R 12d It is a C1-C6 alkyl group.
[0814] In some embodiments, R 12d It is a C1-C6 alkoxy group.
[0815] In some embodiments, R 12d yes In some embodiments, R 12d In some embodiments, R 12d It is a C3-C8 heterocycle.
[0816] In some embodiments, R 12d It is an aryl group.
[0817] In some embodiments, R 12d It is a heteroaryl group.
[0818] In some embodiments, R 13 It's hydrogen.
[0819] In some embodiments, R 13 It is a C1-C6 alkyl group.
[0820] In some embodiments, R 14 It's hydrogen.
[0821] In some embodiments, R 14 It is a C1-C6 alkyl group.
[0822] In some embodiments, R 15 It is a C1-C6 alkyl group.
[0823] In some embodiments, R 15 It is a C3-C6 cycloalkyl group.
[0824] In some embodiments, R 15 It is a C1-C6 haloalkyl group.
[0825] In some embodiments, R 16 It is a C1-C6 alkyl group.
[0826] In some embodiments, R 16 It is a C3-C6 cycloalkyl group.
[0827] In some embodiments, R16 It is a C1-C6 haloalkyl group.
[0828] In some embodiments, R 17 It is a C1-C6 alkyl group.
[0829] In some embodiments, R 17 It is a C3-C6 cycloalkyl group.
[0830] In some embodiments, R 17 It is a C1-C6 haloalkyl group.
[0831] In some embodiments, R 18 It is a C1-C6 alkyl group.
[0832] In some embodiments, R 18 It is a C3-C6 cycloalkyl group.
[0833] In some embodiments, R 18 It is a C1-C6 haloalkyl group.
[0834] In some embodiments, R 19 It is a C1-C6 alkyl group.
[0835] In some embodiments, R 19 It is a C3-C6 cycloalkyl group.
[0836] In some embodiments, R 19 It is a C1-C6 haloalkyl group.
[0837] In some embodiments, q is 1.
[0838] In some embodiments, q is 2.
[0839] In some embodiments, q is 3.
[0840] In some embodiments, q is 4.
[0841] In some embodiments, q is 5.
[0842] In some embodiments, q is 6.
[0843] To illustrate how the compounds of the present invention are named and referenced herein, the compound has the following formula:
[0844]
[0845] The chemical name is 2-((S)-3-((S)-sec-butyl)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[0846] To illustrate how the compounds of the present invention are named and referenced herein, the compound has the following formula:
[0847]
[0848] The chemical name is 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(N,N-dimethylsulfamoyl)propionamide.
[0849] For the purposes of the present invention, compounds represented by the racemic formula, for example:
[0850]
[0851] The same shall apply to either of the two enantiomers having the formula:
[0852]
[0853] Or:
[0854]
[0855] or mixtures thereof, or, in the case of a second chiral center, all diastereomers.
[0856] In all embodiments provided herein, the examples of suitable optional substituents are not intended to limit the scope of the claimed invention.The compounds of the present invention may contain any substituent or combination of substituents provided herein.
[0857] Craftsmanship
[0858] The present invention also relates to a method for preparing the bio-effector of the present invention.
[0859] The compounds of the present invention can be prepared by the method outlined by the present invention, from commercially available starting materials, compounds known in the literature or easily prepared intermediates, by using standard synthesis methods and steps known to those skilled in the art. Standard synthesis methods and processes for preparing organic molecules and functional group conversions and operations can be easily obtained from the relevant scientific literature or standard textbooks in this area. It should be understood that, in the case of giving typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.), other process conditions may also be used unless otherwise indicated. Optimal reaction conditions may vary with the specific reactants or solvents used, but these conditions may be determined by conventional optimization procedures by those skilled in the art. Those skilled in the art of organic synthesis will recognize that, in order to optimize the formation of the compounds of the present invention, the nature and order of the synthesis steps provided may be changed.
[0860] The processes of the present invention can be monitored by any suitable method known in the art. For example, the formation of products can be monitored by spectroscopic methods, such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic monitoring, such as high pressure liquid chromatography (HPLC), gas chromatography (GC), gel permeation chromatography (GPC), or thin layer chromatography (TLC).
[0861] The preparation of compounds may include the protection and deprotection of various chemical groups. Those skilled in the art can readily determine the need for protection and deprotection and the selection of suitable protecting groups. For example, the chemical properties of protecting groups can be found in Greene et al., Protective Groups in Organic Synthesis, 2d. Ed. (Wiley & Sons, 1991), the entire disclosure of which is incorporated herein by reference for all purposes.
[0862] Reaction or method of the present invention can be carried out in a suitable solvent, and solvent can be easily selected by those skilled in the art of organic synthesis. Suitable solvent is usually at the temperature at which the reaction is carried out, that is, at a temperature within the range of the freezing temperature of the solvent to the boiling temperature of the solvent, substantially not reacting with reactants, intermediates and / or products. A given reaction can be carried out in a solvent or a mixture of more than one solvent. According to specific reactions steps, the suitable solvent for specific reactions steps can be selected.
[0863] The compounds of these teachings can be prepared by methods known in the field of organic chemistry. The reagents used to prepare the compounds of these teachings can be commercially available, or can be prepared by standard methods described in the literature. For example, the compounds of the present invention can be prepared according to the methods described in the general synthesis schemes.
[0864] General synthetic scheme for compound preparation
[0865] The reagents used to prepare the compounds of the present invention are either commercially available or can be prepared by standard methods described in the literature. According to the present invention, the compounds of this genus can be prepared by one of the following reaction schemes.
[0866] Compounds of formula (I) can be prepared according to the methods outlined in Schemes 1-36.
[0867]
[0868] Therefore, an appropriately substituted compound of formula (1) (a known compound or a compound prepared by a known method) is reacted with a compound of formula (2) in the presence of a coupling agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., in the presence of a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (3), wherein PG is a protecting group such as tert-butyloxycarbonyl, benzylcarbonyl, fluorenylmethoxycarbonyl, etc. The compound of formula (3) is reacted with an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc. in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (4). Alternatively, the compound of formula (3) is reacted with a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc. in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (4). Alternatively, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis (triphenylphosphine) palladium (0), dichlorobis (triphenylphosphine) palladium (II), palladium on carbon, bis (acetonitrile) dichloro palladium (II), 1,1′-bis (diphenylphosphino) ferrocene] dichloro palladium (II), bis palladium-tri (1,3-dibenzylidene) acetone, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (3) is reacted with hydrogen, optionally heated, and optionally irradiated with microwaves to obtain a compound of formula (4). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (4) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated, and optionally irradiated with microwaves to obtain a compound of formula (5). Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, the compound of formula (5) is reacted with the compound of formula (6), optionally heated, optionally microwave irradiated, to obtain a compound of formula (7), wherein LG is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 1is a C1-C6 alkyl group. Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamine, sodium diisopropylamine, potassium diisopropylamine, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., the compound of formula (5) is reacted with the compound of formula (6), optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (7), wherein LG is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 1 The compound of formula (7) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc. in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (8).
[0869]
[0870] In the presence of boron trichloride, in the presence of aluminum trichloride, in the presence of solvents such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (9) (a known compound or a compound prepared by a known method) is reacted with a compound of formula (10) (a known compound or a compound prepared by a known method) and optionally heated and optionally irradiated with microwaves to obtain a compound of formula (11). In the presence of an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc., in a solvent such as toluene, benzene, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (11) is reacted with a compound of formula (12) and optionally heated and optionally irradiated with microwaves to obtain a compound of formula (13).
[0871] Option 3
[0872]
[0873] The compound of formula (14) (known compound or compound prepared by known method) is reacted with aqueous hydrogen peroxide in the presence of a solvent such as methanol, ethanol, isopropanol, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally under heating, optionally under microwave irradiation, to obtain the compound of formula (14). The compound of formula (15) is reacted with the compound of formula (16) in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally under heating, optionally under microwave irradiation, to obtain the compound of formula (17). In the presence of a palladium catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium-carbon, bis(acetonitrile)dichloropalladium(II), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bispalladium-tri(1,3-dibenzylidene)acetone, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (17) is reacted with hydrogen, optionally heated, optionally microwave irradiated, to obtain a compound of formula (18).
[0874] Option 4
[0875] In the presence of a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (19) (a known compound or a compound prepared by a known method) is reacted with N-bromosuccinimide, optionally heated, optionally microwave irradiated, to obtain a compound of formula (20).
[0876] Option 5
[0877] In the presence of a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., the compound of formula (21) is reacted with a cyanide salt such as copper cyanide, sodium cyanide, potassium cyanide, lithium cyanide, etc., optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (22).
[0878] Option 6
[0879] In the presence of a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (23) (a known compound or a compound prepared by a known method) is reacted with a compound of formula (24) (a known compound or a compound prepared by a known method), optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (25).
[0880]
[0881] The compound of formula (26) is reacted with the compound of formula (27) in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., and the compound is optionally heated and optionally irradiated with microwaves to obtain the compound of formula (28). The compound of formula (28) is reacted with the compound of formula (29) (a known compound or a compound prepared by a known method) in the presence of a base such as n-butyllithium, sec-butyllithium, tert-butyllithium, etc., in the presence of a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, etc., and optionally heated and optionally irradiated with microwaves to obtain the compound of formula (30). The compound of formula (30) is reacted with Dess-Martin periodinane in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated and optionally irradiated with microwaves to obtain a compound of formula (31). The compound of formula (31) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc. in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated and optionally irradiated with microwaves to obtain a compound of formula (32).
[0882] Option 8
[0883] In the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (33) (a known compound or a compound prepared by a known method) is reacted with phosgene, optionally heated, and optionally irradiated with microwaves to obtain a compound of formula (34). Alternatively, a compound of formula (33) (a known compound or a compound prepared by a known method) is reacted with triphosgene in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally with heating, optionally with microwave irradiation, to obtain a compound of formula (34).
[0884] Option 9
[0885] Optionally, in the presence of an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc., in a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (35) is reacted with a reducing agent such as sodium cyanoborohydride, lithium cyanoborohydride, sodium borohydride, lithium borohydride, sodium triacetoxyborohydride, lithium triacetoxyborohydride, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (36).
[0886]
[0887] A compound of formula (37) (a known compound or a compound prepared by a known method) is reacted with benzyl chloroformate, optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally with heating, optionally with microwave irradiation, to obtain a compound of formula (38). In the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (38) is reacted with Dess-Martin periodinane, optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (39). In the presence of a reducing agent such as sodium cyanoborohydride, lithium cyanoborohydride, sodium borohydride, lithium borohydride, sodium triacetoxyborohydride, lithium triacetoxyborohydride, etc., optionally in the presence of an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc., in a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (39) is reacted with a compound of formula (40) (known compound or compound prepared by a known method, wherein Z 2 is C1-C6 alkyl) with optional heating and optional microwave irradiation to obtain a compound of formula (41). In the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., in the presence of a solvent such as N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (41) is reacted with di-tert-butyl dicarbonate, optionally heated, and optionally irradiated with microwaves to obtain a compound of formula (42). The compound of formula (42) is reacted with hydrogen in the presence of a palladium catalyst such as palladium acetate (II), tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bispalladium-tri(1,3-dibenzylidene)acetone, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain the compound of formula (43). The compound of formula (43) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain the compound of formula (44).
[0888]
[0889] In the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (44) and a compound of formula (45) (a known compound or a compound prepared by a known method, wherein Z 3 Is C1-C6 alkyl, LG 1 The compound of formula (46) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc. in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated and optionally microwaved to obtain a compound of formula (47). The compound of formula (47) is reacted with an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc. in a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated and optionally microwaved to obtain a compound of formula (48).
[0890] Plan 12
[0891] In the presence of a coupling agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., in the presence of a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (49) is reacted with a compound of formula (50) (a known compound or a compound prepared by a known method), optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (51).
[0892]
[0893] In the presence of a coupling agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, optionally in the presence of hydroxybenzotriazole, optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., in the presence of a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (52) is reacted with a compound of formula (53) (a known compound or a compound prepared by a known method), optionally heated, optionally subjected to microwave irradiation, to obtain a compound of formula (54).
[0894]
[0895] In the presence of a coupling agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., in the presence of a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (55) (a known compound or a compound prepared by a known method) is reacted with a compound of formula (56) (a known compound or a compound prepared by a known method), optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (57). The compound of formula (57) is then reacted with an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc. in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (58). The compound of formula (58) is reacted in a solvent such as methanol, ethanol, isopropanol, 2-butanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (59).
[0896]
[0897] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (59) and a compound of formula (60) (a known compound or a compound prepared by a known method, wherein Z 4 Is C1-C6 alkyl, LG 2is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.,) and optionally heated and optionally irradiated with microwaves to obtain a compound of formula (61). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (59) and a compound of formula (60) (wherein LG 2 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 4 is a C1-C6 alkyl) and optionally heated and optionally irradiated with microwaves to obtain a compound of formula (61). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (61) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated and optionally irradiated with microwaves to obtain a compound of formula (62).
[0898]
[0899] In the presence of a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (63) (a known compound or a compound prepared by a known method) is reacted with a compound of formula (64), optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (65). In the presence of an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc., in a solvent such as toluene, benzene, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (67). Alternatively, a compound of formula (65) is reacted with a compound of formula (66) in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, cesium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally irradiated with microwaves, to obtain a compound of formula (67). In the presence of a palladium catalyst such as palladium (II) acetate, tetrakis (triphenylphosphine) palladium (0), dichlorobis (triphenylphosphine) palladium (II), palladium on carbon, bis (acetonitrile) dichloropalladium (II), 1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II), bispalladium-tri (1,3-dibenzylidene) acetone, etc., in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, cesium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (68). In the presence of a palladium catalyst such as palladium acetate (II), tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium-carbon, bis(acetonitrile)dichloropalladium(II), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bispalladium-tri(1,3-dibenzylidene)acetone, and in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (68) is reacted with a compound of formula (69), optionally heated, optionally microwave irradiated, to obtain a compound of formula (70).
[0900]
[0901] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (71) and a compound of formula (72) (a known compound or a compound prepared by a known method, wherein Z 5Is C1-C6 alkyl, LG 3 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (73). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (71) and a compound of formula (72) (wherein LG 3 is a leaving group such as chlorine, bromine, iodine, tosylate, mesylate, etc., Z 5 is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (73). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (73) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated and optionally microwave irradiated to obtain a compound of formula (74).
[0902]
[0903] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (75) and a compound of formula (76) (a known compound or a compound prepared by a known method, wherein Z 6 Is C1-C6 alkyl, LG 4 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (77). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (75) is reacted with a compound of formula (76) (known compound or compound prepared by a known method, wherein LG 4 is a leaving group such as chlorine, bromine, iodine, toluenesulfonate, mesylate, etc., Z 6is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (77). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (77) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated and optionally microwave irradiated to obtain a compound of formula (78).
[0904]
[0905] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (78) and a compound of formula (79) (a known compound or a compound prepared by a known method, wherein LG 5 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (80). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (78) is reacted with a compound of formula (79) (a known compound or a compound prepared by a known method, wherein LG 5 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally with heating, optionally with microwave irradiation, to give a compound of formula (80).
[0906]
[0907] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (81) and a compound of formula (82) (a known compound or a compound prepared by a known method, wherein LG 6is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (83). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (81) is reacted with a compound of formula (82) (known compound or compound prepared by a known method, wherein LG 6 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally with heating, optionally with microwave irradiation, to give a compound of formula (83).
[0908]
[0909] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (84) and a compound of formula (85) (a known compound or a compound prepared by a known method, wherein LG 7 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (86). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (84) and a compound of formula (85) (wherein LG 7 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally with heating, optionally with microwave irradiation, to give a compound of formula (86).
[0910]
[0911] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (87) and a compound of formula (88) (a known compound or a compound prepared by a known method, wherein LG 8is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (89). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (87) and a compound of formula (88) (wherein LG 8 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally with heating, optionally with microwave irradiation, to give a compound of formula (89).
[0912]
[0913] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (90) and a compound of formula (91) (a known compound or a compound prepared by a known method, wherein Z 7 Is C1-C6 alkyl, LG 9 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (92). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (90) and a compound of formula (91) (wherein LG 9 is a leaving group such as chlorine, bromine, iodine, tosylate, mesylate, etc., and Z 7 is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (92). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (92) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., and optionally heated and optionally microwave irradiated to obtain a compound of formula (93).
[0914]
[0915] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (94) and a compound of formula (95) (a known compound or a compound prepared by a known method, wherein Z 8 Is C1-C6 alkyl, LG 10 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (96). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (94) and a compound of formula (95) (wherein LG 10 is a leaving group such as chlorine, bromine, iodine, tosylate, mesylate, etc., and Z 8 is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (96). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (96) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated and optionally microwave irradiated to obtain a compound of formula (97).
[0916]
[0917] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (98) and a compound of formula (99) (a known compound or a compound prepared by a known method, wherein Z 9 Is C1-C6 alkyl, LG 11 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (100). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (98) and a compound of formula (99) (wherein LG 11 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 9is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (100). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (100) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., and optionally heated and optionally microwave irradiated to obtain a compound of formula (101).
[0918]
[0919] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (102) and a compound of formula (103) (a known compound or a compound prepared by a known method, wherein Z 10 Is C1-C6 alkyl, LG 12 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (104). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (102) and a compound of formula (103) (wherein LG 12 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 10 is a C1-C6 alkyl group,) and optionally heated and optionally microwave irradiated to obtain a compound of formula (104). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (104) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., and optionally heated and optionally microwave irradiated to obtain a compound of formula (105).
[0920]
[0921] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (106) and a compound of formula (107) (a known compound or a compound prepared by a known method, wherein Z 11 Is C1-C6 alkyl, LG 13is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (108). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (106) and a compound of formula (107) (its LG 13 Is a leaving group such as chlorine, bromine, iodine, tosylate, mesylate, etc., as well as the Z 11 is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (108). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (108) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc. and optionally heated and optionally microwave irradiated to obtain a compound of formula (109).
[0922]
[0923] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (110) and a compound of formula (111) (a known compound or a compound prepared by a known method, wherein Z 12 Is C1-C6 alkyl, LG 14 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (112). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (110) and a compound of formula (111) (wherein LG 14 is a leaving group, such as chlorine, bromine, iodine, tosylate, mesylate, etc., Z 12is a C1-C6 alkyl) and optionally heated and optionally irradiated with microwaves to obtain a compound of formula (112). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (112) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated and optionally irradiated with microwaves to obtain a compound of formula (113).
[0924]
[0925] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (114) and a compound of formula (115) (a known compound or a compound prepared by a known method, wherein Z 13 Is C1-C6 alkyl, LG 15 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (116). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (114) and a compound of formula (115) (wherein LG 15 is a leaving group such as chlorine, bromine, iodine, tosylate, mesylate, etc., Z 13 The reaction is optionally heated and optionally microwave irradiated to obtain a compound of formula (116). The compound of formula (116) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc. in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated and optionally microwave irradiated to obtain a compound of formula (117).
[0926]
[0927] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (118) and a compound of formula (119) (a known compound or a compound prepared by a known method, wherein LG 15is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (120). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (118) and a compound of formula (119) (wherein LG 15 The compound of formula (120) is reacted with sodium azide in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (121).
[0928]
[0929] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (122) and a compound of formula (123) (a known compound or a compound prepared by a known method, wherein LG 16 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (124). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (122) and a compound of formula (123) (wherein LG 16 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally with heating, optionally with microwave irradiation, to give a compound of formula (124).
[0930]
[0931] In the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (125) and a compound of formula (126) (a known compound or a compound prepared by a known method, wherein LG 17 The compound of formula (127) is reacted with tetrabutylammonium fluoride in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (128).
[0932]
[0933] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (129) and a compound of formula (130) (a known compound or a compound prepared by a known method, wherein Z 14 Is C1-C6 alkyl, LG 18 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (131). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (129) and a compound of formula (130) (wherein LG 18 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 14 is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (131). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (131) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., and optionally heated and optionally microwave irradiated to obtain a compound of formula (132).
[0934]
[0935] In the presence of an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc., in a solvent such as toluene, benzene, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (133) is reacted with the compound of formula (134), optionally heated, optionally irradiated with microwaves, to obtain the compound of formula (135). Alternatively, in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, cesium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (133) is reacted with the compound of formula (134), optionally heated, optionally irradiated with microwaves, to obtain the compound of formula (135). In the presence of a palladium catalyst such as palladium (II) acetate, tetrakis (triphenylphosphine) palladium (0), dichlorobis (triphenylphosphine) palladium (II), palladium carbon, bis (acetonitrile) dichloropalladium (II), 1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II), bispalladium-tri (1,3-dibenzylidene) acetone, etc., in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, cesium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (135) reacts with tri-tert-butylphosphine tetrafluoroborate, optionally heated, optionally microwave irradiated, to obtain a compound of formula (136). In the presence of a palladium catalyst such as palladium acetate (II), tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium-carbon, bis(acetonitrile)dichloropalladium(II), 11′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bispalladium-tri(1,3-dibenzylidene)acetone, and in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (136) is reacted with a compound of formula (137) (a known compound or a compound prepared by a known method), optionally heated, optionally microwave irradiated, to obtain a compound of formula (138).
[0936]
[0937] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., optionally in the presence of benzyltributylammonium bromide, a compound of formula (139) and a compound of formula (140) (a known compound or a compound prepared by a known method, wherein Z 15 Is C1-C6 alkyl, LG 19is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (141). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (139) and a compound of formula (140) (wherein LG 19 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc., and Z 15 is a C1-C6 alkyl) and optionally heated and optionally microwave irradiated to obtain a compound of formula (141). In the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (141) is reacted with a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., optionally heated and optionally microwave irradiated to obtain a compound of formula (142).
[0938] Plan 32
[0939]
[0940] In the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., the compound of formula (143) reacts with a cyanide salt such as sodium cyanide, potassium cyanide, lithium cyanide, copper cyanide, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (144).
[0941]
[0942] Optionally in the presence of an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc., optionally in the presence of water, optionally in the presence of a solvent such as toluene, benzene, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 14-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., the compound of formula (145) is reacted with a cyanate such as potassium cyanate, sodium cyanate, lithium cyanate, etc., optionally heated, optionally subjected to microwave irradiation, to obtain a compound of formula (146).
[0943]
[0944] In the presence of a palladium catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium-carbon, bis(acetonitrile)dichloropalladium(II), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bispalladium-tri(1,3-dibenzylidene)acetone, etc., in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, etc., in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (147) (wherein, ZG 16 is C1-C6 alkyl) with a compound of formula (148) (a known compound or a compound prepared by a known method), optionally with heating, optionally with microwave irradiation, to give a compound of formula (149).
[0945]
[0946] In the presence of a palladium catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium-carbon, bis(acetonitrile)dichloropalladium(II), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dipalladium-tris(1,3-dibenzylidene)acetone, etc., in the presence of (2,2′-bis(diphenylphosphino)-1,1′-binaphthyl), in the presence of a base such as potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, etc., in the presence of a solvent such as toluene, benzene, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., a compound of formula (150) (wherein ZG 17 is C1-C6 alkyl) with a compound of formula (151) (wherein HTC is a C3-C8 heterocycle), optionally with heating, optionally with microwave irradiation, to provide a compound of formula (152).
[0947]
[0948] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (153) and a compound of formula (154) (a known compound or a compound prepared by a known method, wherein LG 20is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to obtain a compound of formula (155). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (153) is reacted with a compound of formula (154) (a known compound or a compound prepared by a known method, wherein LG 20 The compound of formula (155) is reacted with an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc. in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (156).
[0949]
[0950] Optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine, etc., and optionally in the presence of benzyltributylammonium bromide, a compound of formula (157) and a compound of formula (158) (known compound or compound prepared by a known method, LG 21 is a leaving group such as chloro, bromo, iodo, tosylate, mesylate, etc.), optionally heated, optionally microwave irradiated, to give a compound of formula (159). Alternatively, in the presence of a base such as sodium hydride, potassium hydride, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, etc., in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, etc., a compound of formula (157) is reacted with a compound of formula (158) (a known compound or a compound prepared by a known method, wherein LG 21 The compound of formula (159) is reacted with an acid such as trifluoroacetic acid, acetic acid, formic acid, hydrochloric acid, sulfuric acid, etc. in the presence of a solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally heated, optionally microwave irradiated, to obtain a compound of formula (160).
[0951] The examples provided below provide representative methods for preparing exemplary compounds of the present invention. One skilled in the art will know how to substitute appropriate reagents, starting materials, and purification methods known to those skilled in the art to prepare the compounds of the present invention.
[0952] The following LC / MS procedure was used to analyze the examples described herein. LC / MS data were measured using a Waters Alliance 2695 HPLC / MS (Waters Symmetry C18, 4.6×75 mm, 3.5 μm) and a 2996 diode array detector from 210-400 nm; the solvent system was 5% to 95% acetonitrile in water (containing 0.1% trifluoroacetic acid) using a linear gradient over 9 minutes, with retention times in minutes. Mass spectrometry analysis was performed on a Waters ZQ using electrospray in positive mode. Alternatively, LC / MS data were measured using an Agilent 6120 mass spectrometer (1200 Agilent LC-MS spectrometer, positive) with an electrospray ionization source, with a mobile phase flow rate of 1.0 mL / min, a gradient from 20% aqueous medium (0.1% formic acid) to 95% CH3CN (0.1% formic acid) over 3 minutes, and a total acquisition time of 9.0 minutes.
[0953] Preparative reverse phase HPLC was performed on a Phenomenex Luna column (19×100 mm, C18, 5 μm) with a 10-minute mobile phase gradient from 10% acetonitrile / water to 90% acetonitrile / water, 0.1% trifluoroacetic acid as buffer, and detection wavelengths of 214 and 254 nm. Trilution LC software was used, and injection and fraction collection were performed with a Gilson 215 liquid handling device.
[0954] The results were obtained on a Varian 300 MHz NMR spectrometer using tetramethylsilane (TMS) as an internal standard (=0.00). 1 H-NMR, peaks are reported downfield from TMS. Alternatively, tetramethylsilane (TMS) was used as an internal standard (=0.00) and measurements were performed on a Varian 400 MHz NMR. 1 H-NMR, peaks are reported downfield from TMS.
[0955] The Examples provide methods for preparing representative compounds of Formula (I) to (XXIX). One skilled in the art will know how to substitute appropriate reagents, starting materials, and purification methods known to those skilled in the art to prepare other compounds of the invention.
[0956] Example
[0957] Examples 1-101 provide methods for preparing representative compounds of formula (I) to (XXIX). One skilled in the art will know how to substitute appropriate reagents, starting materials, and purification methods known to those skilled in the art to prepare other compounds of the invention.
[0958] Example 1: Synthesis of 2-((S)-3-((S)-sec-butyl)-8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[0959]
[0960] Step 1: Dicyclohexylcarbodiimide 1M in dichloromethane (1.5 mL, 1.5 mmol) was added to a solution of LN-Boc-isoleucine (350 mg, 1.52 mmol) in 0.77 mL of dichloromethane at 0° C. The resulting mixture was stirred at 23° C. for 1 hour and then cooled back to 0° C. A solution of (2-amino-4-chlorophenyl)(phenyl)methanone (351 mg, 1.52 mmol) in 1.4 mL of dichloromethane was then added dropwise and the resulting mixture was stirred at 23° C. for 3 days. The insoluble material was filtered off and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / hexane 5 / 95-100 / 0, then ethyl acetate / dichloromethane 20 / 80-50 / 50) to give 596 mg of impure tert-butyl ((2S,3S)-1-((2-benzoyl-5-chlorophenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next step without further purification. MS (ESI) m / z 467.22 (M+Na) + .
[0961]
[0962] Step 2: 4M hydrochloric acid in 1,4-dioxane (3.35 mL, 13.4 mmol) was added to a solution of impure tert-butyl ((2S,3S)-1-((2-benzoyl-5-chlorophenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (296 mg, 1.34 mmol) in 3.6 mL of 1,4-dioxane at 23°C. The resulting mixture was stirred at 23°C for 16 hours and then evaporated. The residue was dissolved in dichloromethane and the solution was washed first with saturated aqueous sodium bicarbonate solution and then with water, then dried over magnesium sulfate, filtered, and evaporated to give 319 mg of crude (2S,3S)-2-amino-N-(2-benzoyl-5-chlorophenyl)-3-methylpentanamide, which was used in the next step without purification. MS (ESI) m / z 345.2 (M+H) + .
[0963]
[0964] Step 3: To a solution of crude (2S,3S)-2-amino-N-(2-benzoyl-5-chlorophenyl)-3-methylpentanamide (319 mg, theoretical 0.924 mmol) in 2.64 mL of methanol and 0.26 mL of water at 0°C were added a few drops of 1 M aqueous sodium hydroxide solution to adjust the pH to 8-9. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was taken up in water and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 40 / 60) to give 125 mg of (S)-3-((S)-sec-butyl)-8-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. MS (ESI) m / z 327.22 (M+H) + .
[0965]
[0966] Step 4: A 60% dispersion of sodium hydride in oil (31 mg, 0.8 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-8-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (125 mg, 0.4 mmol) in 1.7 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2.5 hours, then ethyl bromoacetate (0.063 mL, 0.6 mmol) was added. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, quenched by the addition of water, and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 50 / 50) to give 69 mg of ethyl 2-((S)-3-((S)-sec-butyl)-8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (44% yield). MS (ESI) m / z 413.36 (M+H) + .
[0967]
[0968] Step 5: Lithium hydroxide monohydrate (38 mg, 0.9 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (69 mg, 0.2 mmol) in 4 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then concentrated to half its volume. The solution was cooled to 0°C and the pH was adjusted to 5-6 by adding 10% aqueous citric acid solution and then extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was crystallized and recrystallized three times from dichloromethane / hexane to give 58 mg of 2-((S)-3-((S)-sec-butyl)-8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1 H NMR (400MHz, DMSO-d6) δ12.83(s,1H),7.63-7.58(m,1H),7.52-7.47(m,5H),7.27-7.21(m,2H),4.62(d,J=17.6Hz,1H),4. 48(d,J=17.6Hz,1H),3.14(d,J=10.0Hz,1H),2.37-2.32(m,1H),1.89-1.84(m,1H),1.14-1.06(m,1H),0.87-0.82(m,6H). MS(ESI): m / z 385.30(M+H) + .
[0969] Example 2: Synthesis of 2-((S)-3-((S)-sec-butyl)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[0970]
[0971] Step 1: At 0 ° C, 2-chloroaniline (908 μ L, 8.65 mmol) in 9.6 mL of dichloroethane was added dropwise to a 1 M solution of boron trichloride in dichloromethane (5.6 mL, 5.6 mmol). The resulting mixture was stirred at 0 ° C for 30 minutes, then benzonitrile (445 μ L, 4.32 mmol) was added, followed by aluminum chloride (748 mg, 5.61 mmol). The resulting mixture was stirred at 23 ° C for 30 minutes, then at 90 ° C for 18 hours. The reaction mixture was then cooled to 0 ° C and quenched by adding 10 mL of 2 M aqueous hydrochloric acid solution. The resulting mixture was stirred at 90 ° C for 30 minutes, cooled back to 23 ° C, and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 73 / 27) to give 534 mg of (2-amino-3-chlorophenyl)(phenyl)methanone MS (ESI) m / z 232.13 (M+H) + .
[0972]
[0973] Step 2: A mixture of (2-amino-3-chlorophenyl)(phenyl)methanone (367 mg, 1.58 mmol), (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione (598 mg, 3.8 mmol) and trifluoroacetic acid (364 μL, 4.75 mmol) in 7.9 mL of toluene was stirred at 60° C. for 48 hours, followed by the addition of triethylamine (359 μL, 2.56 mmol). The resulting mixture was then stirred at 80° C. for 1 hour, then cooled to 23° C. and evaporated. The residue was taken up in dichloromethane and the insoluble material was filtered off. The filtrate was evaporated and the residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 60 / 40) to give 120 mg of (S)-3-((S)-sec-butyl)-9-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (23% yield). MS (ESI) m / z 327.21 (M+H) + .
[0974]
[0975] Step 3: A 60% dispersion of sodium hydride in oil (58 mg, 1.46 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-9-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (235 mg, 0.719 mmol) in 3.3 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 30 minutes, then ethyl bromoacetate (120 μL, 1.08 mmol) was added. The reaction mixture was stirred at 23°C for 2 hours, then cooled back to 0°C, quenched by the addition of ice water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 50 / 50) to give 247 mg of ethyl 2-((S)-3-((S)-sec-butyl)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate. MS (ESI) m / z 413.08 (M+H) + .
[0976]
[0977] Step 4: Lithium hydroxide monohydrate (138 mg, 3.29 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (247 mg, 0.598 mmol) in 14 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, acidified to pH 5-6 by the addition of 10% aqueous citric acid, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was crystallized from dichloromethane / hexane to give 210 mg of 2-((S)-3-((S)-sec-butyl)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, DMSO-d6) δ7.74(dd,J=8.2,1.4Hz,1H),7.56-7.54(m,2H),7.46-7.30(m,4H),7.14(dd,J=8.2,1.4Hz,1H),4.67(d,J=17. 6Hz,1H),4.14(d,J=17.6Hz,1H),3.12(d,J=10.0Hz,1H),2.35-2.28(m,1H),1.86-1.80(m,1H),1.11-0.99(m,1H),0.85-0.80(m,6H). MS(ESI): m / z 385.15(M+H) + .
[0978] Example 4: 2-((S)-3-((S)-sec-butyl)-7-(dimethylamino)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[0979]
[0980] Step 1: 30% aqueous hydrogen peroxide (14 mL, 125 mmol) was added dropwise to a refluxing solution of (2-amino-5-chlorophenyl)(phenyl)methanone (5.79 g, 25 mmol) in 25 mL of trifluoroacetic acid. The resulting mixture was stirred at reflux for 2 hours, then cooled to 23°C and poured into ice-water. The mixture was extracted with ethyl acetate, and the combined organic layers were washed sequentially with saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered, and evaporated to yield 5.53 g of (5-chloro-2-nitrophenyl)(phenyl)methanone. 1 H NMR (400MHz, DMSO-d6) δ8.27(d,J=8.8Hz,1H),7.86(dd,J=18.5,2.3Hz,2H),7.73–7.63(m,3H),7.53–7.48(m,2H).
[0981]
[0982] Step 2: A mixture of (5-chloro-2-nitrophenyl)(phenyl)methanone (460 mg, 1.76 mmol), potassium carbonate (972 mg, 7.03 mmol) and dimethylamine hydrochloride (359 mg, 4.4 mmol) in 3 mL of N,N-dimethylformamide was stirred at reflux for 3 hours, then cooled to 23°C and poured onto ice. The resulting precipitate was filtered, rinsed with water and dried. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 55 / 45) to give 286 mg of (5-(dimethylamino)-2-nitrophenyl)(phenyl)methanone.1 H NMR(400MHz,DMSO-d6)δ8.08(d,J=9.5Hz,1H),7.66–7.62(m,2H),7.61–7.56(m,1H) ,7.48–7.42(m,2H),6.85(dd,J=9.5,2.8Hz,1H),6.61(d,J=2.8Hz,1H),3.05(s,6H). MS(ESI)m / z 271.17(M+H) + .
[0983]
[0984] Step 3: A mixture of (5-(dimethylamino)-2-nitrophenyl)(phenyl)methanone (286 mg, 1.06 mmol) and 10% palladium on carbon in 5 mL of dichloromethane was stirred at 23° C. under 1 atm of hydrogen for 18 hours and then filtered through celite. The celite plug was rinsed with dichloromethane and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 55 / 45) to give (2-amino-5-(dimethylamino)phenyl)(phenyl)methanone. 1 H NMR (400MHz, DMSO-d6) δ7.55–7.49(m,3H),7.49–7.41(m,2H),7.00(dd,J=9.0,3.0Hz,1H),6.75(d,J=9.0Hz,1H),6.58(d,J=2.9Hz,1H),6.48(br s,2H),2.56(s,6H); MS(ESI)m / z 241.19(M+H) + .
[0985]
[0986] Step 4: A mixture of (2-amino-5-(dimethylamino)phenyl)(phenyl)methanone (124 mg, 0.516 mmol), (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione (97 mg, 0.619 mmol) and trifluoroacetic acid (115 μL, 1.55 mmol) in 2.6 mL of toluene was stirred at 70° C. for 19 hours, then triethylamine (216 μL, 1.55 mmol) was added. The resulting mixture was then stirred at 80° C. for 30 minutes, then cooled to 23° C., diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate solution, brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 0 / 100) to give 123 mg of (S)-3-((S)-sec-butyl)-7-(dimethylamino)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1 H NMR (400MHz, DMSO-d6) δ10.18(s,1H),7.53–7.34(m,5H),7.05(d,J=3.8Hz,2H),6.44(d,J=2.4Hz,1H),3.08(d,J=9.8Hz,1H),2 .76(s,5H),2.33–2.19(m,1H),1.91–1.80(m,1H),1.23–1.15(m,1H),0.89(d,J=6.5Hz,3H),0.84(t,J=7.4Hz,3H); MS(ESI)m / z 336.32(M+H) + .
[0987]
[0988] Step 5: A 60% dispersion of sodium hydride in oil (29 mg, 0.734 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-(dimethylamino)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (123 mg, 0.367 mmol) in 2 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2 hours, then ethyl bromoacetate (61 μL, 0.551 mmol) was added. The resulting mixture was stirred at 23°C for 16 hours, then quenched by addition of saturated aqueous ammonium chloride, diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 55 / 45) to give 108 mg of still impure ethyl 2-((S)-3-((S)-sec-butyl)-7-(dimethylamino)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate, which was purified a second time by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 50 / 40) to give 86 mg of pure ethyl 2-((S)-3-((S)-sec-butyl)-7-(dimethylamino)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate. 1 H NMR (400MHz, DMSO-d6) δ7.58–7.53(m,2H),7.45–7.33(m,3H),7.29(dd,J=9.1,5.0Hz,1H),6.96( dd,J=9.1,3.0Hz,1H),6.35(d,J=3.0Hz,1H),4.57(d,J=17.4Hz,1H),4.43(d,J=17.4Hz,1H),4.0 1–3.85(m,2H),3.21–3.15(m,1H),2.77(s,6H),2.30(ddt,J=13.1,6.5,3.2Hz,1H),1.84(ddd,J= 13.2,7.7,3.1Hz,1H),1.08–1.03(m,1H),0.99(t,J=7.1Hz,3H),0.85–0.80(m,6H).;MS(ESI)m / z 422.19(M+H) + .
[0989]
[0990] Step 6: Lithium hydroxide monohydrate (43 mg, 1.02 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-(dimethylamino)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (86 mg, 0.204 mmol) in 4 mL of a 1 / 3 mixture of degassed tetrahydrofuran and water at 23°C. The resulting mixture was stirred at 23°C for 20 hours, then neutralized by adding Dowex 50WX4 and filtered. The resin was rinsed with ethyl acetate, and the filtrate was dried over magnesium sulfate, filtered, and evaporated. The residue was crystallized from ethyl acetate / hexane to give 21 mg of 2-((S)-3-((S)-sec-butyl)-7-(dimethylamino)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[0991] Example 5: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[0992]
[0993] Step 1: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (1.63 mL, 1.63 mmol) was added to a solution of LN-Boc-isoleucine (377 mg, 1.63 mmol) in 0.83 mL of dichloromethane at 0° C. The resulting mixture was stirred at 23° C. for 2.5 hours and then cooled to 0° C. A solution of (2-amino-5-fluorophenyl)(phenyl)methanone (350 mg, 1.63 mmol) in 1.5 mL of dichloromethane was then added dropwise and the resulting mixture was stirred at 23° C. for 72 hours. The insoluble material was filtered off and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / hexane 12 / 88, then dichloromethane / ethyl acetate 90 / 10) to give 538 mg of impure tert-butyl ((2S,3S)-1-((2-benzoyl-4-fluorophenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next step without further purification. MS (ESI) m / z 451.17 (M+Na) + .
[0994]
[0995] Step 2: A 4M solution of hydrochloric acid in 1,4-dioxane (3.14 mL, 12.56 mmol) was added to a solution of impure tert-butyl ((2S,3S)-1-((2-benzoyl-4-fluorophenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (538 mg, theoretical 1.256 mmol) in 3.4 mL of 1,4-dioxane at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was dissolved in dichloromethane and the solution was washed with saturated aqueous sodium bicarbonate solution and then with water, then dried over magnesium sulfate, filtered, and evaporated to give 363 mg of crude (2S,3S)-2-amino-N-(2-benzoyl-5-chlorophenyl)-3-methylpentanamide, which was used in the next step without purification. MS (ESI) m / z 319.06 (M+H) + .
[0996]
[0997] Step 3: To a solution of (2S,3S)-2-amino-N-(2-benzoyl-5-chlorophenyl)-3-methylpentanamide (363 mg, 1.105 mmol) in 3.2 mL of methanol and 0.32 mL of water at 0°C were added a few drops of 1 M aqueous sodium hydroxide solution to adjust the pH to 8-9. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was taken up in water and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 90 / 10 to 40 / 60) to give 72 mg of (S)-3-((S)-sec-butyl)-7-fluoro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (10% yield over three steps). MS (ESI) m / z 311.21 (M+H) + .
[0998]
[0999] Step 4: A 60% dispersion of sodium hydride in oil (18 mg, 0.46 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-fluoro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (72 mg, 0.23 mmol) in 1.1 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2 hours, then ethyl bromoacetate (40 μL, 0.345 mmol) was added. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, quenched by the addition of water, and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 60 / 40) to give 68 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (76% yield). MS (ESI) m / z 397.27 (M+H) + .
[1000]
[1001] Step 5: Lithium hydroxide monohydrate (39 mg, 0.94 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (68 mg, 0.17 mmol) in 4 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then concentrated to half its volume. The solution was cooled to 0°C and the pH was adjusted to 5-6 by adding 10% aqueous citric acid solution, then extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / methanol 100 / 0 to 80 / 20) and then by preparative thin layer chromatography (dichloromethane / methanol 95 / 5 + 1 drop of acetic acid) to give 37 mg of 2-((S)-3-((S)-sec-butyl)-7-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, CDCl3) δ7.60-7.58(m,2H),7.50-7.42(m,1H),7.40-7.36(m,2H),7.36-7.25(m,1H),7.02(dd,J=12,2.4Hz, 1H), 4.61-4.50 (m, 2H), 3.26 (d, J = 10Hz, 1H), 2.63-2.56 (m, 1H), 2.03-1.96 (m, 1H), 1.26-1.13 (m, 2H), 0.99-0.92 (m, 6H). MS(ESI): m / z 369.29(M+H) + .
[1002] Example 6: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1003]
[1004] Step 1: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (1.5 mL, 1.5 mmol) was added to a solution of LN-Boc-isoleucine (350 mg, 1.51 mmol) in 0.8 mL of dichloromethane at 0°C. The resulting mixture was stirred at 23°C for 20 minutes and then cooled back to 0°C. A solution of (2-amino-5-methylphenyl)(phenyl)methanone (350 mg, 1.51 mmol) in 1.4 mL of dichloromethane was then added dropwise, and the resulting mixture was stirred at 23°C for 24 hours. The insoluble material was filtered off and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 80 / 20) to give 331 mg of still impure tert-butyl ((2S,3S)-1-((2-benzoyl-4-methylphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next step without further purification. MS (ESI) m / z 447.15 (M+Na) + .
[1005]
[1006] Step 2: 4M hydrochloric acid in 1,4-dioxane (2 mL, 8 mmol) was added to a solution of impure tert-butyl ((2S,3S)-1-((2-benzoyl-4-methylphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (330 mg, theoretical 0.78 mmol) in 2.1 mL 1,4-dioxane at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was dissolved in dichloromethane and the solution was washed first with saturated aqueous sodium bicarbonate solution and then with water, then dried over sodium sulfate, filtered and evaporated to give 201 mg of crude (2S,3S)-2-amino-N-(2-benzoyl-4-methylphenyl)-3-methylpentanamide, which was used in the next step without purification. MS (ESI) m / z 325.16 (M+H) + .
[1007]
[1008] Step 3: To a solution of (2S,3S)2-amino-N-(2-benzoyl-4-methylphenyl)-3-methylpentanamide (200 mg, theoretical 0.62 mmol) in 2 mL of methanol and 0.2 mL of water at 0°C were added a few drops of 1 M aqueous sodium hydroxide solution to adjust the pH to 8-9. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was taken up in water and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 117 mg of (S)-3-((S)-sec-butyl)-7-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. MS (ESI) m / z 307.3 (M+H) + .
[1009]
[1010] Step 4: A 60% dispersion of sodium hydride in oil (28 mg, 0.66 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (102 mg, 0.33 mmol) in 1.5 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2.5 hours before the addition of ethyl bromoacetate (0.06 mL, 0.5 mmol). The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, quenched by the addition of water, and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 94 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (73% yield). MS (ESI) m / z 393.29 (M+H) + .
[1011]
[1012] Step 5: Lithium hydroxide monohydrate (55 mg, 1.32 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (94 mg, 0.24 mmol) in 6 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then concentrated to half its volume. The solution was cooled to 0°C and the pH was adjusted to 5-6 by adding 10% aqueous citric acid solution, then extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was crystallized and recrystallized twice from dichloromethane / hexane to give 61 mg of 2-((S)-3-((S)-sec-butyl)-7-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, DMSO-d6) δ12.78(s,1H),7.51-7.38(m,7H),7.00(s,1H),4.59(d,J=17.2Hz,1H),4.45(d,J=17.6Hz,1H), 3.06(d,J=10.0Hz,1H),2.37-2.30(m,1H),2.25(s,3H),2.05-1.83(m,1H),1.14-1.05(m,1H),0.85(t,J=13.6Hz,6H). MS(ESI): m / z 365.32(M+H)+.
[1013] Example 7: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1014]
[1015] Step 1: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (1 mL, 1 mmol) was added to a solution of LN-Boc-isoleucine (231 mg, 1 mmol) in 0.5 mL of dichloromethane at 23°C. The resulting mixture was stirred at 23°C for 2 hours, then a solution of (2-amino-5-methoxyphenyl)(phenyl)methanone (229 mg, 1 mmol) in 2 mL of dichloromethane was added. The resulting mixture was stirred at 23°C for 18 hours, then filtered. The solid was rinsed with dichloromethane, and the filtrate was filtered again through a short plug of silica. After rinsing the silica plug with ethyl acetate, the filtrate was evaporated to give crude tert-butyl ((2S,3S)-1-((2-benzoyl-4-methoxyphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next step without purification.
[1016]
[1017] Step 2: 4M hydrochloric acid in 1,4-dioxane (2.5 mL, 10 mmol) was added to a solution of crude tert-butyl ((2S,3S)-1-((2-benzoyl-4-methoxyphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (theoretical 1 mmol) in 2 mL of 1,4-dioxane at 23°C. The resulting mixture was stirred at 23°C for 4 hours and then evaporated. The residue was dissolved in dichloromethane and the solution was washed with saturated aqueous sodium bicarbonate solution, then dried over magnesium sulfate and evaporated to give (2S,3S)-2-amino-N-(2-benzoyl-4-methoxyphenyl)-3-methylpentanamide, which was used crude in the next reaction without purification.
[1018]
[1019] Step 3: To a solution of crude 2-((S)-3-((S)-sec-butyl)-7-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (theoretical 1 mmol) in 5 mL of methanol and 0.5 mL of water at 0°C, a few drops of 1 M aqueous sodium hydroxide solution were added to adjust the pH to 8-9. The resulting mixture was slowly heated to 23°C, stirred for 48 hours, and then evaporated. The residue was taken up in water and extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 52 / 48) to give 230 mg of (S)-3-((S)-sec-butyl)-7-methoxy-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (73% yield over three steps). 1H NMR (400MHz, DMSO-d6) δ10.31(s,1H),7.52–7.36(m,5H),7.22–7.12(m,2H),6.69(d,J=2.5Hz,1H),3.65(s,3H),3.05( d,J=9.6Hz,1H),2.30(s,1H),1.88(d,J=9.2Hz,1H),1.24–1.16(m,1H),0.91(d,J=6.5Hz,3H),0.87(t,J=7.4Hz,3H). MS(ESI)m / z323.31(M+H) + .
[1020]
[1021] Step 4: A 60% dispersion of sodium hydride in oil (57 mg, 1.43 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-methoxy-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (230 mg, 0.713 mmol) in 3.5 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 3 hours, then ethyl bromoacetate (0.12 mL, 1.08 mmol) was added. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, quenched by the addition of water, and extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 55 / 45) to give 236 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate. 1 H NMR (400MHz, DMSO-d6) δ7.58–7.53(m,2H),7.50–7.39(m,4H),7.20(dd,J=9.1,3.0Hz,1H),6. 67(d,J=2.9Hz,1H),4.63(d,J=17.5Hz,1H),4.51(d,J=17.5Hz,1H),3.99–3.92(m,2H),3.68( s,3H),3.18(d,J=10.1Hz,1H),2.39–2.28(m,1H),1.87(ddd,J=13.2,7.5,3.1Hz,1H),1.18–1 .07(m,1H),1.02(t,J=7.1Hz,3H),0.86(d,J=7.0Hz,3H),0.85(t,J=7.4Hz,3H).;MS(ESI)m / z 409.30(M+H) + .
[1022]
[1023] Step 5: Lithium hydroxide monohydrate (121 mg, 2.89 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (236 mg, 0.578 mmol) in 12 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then concentrated to half its volume. The solution was cooled to 0°C and the pH was adjusted to 5-6 by adding 10% aqueous citric acid solution, then extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was taken up in ethyl acetate, and the insoluble matter was filtered. The filtrate was evaporated and the residue was crystallized from ethyl acetate / hexane to give 211 mg of 2-((S)-3-((S)-sec-butyl)-7-methoxy-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1024] Example 8: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-cyano-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1025]
[1026] Step 1: N-Bromosuccinimide (541 mg, 3.04 mmol) dissolved in 25 mL of dichloromethane was added to a solution of (2-aminophenyl)(phenyl)methanone (600 mg, 3.04 mmol) in 10 mL of dichloromethane at -10°C. The resulting mixture was stirred at -10°C for 1 hour, then diluted with dichloromethane, washed with saturated aqueous sodium carbonate solution, dried over sodium sulfate, filtered and evaporated. The residue was combined with a second crop obtained from 600 mg of (2-aminophenyl)(phenyl)methanone using the same method and purified by flash chromatography on silica gel (95 / 5 to 60 / 40) to give 1.35 g of (2-amino-5-bromophenyl)(phenyl)methanone. MS (ESI) m / z 276.20, 278.11 (M+H) + .
[1027]
[1028] Step 2: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (5.38 mL, 5.38 mmol) was added to a solution of LN-Boc-isoleucine (1.24 g, 5.38 mmol) in 2.7 mL of dichloromethane at 0° C. The resulting mixture was heated to 23° C. and then cooled to 0° C. A solution of (2-amino-5-bromophenyl)(phenyl)methanone (1.35 g, 4.89 mmol) in 4.6 mL of dichloromethane was then added dropwise, and the resulting mixture was stirred at 23° C. for 18 hours. The insoluble material was filtered off and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / hexane 12 / 88 to 100 / 0, then ethyl acetate / dichloromethane 80 / 20) to give 1.475 g of tert-butyl ((2S,3S)-1-((2-benzoyl-4-bromophenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next step without further purification. MS (ESI) m / z 489.24 (M+H) + .
[1029]
[1030] Step 3: 4M hydrochloric acid in 1,4-dioxane (7.5 mL, 30.1 mmol) was added to a solution of impure tert-butyl ((2S,3S)-1-((2-benzoyl-4-bromophenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (1.475 mg, theoretical 3.01 mmol) in 8 mL 1,4-dioxane at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was dissolved in dichloromethane and the solution was washed first with saturated aqueous sodium bicarbonate solution and then with water, then dried over sodium sulfate, filtered and evaporated to give 912 mg of crude (2S,3S)-2-amino-N-(2-benzoyl-4-bromophenyl)-3-ethylpentanamide, which was used in the next step without purification. MS (ESI) m / z 389.3 (M+H) + .
[1031]
[1032] Step 4: To a solution of crude (2S,3S)-2-amino-N-(2-benzoyl-4-bromophenyl)-3-methylpentanamide (912 mg, theoretical 2.35 mmol) in 10 mL of methanol and 1 mL of water at 0°C were added a few drops of 1 M aqueous sodium hydroxide solution to adjust the pH to 8-9. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was taken up in water and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 40 / 60) to give 542 mg of (S)-7-bromo-3-((S)-sec-butyl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (30% yield over three steps). MS (ESI) m / z 371.35 (M+H) + .
[1033]
[1034] Step 5: A mixture of (S)-7-bromo-3-((S)-sec-butyl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepine-2-one (543 mg, 1.46 mmol) and copper cyanide (222 mg, 2.48 mmol) in 9 mL of N,N-dimethylacetamide was stirred at 180°C for 11 hours under microwave irradiation, then cooled to 23°C and partitioned between water and dichloromethane. The formed precipitate was filtered and rinsed with water. The filtrate was washed with water, dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 20 / 80) to give 184 mg of (S)-3-((S)-sec-butyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine-7-carbonitrile (40% yield). MS (ESI) m / z 318.31 (M+H) + .
[1035]
[1036] Step 6: A 60% dispersion of sodium hydride in oil (47 mg, 1.16 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine-7-carbonitrile (184 mg, 0.58 mmol) in 2.7 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2.5 hours, then ethyl bromoacetate (100 μL, 0.87 mmol) was added. The resulting mixture was stirred at 23°C for 2.5 hours, then quenched by the addition of water and extracted three times with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 221 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-cyano-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (94% yield). MS (ESI) m / z 404.3 (M+H) + .
[1037]
[1038] Step 7: Lithium hydroxide monohydrate (127 mg, 3.03 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-cyano-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (221 mg, 0.55 mmol) in 18 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 5 hours and then concentrated to half its volume. The solution was cooled to 0°C and the pH was adjusted to 5-6 by adding 10% aqueous citric acid solution and then extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified twice by flash chromatography on silica gel (dichloromethane / methanol 100 / 0 to 90 / 10) to give 67 mg of 2-((S)-3-((S)-sec-butyl)-7-cyano-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, CDCl3) δ7.81-7.78(m,1H),7.65-7.64(m,1H),7.54-7.51(m,2H),7.49-7.45(m,1H),7.41-7.24(m,3H),4.67(d,J =18Hz,1H),4.57-4.47(m,1H),3.24-3.19(m,1H),2.62-2.50(m,1H),2.04-1.95(m,1H),1.16-1.12(m,1H),0.98-0.91(m,6H). MS(ESI): m / z 376.33(M+H) + .
[1039] Example 9: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-fluoro-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1040]
[1041] Step 1: At 0 ° C, 4-fluoroaniline (758 μ L, 8 mmol) in 8.9 mL of dichloroethane was added dropwise to a 1 M solution of boron trichloride in dichloromethane (5.2 mL, 5.2 mmol). The resulting mixture was stirred at 0 ° C for 30 minutes, then 4-methoxybenzonitrile (533 mg, 4 mmol) was added, followed by aluminum chloride (693 mg, 5.2 mmol). The resulting mixture was stirred at 23 ° C for 30 minutes, then at 90 ° C for 18 hours. The reaction mixture was then cooled to 0 ° C and quenched by adding 9 mL of 2 M aqueous hydrochloric acid. The resulting mixture was stirred at 90 ° C for 30 minutes, cooled to 23 ° C, and extracted three times with dichloromethane. The combined organic layer was dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 60 / 40) to give 188 mg (2-amino-5-fluorophenyl)(4-methoxyphenyl)methanone (10% yield). MS (ESI) m / z 246.16 (M+H) + .
[1042]
[1043] Step 2: A mixture of (2-amino-5-fluorophenyl)(4-methoxyphenyl)methanone (188 mg, 0.77 mmol), (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione (145 mg, 0.92 mmol), and trifluoroacetic acid (176 μL, 2.3 mmol) in 3.8 mL of toluene was stirred at 60°C for 18 hours, after which triethylamine (321 μL, 2.3 mmol) was added. The resulting mixture was then stirred at 80°C for 3 hours, then cooled to 23°C and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 20 / 80) to afford 211 mg of (S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. MS (ESI) m / z 341.25 (M+H) + .
[1044]
[1045] Step 3: A 60% dispersion of sodium hydride in oil (50 mg, 1.25 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (210 mg, 0.627 mmol) in 2.8 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 1 hour, then ethyl bromoacetate (103 μL, 0.925 mmol) was added. The reaction mixture was then stirred at 23°C for 1.5 hours, then cooled back to 0°C, quenched by the addition of ice water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 93 / 7 to 40 / 60) to give 263 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-fluoro-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate. MS (ESI) m / z 427.09 (M+H) + .
[1046]
[1047] Step 4: Lithium hydroxide monohydrate (142 mg, 3.39 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-fluoro-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (263 mg, 0.617 mmol) in 14 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, acidified to pH 5-6 by addition of 10% aqueous citric acid, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was crystallized twice from dichloromethane / hexane to give 202 mg of 2-((S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1 H NMR (400MHz, DMSO-d6) δ12.77(s,1H),7.55-7.51(m,1H),7.48-7.43(m,3H),7.01(dd,J=9.0,2.6Hz,1H),6.96-6.94(m,2H),4.56(d,J=17.8Hz ,1H),4.42(d,J=17.8Hz,1H),3.75(s,3H),3.11(d,J=10.0Hz,1H),2.33 -2.28(m,1H),1.86-1.79(m,1H),1.12-1.04(m,1H),0.90-0.80(m,6H). MS(ESI): m / z 399.13(M+H) + .
[1048] Example 10: Synthesis of 2-((S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1049]
[1050] Step 1: At 0 ° C, 4-methoxyaniline (2g, 16.2mmol) in 8.5mL dichloroethane was added dropwise to a solution of 1M boron trichloride in dichloromethane (10.6mL, 10.6mmol). The resulting mixture was stirred at 0 ° C for 30 minutes, then 4-fluorobenzonitrile (987mg, 8.15mmol) was added, followed by aluminum chloride (1.41g, 10.6mmol). The resulting mixture was stirred at 0 ° C for 30 minutes, then at 90 ° C for 19 hours. The reaction mixture was then cooled to 23 ° C, then cooled to 0 ° C, and then quenched by adding 17mL 2M hydrochloric acid aqueous solution. The resulting mixture was stirred at 90 ° C for 30 minutes, then cooled to 23 ° C, and extracted three times with dichloromethane. The combined organic layer was dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 1.36 g of (2-amino-5-methoxyphenyl)(4-fluorophenyl)methanone. MS (ESI) m / z 246.17 (M+H) + .
[1051]
[1052] Step 2: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (1.43 mL, 1.43 mmol) was added to a solution of LN-Boc-isoleucine (331 mg, 1.43 mmol) in 0.8 mL of dichloromethane at 0° C. The resulting mixture was stirred at 23° C. for 30 minutes and then cooled back to 0° C. (2-amino-5-methoxyphenyl)(4-fluorophenyl)methanone (350 mg, 1.43 mmol) in 1.3 mL of dichloromethane was then added and the resulting mixture was stirred at 23° C. for 2 days. The insoluble material formed during the reaction was filtered and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 80 / 20) to give impure tert-butyl ((2S,3S)-1-((2-(4-fluorobenzoyl)-4-methoxyphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next reaction without further purification. MS (ESI) m / z 459.04 (M+H) + .
[1053]
[1054] Step 3: To a solution of impure tert-butyl ((2S,3S)-1-((2-(4-fluorobenzoyl)-4-methoxyphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (theoretical 1.43 mmol) in 2.4 mL of dichloromethane was added 4M hydrochloric acid in 1,4-dioxane (2.25 mL, 9 mmol) at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was dissolved in dichloromethane and the resulting solution was washed with saturated aqueous sodium bicarbonate solution and then with water, dried over sodium sulfate, filtered and evaporated to give crude (2S,3S)-2-aminoketone-(2-(4-fluorobenzoyl)-4-methoxyphenyl)-3-methylpentanamide, which was used in the next step without purification. MS (ESI) m / z 359.19 (M+H) + .
[1055]
[1056] Step 4: (2S,3S)-2-amino-N-(2-(4-fluorobenzoyl)-4-methoxyphenyl)-3-methylpentanamide (theoretical 1.43 mmol) prepared in Step 3 was dissolved in 4.2 mL of methanol and 0.42 mL of water. The resulting solution was cooled to 0°C and the pH was adjusted to 8-9 by adding 1 M aqueous sodium hydroxide solution. The resulting mixture was warmed to 23°C and stirred for 18 hours before evaporation. The residue was partitioned between water and dichloromethane. The aqueous layer was then extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 0 / 100) to give 347 mg of (S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. MS (ESI) m / z 341.31 (M+H) + .
[1057]
[1058] Step 5: A 60% dispersion of sodium hydride in oil (82 mg, 1.02 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (347 mg, 1.02 mmol) in 4.7 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2 hours, then ethyl bromoacetate (170 μL, 1.53 mmol) was added. The reaction mixture was then stirred at 23°C for 2.5 hours, then quenched with ice water and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 20 / 80) to give 256 mg of ethyl 2-((S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (59% yield). MS (ESI) m / z 427.37 (M+H) + .
[1059]
[1060] Step 6: Lithium hydroxide monohydrate (139 mg, 3.3 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (256 mg, 0.6 mmol) in 20 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23° C. The resulting mixture was stirred at 23° C. for 5 h, then cooled to 0° C., acidified to pH 5-6 by the addition of 10% aqueous citric acid solution, and extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated to give 167 mg of 2-((S)-3-((S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1HNMR(400MHz,DMSO-d6)δ12.75(s,1H),7.56-7.51(m,2H),7.43(d,J=8.8Hz,1H),7.23-7.15(m,3H),6.62(d,J=3.2Hz,1H),4.55(d,J=17.6H z,1H),4.36(d,J=18Hz,1H),3.64(s,3H),3.13(d,J=10Hz,1H),2.32-2.25(m,1H),1.85-1.79(m,1H),1.09-1.02(m,1H),0.83-0.79(m,6H). MS(ESI): m / z 399.36(M+H) + .
[1061] Example 11: 2-((S)-3-((S)-sec-butyl)-7-chloro-5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1062]
[1063] Step 1: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (2.1 mL, 2.1 mmol) was added to a solution of LN-Boc-isoleucine (486 mg, 2.1 mmol) in 1.2 mL of dichloromethane at 0°C. The resulting mixture was heated to 23°C and then cooled back to 0°C. A solution of (2-amino-5-chlorophenyl)(cyclohexyl)methanone (500 mg, 2.1 mmol) in 1.9 mL of dichloromethane was then added, and the reaction mixture was stirred at 23°C for two days before being filtered. The filtrate was evaporated, and the residue was purified by flash chromatography on silica gel (hexane / dichloromethane 80 / 20 to 60 / 40) to give 478 mg of tert-butyl ((2S,3S)-1-((4-chloro-2-(cyclohexanecarbonyl)phenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate. MS (ESI) m / z 451.03 (M+H) + .
[1064]
[1065] Step 2: 4 M hydrochloric acid in 1,4-dioxane (2.7 mL, 1.08 mmol) was added to a solution of impure tert-butyl ((2S,3S)-1-((4-chloro-2-(cyclohexanecarbonyl)phenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (478 mg, theoretical 1.062 mmol) in 2.8 mL of 1,4-dioxane at 23°C. The resulting mixture was stirred at 23°C for 6 hours and then evaporated. The residue was dissolved in dichloromethane and the solution was washed with saturated aqueous sodium bicarbonate solution and then with water, then dried over sodium sulfate, filtered, and evaporated to give 310 mg of crude (2S,3S)-2-amino-N-(4-chloro-2-(cyclohexanecarbonyl)phenyl)-3-methylpentanamide, which was used in the next reaction without purification. MS (ESI) m / z 351.22 (M+H) + .
[1066]
[1067] Step 3: To a solution of crude (2S,3S)-2-amino-N-(4-chloro-2-(cyclohexylcarbonyl)phenyl)-3-methylpentanamide (theoretical 1.062 mmol) in 3.8 mL of methanol and 0.38 mL of water at 0°C were added a few drops of 1 M aqueous sodium hydroxide solution to adjust the pH to 8-9. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was taken up in water and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 20 / 80) to give 86 mg of (S)-3-((S)-sec-butyl)-7-chloro-5-cyclohexyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. MS (ESI) m / z 333.37 (M+H) + .
[1068]
[1069] Step 4: A 60% dispersion of sodium hydride in oil (20 mg, 0.38 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-cyclohexyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (86 mg, 0.25 mmol) in 1.2 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2 hours, then ethyl bromoacetate (40 μL, 0.38 mmol) was added. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, quenched by the addition of water, and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 79 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (76% yield). MS (ESI) m / z 419.44 (M+H) + .
[1070]
[1071] Step 6: Lithium hydroxide monohydrate (43 mg, 1.034 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (79 mg, 0.188 mmol) in 6 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 5 hours and then concentrated to half its volume. The solution was cooled to 0°C and the pH was adjusted to 5-6 by adding 10% aqueous citric acid solution and then extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / methanol 100 / 0 to 90 / 10) followed by a second column purification (hexane / ethyl acetate 50 / 50 to 0 / 100 then dichloromethane / methanol 100 / 0 to 80 / 20) to give 24 mg of 2-((S)-3-((S)-sec-butyl)-7-chloro-5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, CDCl3) δ7.49(s,1H),7.42(d,J=8.8Hz,1H),7.17-7.15(m,1H),4.57(d,J=17.2Hz,1H),4.38(d,J=18 Hz, 1H), 3.04 (d, J = 10Hz, 1H), 2.72 (m, 1H), 2.43 (m, 1H), 1.95-1.53 (m, 5H), 1.40-1.00 (m, 7H), 0.90-0.81 (m, 6H). MS(ESI): m / z 391.37(M+H) + .
[1072] Example 12: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid
[1073]
[1074] Step 1: 4-Chloroaniline (1.02 g, 8 mmol) in 15 mL of tetrachloroethane was added dropwise to a 1 M solution of boron trichloride in dichloromethane (12 mL, 12 mmol) at 0°C. The resulting mixture was stirred at 0°C for 30 minutes, then isonicotinonitrile (1 g, 9.6 mmol) was added, followed by aluminum trichloride (1.5 g, 11.2 mmol). The resulting mixture was stirred at 23°C for 30 minutes, then at 120°C for 4 hours, and then at 23°C for 18 hours. The reaction mixture was then cooled to 0°C and quenched by the addition of 15 mL of 3 M aqueous hydrochloric acid and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and evaporated to yield 749 mg of (2-amino-5-chlorophenyl)(pyridin-4-yl)methanone. MS (ESI) m / z 233.14 (M+H) + .
[1075]
[1076] Step 2: A mixture of (2-amino-5-chlorophenyl)(pyridin-4-yl)methanone (200 mg, 0.86 mmol), (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione (162 mg, 0.103 mmol) and trifluoroacetic acid (197 μL, 2.58 mmol) in 4.3 mL of toluene was stirred at 60° C. for 19 hours, followed by the addition of triethylamine (359 μL, 2.56 mmol). The resulting mixture was then stirred at 80° C. for 3 hours, then cooled to 23° C. and evaporated. The residue was taken up in dichloromethane and the insoluble material was filtered off. The filtrate was evaporated and the residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 80 / 20 to 0 / 100) to give 119 mg of (S)-3-((S)-sec-butyl)-7-chloro-5-(pyridin-4-yl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (42% yield). MS (ESI) m / z 328.3 (M+H) + .
[1077]
[1078] Step 3: A 60% dispersion of sodium hydride in oil (30 mg, 0.74 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-(pyridin-4-yl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (119 mg, 0.36 mmol) in 1.7 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 30 minutes, then ethyl bromoacetate (60 μL, 0.54 mmol) was added. The reaction mixture was stirred at 23°C for 3 hours, then cooled back to 0°C, quenched by the addition of ice water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 20 / 80) to give 104 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate. MS (ESI) m / z 414.37 (M+H) + .
[1079]
[1080] Step 4: Lithium hydroxide monohydrate (58 mg, 1.38 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (104 mg, 0.251 mmol) in 5.7 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, acidified to pH 5-6 by the addition of 10% aqueous citric acid, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was crystallized from dichloromethane / hexane to give 95 mg of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1 H NMR (400MHz, DMSO-d6) δ12.88(s,1H),8.64(dd,J=4.6,1.8Hz,2H),7.68(dd,J=8.8,2.4Hz,1H),7.57(d,J=9.2Hz,1H),7.42(dd,J=4.8,1.6Hz,2H),7.28( d,J=2.4Hz,1H),4.62(d,J=17.6Hz,1H),4.45(d,J=17.6Hz,1H),3.23(s,1H) ,2.36-2.30(m,1H),1.88-1.82(m,1H),1.14-1.06(m,1H),0.86-0.83(m,6H). MS (ESI): m / z 386.36 (M+H) + .
[1081] Example 13: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid
[1082]
[1083] Step 1: To a solution of 4-chloroaniline (2.55 g, 20 mmol) in 57 mL of dichloromethane was added triethylamine (4.2 mL, 30 mmol) followed by pivaloyl chloride (3 mL, 24 mmol) at 23°C. The resulting mixture was stirred at 23°C for 17 hours, then quenched with 20 mL of 1 M aqueous hydrochloric acid and extracted with dichloromethane. The organic layer was washed sequentially with saturated aqueous sodium bicarbonate solution and brine, then dried over magnesium sulfate, filtered, and evaporated to afford 3.9 g of N-(4-chlorophenyl)pivalamide (92% yield). 1 H NMR (400MHz, DMSO-d6) δ9.25 (s, 1H), 7.64–7.58 (m, 2H), 7.30–7.24 (m, 2H), 1.15 (s, 9H); MS (ESI) m / z 212.20 (M+H) + .
[1084]
[1085] Step 2: A 1.6 M solution of n-butyllithium in hexane (9.1 mL, 14.5 mmol) was added to a solution of N-(4-chlorophenyl)pivalamide (1.02 g, 4.83 mmol) in 5 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 1 hour, then picolinaldehyde (920 μL, 9.66 mmol) in 5 mL of tetrahydrofuran was added. The mixture was heated to 23°C over 1 hour, then quenched by the addition of water and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate solution, brine, dried over magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 65 / 35) to give 0.97 g of N-(4-chloro-2-(hydroxy(pyridin-2-yl)methyl)phenyl)pivalamide. 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.42(ddd,J=4.9,1.8,0.9Hz,1H),7.82(td,J=7.7,1.8Hz,1H),7.74(d,J=8.7Hz,1H),7.60(dd,J=7.9,1.3Hz ,1H),7.50(d,J=2.6Hz,1H),7.30–7.25(m,1H),7.21(dd,J=8.7,2.6Hz,1H ),6.58(d,J=3.9Hz,1H),5.84(d,J=3.9Hz,1H),1.22(s,9H).;MS(ESI)m / z 319.22(M+H) + .
[1086]
[1087] Step 3: Dess-Martin periodinane (DMP) (1.68 g, 3.97 mmol) was added to a solution of N-(4-chloro-2-(hydroxy(pyridin-2-yl)methyl)phenyl)pivalamide (970 mg, 3.05 mmol) in 100 mL of dichloromethane at 23° C. The resulting mixture was stirred at 23° C. for 18 hours and then quenched by the addition of saturated aqueous sodium bicarbonate solution. The organic layer was dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 65 / 35) to give 850 mg of N-(4-chloro-2-pyridinylphenyl)pivalamide (88% yield). 1 H NMR(400MHz,DMSO-d6)δ9.78(s,1H),8.51(dt,J=4.7,1.2Hz,1H),7.95(td,J=7.7,1 .7Hz,1H),7.87(dt,J=7.9,1.1Hz,1H),7.62–7.48(m,4H),0.82(s,9H).;MS(ESI)m / z 317.18(M+H) + .
[1088]
[1089] Step 4: To a solution of N-(4-chloro-2-pyridinylphenyl)pivalamide (850 mg, 2.68 mmol) in 27 mL of methanol was added 40% aqueous potassium hydroxide solution (5.2 mL) at 23°C. The resulting mixture was stirred at 65°C for 24 hours, then cooled to 23°C and evaporated. The residue was taken up in ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 65 / 35) to give 660 mg of (2-amino-5-chlorophenyl)(pyridin-2-yl)methanone (quantitative yield). 1 H NMR (400MHz, DMSO-d6) δ8.63 (ddd, J=4.8, 1.7, 0.9Hz, 1H), 7.97 (td, J=7.7, 1.7Hz, 1H), 7.7 3(dt,J=7.8,1.1Hz,1H),7.54(ddd,J=7.7,4.8,1.2Hz,1H),7.47(d,J=2.6Hz,1H),7.38(br s,2H),7.26(dd,J=9.0,2.6Hz,1H),6.84(d,J=9.0Hz,1H).;MS(ESI)m / z 233.12(M+H) + .
[1090]
[1091] Step 5: A mixture of L-isoleucine (2.67 g, 10.4 mmol) and triphosgene (4.83 g, 16.3 mmol) in 136 mL of tetrahydrofuran was stirred at reflux for 3 hours, then cooled to 23° C. and concentrated. The residue was taken up in hexane and maintained at −20° C. The liquid was removed with a pipette and the solid was taken up in hexane and tetrahydrofuran. The mixture was passed through silica gel and then rinsed with dichloromethane. The filtrate was evaporated to give 1.95 g of (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione. 1 H NMR(400MHz, DMSO-d6)δ9.03(s,1H),4.34(dd,J=4.1,1.2Hz,1H),1.73(ddtd,J=10.9,8.4,6.7,4.3Hz,1H), 1.29(dddd,J=14.9,12.3,7.5,4.9Hz,1H),1.21–1.09(m,1H),0.86(d,J=6.9Hz,3H),0.80(t,J=7.4Hz,3H).
[1092]
[1093] Step 6: A mixture of (2-amino-5-chlorophenyl)(pyridin-2-yl)methanone (237 mg, 1.02 mmol) prepared in Step 4 and (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione (192 mg, 1.22 mmol) prepared in Step 5 and trifluoroacetic acid (227 μL, 3.06 mmol) in 5.1 mL of toluene was stirred at 60° C. for 4.5 hours, and then triethylamine (430 μL, 3.06 mmol) was added. The resulting mixture was then stirred at 80° C. for 19 hours and then cooled to 23° C. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 90 / 10 to 40 / 60) to give 194 mg of (S)-3-((S)-sec-butyl)-7-chloro-5-(pyridin-2-yl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 11H NMR (400MHz, DMSO-d6) δ10.60(s,1H),8.50(ddd,J=4.9,1.8,0.9Hz,1H),7.99(dt,J=7.9,1.2Hz,1H) ,7.90(td,J=7.7,1.8Hz,1H),7.54(dt,J=8.8,2.2Hz,1H),7.49–7.42(m,1H),7.30(d,J=2.5Hz,1H),7 .17(d,J=8.8Hz,1H),3.15(d,J=9.3Hz,1H),2.27(dt,J=9.3,6.4Hz,1H),1.85(ddt,J=15.2,7.6,4.2H z,1H),1.18(ddd,J=13.5,9.3,7.2Hz,1H),0.90(d,J=6.5Hz,3H),0.84(t,J=7.5Hz,3H).;MS(ESI)m / z 328.26(M+H) + .
[1094]
[1095] Step 7: A 60% dispersion of sodium hydride in oil (47 mg, 1.17 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-(pyridin-2-yl)-1,3-dihydro-2H-benzo[e][1,4]diazepine-2-one (197 mg, 0.592 mmol) in 3 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 3 hours, then ethyl bromoacetate (98 μL, 0.888 mmol) was added. The resulting mixture was stirred at 23°C for 16 hours, then quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 55 / 45) to afford 203 mg of impure ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate, which was then purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 70 / 30) to afford 66 mg of pure material. 1H NMR(400MHz,DMSO-d6)δ8.52(ddd,J=4.8,1.8,0.9Hz,1H),8.08–8.05(m,1H),7 .90(td,J=7.7,1.8Hz,1H),7.61(dd,J=8.9,2.6Hz,1H),7.48–7.40(m,2H),7.3 8(t,J=2.3Hz,1H),4.50(d,J=4.8Hz,2H),3.25(d,J=9.3Hz,1H),2.36–2.22(m, 1H), 1.83 (ddd, J=13.3, 7.6, 3.1Hz, 1H), 1.18–1.06 (m, 0H), 0.87–0.80 (m, 5H). MS (ESI) m / z 414.35 (M+H) + .
[1096]
[1097] Step 8: A mixture of pure ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (66 mg, 0.16 mmol) and lithium hydroxide monohydrate (34 mg, 0.8 mmol) in 3.2 mL of tetrahydrofuran and 10 mL of water was stirred at 23°C for 48 hours and then quenched by the addition of Dowex 50WX8 chloride form. The mixture was filtered and the resin was washed with tetrahydrofuran. The filtrate was evaporated and then extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and evaporated. The residue was taken up in dichloromethane and hexane. After evaporation, the sticky residue was taken up in 1 mL of ethyl acetate and 3 mL of hexane and kept at 23°C for two days. The supernatant was removed and the solid material was dried in vacuo to give 25 mg of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, DMSO-d6) δ12.83 (s, 1H), 8.56-8.49 (m, 1H), 8.06 (dd, J = 8.3, 7.0Hz, 1H), 7.91 (t d,J=7.7,1.7Hz,1H),7.62(dd,J=8.9,2.6Hz,1H),7.46(ddd,J=7.5,4.8,1.2Hz,1H),7.43-7. 36(m,2H),4.48-4.32(m,2H),3.26(dd,J=18.53,9.04Hz,1H),2.32(dt,J=9.7,6.5Hz,1H),1. 84(ddd,J=13.3,7.6,3.0Hz,1H), 1.11(dtd,J=11.0,9.0,8.2,5.6Hz,1H), 0.94–0.77(m,6H). MS(ESI): m / z 386.37(M+H) + .
[1098] Example 14: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-5-isopropyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1099]
[1100] Step 1: At 0 ° C, 4-chloroaniline (7.38 g, 57.9 mmol) in 30 mL of dichloroethane was added dropwise to a solution of 1 M boron trichloride in dichloromethane (37.62 mL, 37.62 mmol). The resulting mixture was stirred at 0 ° C for 30 minutes, then isobutyronitrile (2.63 mL, 28.94 mmol) was added, followed by aluminum chloride (6.02 g, 37.62 mL). The resulting mixture was stirred at 0 ° C and then at 90 ° C for 18 hours. The reaction mixture was then cooled to 23 ° C, then cooled to 0 ° C, and then quenched by adding 60 mL of 2 M aqueous hydrochloric acid. The resulting mixture was stirred at 90 ° C for 30 minutes, then cooled to 23 ° C and extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95-5 to 60 / 40) to give 1.64 g of 1-(2-amino-5-chlorophenyl)-2-methylpropan-1-one. MS (ESI) m / z 198.07 (M+H) + .
[1101]
[1102] Step 2: A 1 M solution of dicyclohexylcarbodiimide in dichloromethane (3.04 mL, 3.04 mmol) was added to a solution of LN-Boc-isoleucine (703 mg, 3.04 mmol) in 1.5 mL of dichloromethane at 0° C. The resulting mixture was stirred at 23° C. for 30 minutes and then cooled back to 0° C. 1-(2-amino-5-chlorophenyl)-2-methylpropan-1-one (600 mg, 3.04 mmol) in 2.8 mL of dichloromethane was then added and the resulting mixture was stirred at 23° C. for 2 days. The insoluble material formed during the reaction was filtered and the filtrate was evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 80 / 20 to 40 / 60) to give 862 mg of impure tert-butyl ((2S,3S)-1-((4-chloro-2-isobutyrylphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate, which was used in the next reaction without further purification. MS (ESI) m / z 433.14 (M+Na) + .
[1103]
[1104] Step 3: Hydrochloric acid 4M in 1,4-dioxane (5.25 mL, 21 mmol) was added to a solution of impure tert-butyl ((2S,3S)-1-((4-chloro-2-isobutyrylphenyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (862 mg, theoretical 2.1 mmol) in 5.6 mL of dichloromethane at 23°C. The resulting mixture was stirred at 23°C for 18 hours and then evaporated. The residue was dissolved in dichloromethane, washed with saturated aqueous sodium bicarbonate solution and then with water, dried over sodium sulfate, filtered and evaporated to give 429 mg of crude (2S,3S)-2-amino-N-(4-chloro-2-isobutyrylphenyl)-3-methylpentanamide, which was used in the next step without further purification. MS (ESI) m / z 311.18 (M+H) + .
[1105]
[1106] Step 2: (2S,3S)-2-amino-N-(4-chloro-2-isobutyrylphenyl)-3-methylpentanamide (429 mg, 1.38 mmol) was dissolved in 4 mL of methanol and 0.4 mL of water. The resulting solution was cooled to 0°C and the pH was adjusted to 8-9 by adding 1 M aqueous sodium hydroxide solution. The resulting mixture was warmed to 23°C and stirred for 18 hours before evaporation. The residue was partitioned between water and dichloromethane. The aqueous layer was then washed three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to yield 210 mg of (S)-3-((S)-sec-butyl)-7-chloro-5-isopropyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. MS (ESI) m / z 293.28 (M+H) + .
[1107]
[1108] Step 5: A 60% dispersion of sodium hydride in oil (58 mg, 1.44 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-isopropyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (210 mg, 0.71 mmol) in 3.4 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2.5 hours, then ethyl bromoacetate (0.12 mL, 1.08 mmol) was added. The resulting mixture was slowly warmed to 23°C and stirred for 18 hours, then cooled back to 0°C, quenched by the addition of ice water, and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 255 mg of ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-5-isopropyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate. MS (ESI) m / z 379.33 (M+H) + .
[1109]
[1110] Step 6: Lithium hydroxide monohydrate (153 mg, 3.7 mmol) was added to a solution of ethyl 2-((S)-3-((S)-sec-butyl)-7-chloro-5-isopropyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (255 mg, 0.673 mmol) in 24.2 mL of a 1 / 1 mixture of 1,4-dioxane and water at 23°C. The resulting mixture was stirred at 23°C for 18 hours, then cooled to 0°C, acidified to pH 5-6 by addition of 10% aqueous citric acid, and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 20 / 80, then dichloromethane / methanol 100 / 0 to 80 / 20) to give 85 mg of 2-((S)-3-((S)-sec-butyl)-7-chloro-5-isopropyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1H NMR (400MHz, CDCl3) δ7.50(d,J=2.4Hz,1H),7.43(dd,J=2.8,2.4Hz,1H),7.15(d,J=8.8Hz,1H),4.451(dd,J=17.6,50Hz,2H),3.13-3 .07(m,1H),3.04(d,J=9.6Hz,1H),2.47-2.39(m,1H),1.26(d,J=6.4Hz,3H),1.14-0.99(m,2H),0.97-0.93(m,3H),0.91-0.83(m,6H). MS(ESI): m / z 351.37(M+H) + .
[1111] Example 15: Synthesis of 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid.
[1112]
[1113] Step 1: Sodium cyanoborohydride (9 mg, 0.143 mmol) and acetic acid (9 μL, 0.143 mmol) were added sequentially to a solution of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (50 mg, 0.13 mmol) in 1.5 mL of methanol at 0°C. The resulting mixture was stirred for 18 hours before a second portion of sodium cyanoborohydride (9 mg, 0.143 mmol) and acetic acid (9 mL, 0.143 mmol) were added. The reaction mixture was stirred at 23°C for 18 hours before being quenched by the addition of a 1 / 1 mixture of saturated aqueous sodium bicarbonate solution and water, extracted three times with dichloromethane, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 20 / 80, then dichloromethane / methanol 100 / 0 to 80 / 20) to give 28 mg of 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1 H NMR(400MHz,DMSO-d6)δ7.41-7.26(m,7H),6.24(s,1H),5.59(s,1H),4.48(d,J=17.0Hz,1H),4.3 5(d,J=17.0Hz,1H),2.77(m,1H),1.82(m,1H),1.64(m,1H),1.13-1.06(m,1H),0.75–0.69(m,6H). MS(ESI): m / z 387.2(M+H) + .
[1114] Example 16: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)acetamide.
[1115]
[1116] Step 1: A mixture of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (50 mg, 1.3 mmol), methanesulfonamide (1.25 mg, 0.26 mmol), 1-hydroxybenzotriazole hydrate (41 mg, 0.3 mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (58 mg, 0.3 mmol), and diisopropylethylamine (52 μL, 0.3 mmol) in 1.5 mL of dichloromethane and 1.5 mL of dimethylformamide was stirred at 23°C for 48 hours and then partitioned between water and dichloromethane. The organic layer was washed with water, dried over sodium sulfate, filtered, and evaporated. A second crop of product was prepared in the same manner. The combined crude residues were purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 0 / 100, then dichloromethane / methanol 100 / 0 to 80 / 20) and then by preparative thin layer chromatography (dichloromethane / methanol 95 / 5) to give 24 mg of 2-((S)-3-(S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)acetamide. 1 H NMR (400MHz, DMSO-d6) δ7.59(dd,J=8.8,2.4Hz,1H),7.52-7.49(m,2H),7.47-7.37(m,4H),7.10(d,J=2.8Hz,1H),4.29(d ,J=17.0Hz,1H),4.14(d,J=17.0Hz,1H),3.08(d,J=10.0Hz,1H),2.95(s,3H),2.34-2.31(m,1H),1.91-1.84(m,1H),1.13 -1.06(m,1H),0.86-0.82(m,6H). MS(ESI): m / z 462.19(M+H) + .
[1117] Example 17: Synthesis of target 29: (S)-1-((2H-tetrazol-5-yl)methyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one.
[1118]
[1119] Step 1: A mixture of (2-amino-5-chlorophenyl)(phenyl)methanone (923 mg, 3.98 mmol), (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione (751 mg, 4.78 mmol), and trifluoroacetic acid (590 μL, 4.75 mmol) in 13 mL of toluene was stirred at 65°C for 17 hours, after which triethylamine (1.1 mL, 7.96 mmol) was added. The resulting mixture was then stirred at 80°C for 30 minutes, then cooled to 23°C and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 60 / 40) to afford 1.06 mg of (S)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1 H NMR (400MHz, DMSO-d6) δ10.61(s,1H),7.59(dd,J=8.7,2.5Hz,1H),7.49–7.32(m,5H),7.26–7.16(m,2H),3.06(d,J=9.4H z,1H),2.32–2.18(m,1H),1.90–1.77(m,1H),1.22–1.14(m,1H),0.89(d,J=6.5Hz,3H),0.84(t,J=7.4Hz,3H); MS(ESI)m / z 326.84(M+H) + .
[1120]
[1121] Step 2: A 60% dispersion of sodium hydride in oil (40 mg, 0.997 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepine-2-one (163 mg, 0.499 mmol) in 2.5 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 2 hours, then 2-chloroacetonitrile (47 μL, 0.749 mmol) was added. The reaction mixture was stirred at 23°C for 20 hours, then quenched by the addition of saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 65 / 35) to give 99 mg of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetonitrile. 1H NMR (400MHz, DMSO-d6) δ7.77(dd,J=8.8,2.5Hz,1H),7.64(d,J=8.9Hz,1H),7.49–7.40(m,5H),7.27(d,J=2.5Hz,1H),5.03(d,J=17.9 Hz,1H),4.89(d,J=17.8Hz,1H),3.27–3.25(m,1H),2.36–2.25(m,1H),1.90–1.78(m,1H),1.11(t,J=7.1Hz,1H),0.90–0.80(m,6H). MS(ESI)m / z 366.26(M+H) + .
[1122]
[1123] Step 3: A solution of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetonitrile (99 mg, 0.27 mmol), ammonium chloride (19 mg, 0.35 mmol) and sodium azide (23 mg, 0.35 mmol) in 2.7 mL of dimethylformamide was stirred at 125° C. for 21 hours, then cooled to 23° C. and partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane (methanol + 2% ammonium hydroxide)) to give 30 mg of impure (S)-1-((2H-tetrazol-5-yl)methyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one, which was purified a second time (hexane / ethyl acetate 100 / 0 to 30 / 70). The aqueous layer from the reaction mixture extraction was acidified to pH 2 by addition of 1 M aqueous hydrochloric acid solution and extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 100 / 0 to 30 / 70). The two crops were combined and crystallized from ethyl acetate / hexanes to give 21 mg of (S)-1-((2H-tetrazol-5-yl)methyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1H NMR (400MHz, DMSO-d6) δ7.78(d,J=8.9Hz,1H),7.69(dd,J=8.9,2.6Hz,1H),7.50-7.37(m,5H),7.17(d,J=2.4Hz,1H),5.38(d,J=16.5Hz ,1H),5.24(d,J=16.4Hz,1H),3.21(dd,J=9.8,7.1Hz,1H),2.36-2.20(m,1H),1.92-1.72(m,1H),1.24-0.99(m,2H),0.88-0.75(m,6H)). HPLC: Waters XBridge C18, 4.6 x 150 mm, (10% MeCN in 0.1% aqueous TFA) (100% MeCN in 0.1% aqueous TFA) at 1 mL / min for 10 minutes and 100% MeCN in 0.1% aqueous TFA at 1 mL / min for 5 minutes; PDA detection at 254 nm; RT = 11.58 minutes, purity 99.4%. MS (ESI): m / z 408.95 (M+H) + .
[1124] Example 18: Synthesis of 1-(2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)ethyl)sulfonamide
[1125]
[1126] Step 1: Potassium tert-butoxide (0.412 g, 3.67 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (1 g, 3.06 mmol) in 6 mL of N,N-dimethylformamide at 0°C. The resulting mixture was stirred at 0°C for 15 minutes, followed by the addition of tert-butyl (2-bromoethyl)carbamate (994 μL, 4.44 mmol) in 4 mL of N,N-dimethylformamide. The reaction mixture was then stirred at 23°C for 18 hours, then quenched with 1.5 mL of water and extracted with 50 mL of ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over sodium sulfate, filtered, and evaporated. The crude residue of tert-butyl (2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)ethyl)carbamate was used in the next step without further purification or characterization.
[1127]
[1128] Step 2: To a solution of crude tert-butyl (2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)ethyl)carbamate (theoretical 3.06 mmol) prepared in Step 1 in 6 mL of dichloromethane was added 2 mL of trifluoroacetic acid at 23°C. The reaction mixture was then stirred at 23°C for 18 hours and then evaporated. The residue was diluted with ethyl acetate, and the resulting solution was washed with saturated aqueous sodium bicarbonate, brine, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / methanol 99 / 1 to 80 / 20) to give 0.893 g of (S)-1-(2-aminoethyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (79% yield over two steps).
[1129]
[1130] Step 3: To a solution of (S)-1-(2-aminoethyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (0.15 g, 0.405 mmol) in 10 mL of dichloromethane was added diisopropylethylamine (706 μL, 4.055 mmol) followed by sulfamoyl chloride (0.353 g, 3.041 mmol) at 23° C. The resulting mixture was stirred at 23° C. for 18 hours then diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (dichloromethane / methanol 99 / 1 to 90 / 10) to give 34 mg of 1-(2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)ethyl)sulfonamide. 1 H NMR(400MHz, DMSO-d6):7.73(d,J=1.6Hz,2H),7.56-7.44(m,5H),7.23(s,1H),6.64(t,J=6.2HZ,1H),6.53(s,2H),4.19-4.12(m,1H),3. 88-3.81(m,1H),3.14(d,J=10.4Hz,1H),2.92-2.87(m,2H),2.41-2.35(m,1H),1.92-1.87(m,1H),1.90-1.10(m,1H),0.91-0.87(m,6H). MS(ESI): m / z 449.09(M+H)+ .
[1131] Example 19: Synthesis of (S)-3-((S)-sec-butyl)-7-chloro-1-(2-hydroxyethyl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one.
[1132]
[1133] Step 1: (2-Bromoethoxy)(tert-butyl)dimethylsilane (410 μL, 1.9 mmol), potassium carbonate (0.317 g, 2.3 mmol) and sodium iodide (0.023 g, 0.15 mmol) were added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (0.5 g, 1.5 mmol) in 25 mL of acetonitrile at 23° C. The resulting mixture was stirred at reflux for 48 hours and then evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 60 / 40) to give 0.34 g of (S)-3-((S)-sec-butyl)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1 H NMR (400MHz, DMSO-d6): 7.86 (dd, J=9.2, 2.8Hz, 1H), 7.69 (dd, J=8.8, 2.8Hz, 1H ),7.55-7.43(m,5H),7.23(d,J=2.4Hz,1H),4.14–4.08(m,1H),3.87-3.73(m,2 H),3.59-3.54(m,1H),3.13(d,J=10.4Hz,1H),2.40-2.36(m,1H),1.90-1.86(m ,1H),0.91-0.86(m,6H),0.73(s,9H),-0.08(s,3H),-0.09(s,3H); MS(ESI): m / z 485.18 (M+H) + .
[1134]
[1135] Step 2: A 1 M solution of tert-butylammonium fluoride in tetrahydrofuran (488 μL, 0.69 mmol) was added to a solution of (S)-3-((S)-sec-butyl)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (90.167 mg, 0.34 mmol) prepared in Step 1 in 5 mL of tetrahydrofuran at 0°C. The resulting mixture was heated to 23°C over 90 minutes and then evaporated. The residue was diluted with ethyl acetate, and the solution was washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexane / ethyl acetate 95 / 5 to 0 / 100) to give 0.11 g of (S)-3-((S)-sec-butyl)-7-chloro-1-(2-hydroxyethyl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1 H NMR(400MHz, DMSO-d6):7.83(d,J=8.8Hz,1H),7.70(dd,J=9.2,2.8Hz,1H),7.53-7.44(m,5H),7.19(d,J=2.4Hz,1H),4.74-4.71(m,1H),4.12–4.02 (m,1H),3.81-3.75(m,1H),3.50-3.38(m,2H),3.13(d,J=10.0Hz,1H),2. 41-2.35(m,1H),1.92-1.86(m,1H),1.12-1.06(m,1H),0.91-0.86(m,6H). MS(ESI): m / z 371.04(M+H) + .
[1136] Example 20: Synthesis of (S)-3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-1-yl)-N-(methylsulfonyl)propionamide
[1137]
[1138] Step 1: Triphosgene (9 g, 30.3 mmol) was added to a solution of L-valine (4.44 g, 37.9 mmol) in 250 mL of tetrahydrofuran at 23 ° C. The resulting mixture was stirred at reflux for 3 hours, then cooled to 23 ° C and evaporated. The residue was placed in 20 mL of tetrahydrofuran, and then 450 mL of hexane was added. The solution was cooled to -20 ° C and then decanted to remove the separated dark oil. This process was repeated twice, and the solution was cooled to -20 ° C again. The precipitate formed was filtered, rinsed with hexane, and dried under vacuum to give 2.61 g of (S)-4-isopropyloxazolidine-2,5-dione (60% yield). H NMR (400MHz, DMSO-d6): 9.07 (s, 1H), 4.32 (dt, J=4.2, 1.2Hz, 1H), 2.02 (tdd, J= 6.8, 4.2, 0.9Hz, 1H), 0.92 (dd, J=6.8, 0.9Hz, 3H), 0.82 (dd, J=6.8, 0.9Hz, 3H).
[1139]
[1140] Step 2: Trifluoroacetic acid (1.2 mL, 16.3 mmol) was added to a solution of (2-amino-5-chloro-phenyl)(phenyl)methanone (1.89 g, 8.17 mmol) and (S)-4-isopropyloxazolidine-2,5-dione (1.4 g, 9.8 mmol) prepared in Step 1 in 27 mL of toluene at 23°C. The mixture was stirred at 65°C for 23 hours, after which triethylamine (2.3 mL, 16.3 mmol) was added. The resulting solution was then stirred at 80°C for 3 hours, cooled to 23°C, and evaporated. The residue was purified by flash chromatography on silica gel (hexane, ethyl acetate 100 / 0 to 60 / 40) to afford 2.3 g of (S)-7-chloro-3-isopropyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1 H NMR(400MHz, DMSO-d6):10.64(s,1H),7.61(dd,J=8.7,2.5Hz,1H),7.51–7.39(m,5H),7.24(m ,2H),3.03(d,J=8.8Hz,1H),2.52–2.41(m,1H),1.08(d,J=6.5Hz,3H),0.94(d,J=6.5Hz,3H). MS(ESI)m / z=313.12(M+H) + .
[1141]
[1142] Step 3: Sodium hydride 60% (0.138 g, 3.46 mmol) in oil was added to a solution of (S)-7-chloro-3-isopropyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepine-2-one (0.542 g, 1.73 mmol) in 9 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 3 hours, then ethyl 3-bromo-propionate (330 μL, 2.6 mmol) was added. The solution was then stirred at 23°C for 18 hours, then cooled to 0°C, quenched by the addition of water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexanes, ethyl acetate 100 / 0 to 55 / 45) to give 0.456 g of (S)-ethyl 3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate. 1 H NMR (400MHz, DMSO-d6):7.74–7.64(m,2H),7.55–7.39(m,5H),7.19(t,J=1. 5Hz,1H),4.39(dt,J=14.2,6.3Hz,1H),3.90(dt,J=14.2,6.3Hz,1H),3.70(q ,J=6.7Hz,2H),3.03(dd,J=9.6,0.8Hz,1H),2.54–2.44(m,1H),2.39(t,J=6 .3Hz, 2H), 1.02 (d, J = 6.7Hz, 3H), 0.90 (t, J = 6.7, 3H), 0.89 (d, J = 6.7Hz, 3H). MS (ESI) m / z = 413.11 (M+H) + .
[1143]
[1144] Step 4: Lithium hydroxide monohydrate (0.231 g, 5.5 mmol) was added to a solution of ethyl (S)-3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate (0.456 g, 1.1 mmol) prepared in Step 3 in 11 mL of 1,4-dioxane and 11 mL of water at 23°C. The resulting mixture was stirred at 23°C for 19 hours and then evaporated to half its volume. The pH was adjusted to 5-6 by adding 10% aqueous citric acid, and the resulting solution was extracted with ethyl acetate. The organic layer was evaporated and the residue was triturated with hexanes to give 0.319 g of (S)-3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid. 1 H NMR (400MHz, DMSO-d6): 12.12 (s, 1H), 7.73–7.65 (m, 2H), 7.53–7.46 (m, 3H), 7.46–7.40 (m, 2H), 7.16 (d, J = 2.4Hz, 1H), 4.34 (dt, J = 13.9, 6.9Hz, 1H),3.88(dt,J=13.9,6.9Hz,1H),3.02(d,J=9.5Hz,1H),2.58–2.49(m, 1H), 2.31 (t, J=6.9Hz, 2H), 1.02 (d, J=6.7Hz, 4H), 0.89 (d, J=6.5Hz, 3H). MS(ESI)m / z=385.10(M+H) + .
[1145]
[1146] Step 5: A solution of (S)3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid (0.142 g, 0.369 mmol), methanesulfonamide (0.053 g, 0.553 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.085 g, 0.443 mmol) and 4-dimethylaminopyridine (0.009 g, 74 mol) prepared in step 4 in 4 mL of dichloromethane was stirred at 23 °C for 22 hours and then purified by flash chromatography on silica gel (dichloromethane / methanol 94 / 6 to 90 / 10). The slightly impure product was recovered by washing with ethanol and then methanol to give 0.093 g of (S)-3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)propionamide, Compound 30r (55% yield). 1 H NMR (400MHz, DMSO-d6): 11.56 (s, 1H), 7.75–7.64 (m, 2H), 7.57–7.37 (m, 5H), 7.25–7.13 (m, 1H), 4.37 (dt, J=13.9, 6.8Hz, 1H), 3.89 (dt, J= 13.8, 6.8Hz, 1H), 3.03 (d, J = 9.5Hz, 1H), 2.95 (s, 3H), 2.55–2.48 (m, 1H), 2.41–2.33 (m, 2H), 1.02 (d, J = 6.6Hz, 3H), 0.89 (d, J = 6.6Hz, 3H). MS(ESI):m / z462.12(M+H) + .mp115-118℃.
[1147] Example 21: Synthesis of (S)-1-(2-(2H-tetrazol-5-yl)ethyl)-7-chloro-3-isopropyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
[1148]
[1149] Step 1: Potassium carbonate (0.276 g, 2 mmol) and then acrylonitrile (167 μL, 2 mmol) were added to a solution of (S)-7-chloro-3-isopropyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (0.313 g, 1 mmol) in 6 mL of N,N-dimethylformamide at 23° C. The resulting mixture was stirred at 23° C. for 16 hours and then filtered. The mixture was filtered. The filtrate was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (ethyl acetate / [hexane / dichloromethane 1 / 1] 1 / 99 to 10 / 90) to give 0.194 g of (S)-3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propionitrile. 1 H NMR(400MHz, CDCl3)0.98(d,J=6.8Hz,3H),1.12(d,J=6.4Hz,3H),2.54-2.80(m,3H ), 3.05 (d, J = 9.6Hz, 1H), 3.87-3.94 (m, 1H), 4.43-4.49 (m, 1H), 7.32-7.67 (m, 8H). MS(ESI):m / z 366.12(M+H) + .
[1150]
[1151] Step 2: Triethylammonium chloride (0.256 g, 1.85 mmol) and sodium azide (0.121 g, 1.85 mmol) were added to a solution of (S)-3-(7-chloro-3-isopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propionitrile (0.194 g, 0.53 mmol) prepared in step 1 in 4 mL of N,N-dimethylformamide at 23 °C. The resulting mixture was microwaved at 130 °C for 8 hours, then cooled to 23 °C and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over sodium sulfate, filtered and evaporated. The residue was purified by 1 H NMR indicated residual N,N-dimethylformamide, so it was dissolved in dichloromethane and the resulting solution washed twice with cold water. The organic layer was dried over sodium sulfate, filtered, and evaporated to yield 0.087 g of (S)-1-(2-(2H-tetrazol-5-yl)ethyl)-7-chloro-3-isopropyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1H NMR (400MHz, CDCl3): 0.97 (d, J = 6Hz, 3H), 1.11 (d, J = 6.4Hz, 3H), 2.71-2.79 (m, 1H), 2.96-3.16 (m, 2H), 3.06 (d, J = 1 0Hz,1H),4.08-4.15(m,1H),4.51-4.58(m,1H),7.23(m,1H),7.34-7.45(m,6H),7.56-7.59(dd,J=9.2,2.8Hz,1H). MS(ESI):m / z 409.01(M+H) + .
[1152] Example 22: Synthesis of 1-(2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]-[1,4]diazepin-1-yl)ethyl)urea
[1153]
[1154] Acetic acid (49 μL, 0.811 mmol) was added to a solution of (S)-1-(2-aminoethyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (0.15 g, 0.405 mmol) in 4.5 mL of water at 23°C. The resulting mixture was sonicated to facilitate dissolution of the starting material. Potassium cyanate (0.033 g, 0.405 mmol) was then added, and the reaction mixture was stirred at 23°C for 18 hours before being filtered. The residue was washed with water, dried in vacuo and purified by flash chromatography on silica gel (dichloromethane / methanol 99 / 1 to 90 / 10) to give 0.054 g of 1-(2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-ethyl)urea. 1 HNMR(400MHz, DMSO-d6):7.59–7.53(m,3H),7.49–7.39(m,4H),7.27(d,J=2.0Hz,1H),5.15(s,1H),4.28–4.21(m,1H),3.89–3.8 2(m,1H),3.31–3.19(m,2H),3.16(d,J=10.0Hz,1H),2.61–2.54(m,1H),2.01–1.94(m,2H),1.19–1.12(m,1H),0.98–0.92(m,6H). MS(ESI): m / z 413.09(M+H) + .
[1155] Example 29: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)propionamide
[1156]
[1157] Step 1: Sodium hydride 60% (0.083 g, 2.08 mmol) in liquid oil was added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (0.34 g, 1.04 mmol) in 5 mL of tetrahydrofuran at 0°C. The resulting mixture was stirred at 0°C for 3 hours before the addition of ethyl 3-bromopropionate (200 μL, 1.56 mmol). The solution was then stirred at 23°C for 3 days before being cooled to 0°C, quenched by the addition of water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel (hexanes, ethyl acetate 100 / 0 to 55 / 45) to give 0.41 g of ethyl 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate. 11 H NMR(400MHz, DMSO-d6):7.74–7.64(m,2H),7.57–7.38(m,5H),7.20(d,J=2.6Hz,1H), 4.38(dt,J=13.3,6.3Hz,1H),3.90(dt,J=13.6,6.5Hz,1H),3.71(q,J=6.2Hz,2H),3. 09(d,J=10.0Hz,1H),2.39(t,J=6.5Hz,2H),2.37–2.28(m,1H),1.90–1.78(m,1H),1. 13–1.02(m,1H),0.90(t,J=7.1Hz,3H),0.86(d,J=6.6Hz,3H),0.84(t,J=7.5Hz,3H). MS(ESI): m / z 427.08(M+H) + .
[1158]
[1159] Step 2: Lithium hydroxide monohydrate (0.197 g, 4.69 mmol) was added to a solution of ethyl 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-propanoate (0.41 g, 0.937 mmol) in 9.4 mL of 1,4-dioxane and 9.4 mL of water at 23°C. The resulting mixture was stirred at 23°C for 19 hours and then evaporated to half its volume. The pH was adjusted to 5-6 by adding 10% aqueous citric acid, and the resulting solution was extracted with ethyl acetate. The organic layer was evaporated and the residue was triturated with hexanes to give 0.319 g of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid (55%). 1 H NMR(400MHz,DMSO-d6)12.13(s,1H),7.73–7.64(m,2H),7.52–7.46(m,3H),7.46– 7.40(m,2H),7.16(d,J=2.4Hz,1H),4.33(dt,J=13.7,6.6Hz,1H),3.88(dt,J=13. 9,6.9Hz,1H),3.08(d,J=9.9Hz,1H),2.39–2.33(m,1H),2.30(t,J=6.9Hz,2H),1. 91–1.78(m,1H),1.16–1.03(m,1H),0.86(d,J=6.5Hz,3H),0.83(t,J=7.6Hz,3H). MS (ESI): m / z 323.31 (M+H) + .
[1160]
[1161] Step 3: A solution of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid (0.100 g, 0.25 mmol), methanesulfonamide (0.036 g, 0.376 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.058 g, 0.301 mmol) and 4-dimethylaminopyridine (0.006 g, 50 mol) prepared in step 2 in 1.2 mL of dichloromethane was stirred at 23°C for 22 hours and then purified by flash chromatography on silica gel (dichloromethane / methanol 100 / 0 to 85 / 15). The slightly impure product was recovered by washing with ethanol and then methanol to give 0.045 g of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)propionamide. 1 H NMR(400MHz,DMSO-d6):11.56(s,1H),7.74–7.65(m,2H),7.57–7.38(m,5H),7.1 8(d,J=2.5Hz,1H),4.36(dt,J=13.8,6.8Hz,1H),3.89(dt,J=13.8,6.8Hz,1H),3 .09(d,J=10.0Hz,1H),2.95(s,3H),2.38(t,J=6.8Hz,2H),2.35–2.26(m,1H),1. 90–1.78(m,1H),1.16–1.01(m,1H),0.87(d,J=6.4Hz,3H),0.84(t,J=7.4Hz,3H). MS (ESI): m / z 476.12 (M+H) + .mp113-115℃.
[1162] Example 23: Synthesis of (S)-1-(2-(2H-tetrazol-5-yl)ethyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
[1163]
[1164] Step 1: Potassium carbonate (0.276 g, 2 mmol) and then acrylonitrile (167 μL, 2 mmol) were added to a solution of (S)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]-diazepin-2-one (0.327 g, 1 mmol) in 6 mL of N,N-dimethylformamide at 23°C. The resulting mixture was stirred at 23°C for 16 hours and then filtered. The mixture was filtered. The filtrate was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica gel (ethyl acetate / [hexane / dichloromethane 1 / 1] 1 / 99 to 10 / 90) to give 0.191 g of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propionitrile (50% yield). 1 H NMR(400MHz, CDCl3):0.92-0.98(m,6H),1.13-1.19(m,1H),1.96-2.03(m,1H),2.54 -2.68(m,3H),3.14(d,J=10.4Hz,1H),3.87(m,1H),4.43(m,1H),7.31-7.66(m,8H). MS(ESI):m / z 380.12(M+H) + .
[1165]
[1166] Step 2: Triethylammonium chloride (0.203 g, 1.47 mmol) and sodium azide (0.096 g, 1.47 mmol) were added to a solution of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propionitrile (0.161 g, 0.42 mmol) prepared in Step 1 in 4 mL of N,N-dimethylformamide at 23 °C. The resulting mixture was microwaved at 130 °C for 8 hours, then cooled to 23 °C and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over sodium sulfate, filtered and evaporated. The residue was purified by 1 H NMR indicated residual N,N-dimethylformamide, so it was dissolved in dichloromethane and the resulting solution washed twice with cold water. The organic layer was dried over sodium sulfate, filtered, and evaporated to yield 0.057 g of (S)-1-(2-(2H-tetrazol-5-yl)ethyl)-3-((S)-sec-butyl)-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one. 1H NMR(400MHz, CDCl3):0.90-0.97(m,6H),1.16-1.24(m,1H),1.94-1.99(m,1H),2.57(m,1H),3.00-3.20(m,2H),3. 15(d,J=10.4Hz,1H),4.08-4.15(m,1H),4.52-4.59(m,1H),7.36-7.45(m,6H),7.57-7.50(dd,J=9.2,2.4Hz,1H). MS(ESI): m / z 423.07(M+H) + .
[1167] Example 24: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylacetamide:
[1168]
[1169] To a solution of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (20 mg, 0.052 mmol, 1 eq) in 2 mL of CHCl was added 1.1 eq of sulfonamide, 1.5 eq of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, 1.1 eq of hydroxybenzotriazole, and excess N,N-diisopropylethylamine. After stirring for 18 hours, EtOAc was added to the reaction and the mixture was washed with saturated NHCl and brine. The mixture was then purified by Combi-Flash using a gradient of ethyl acetate:hexanes from 2:8 to 5:5 to afford 10 mg of the title compound. 1 HNMR (300MHz, CDCl3): δ (ppm) 7.60-7.50 (m, 4H), 7.50-7.36 (m, 3H), 7.31-7.28 (m, 1H), 4.52-4.28 (m, 2 H),3.28-3.22(m,1H),2.56-2.40(m,1H),2.06-1.90(m,1H),1.30-1.13(m,1H),0.98-0.92(m,6H); Calculate C 21 H 23 ClN4O4S, 462.11; observed (M+H) + 463.6.
[1170] Example 25: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((trifluoromethyl)sulfonyl)acetamide:
[1171]
[1172] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that trifluoromethanesulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 23.5 mg of the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.56-7.49 (m, 4H), 7.45-7.32 (m, 3H), 7.25-7.23 (m, 1H), 4.44-4.32 (m, 1H) ),4.26-4.15(m,1H),3.21-3.14(m,1H),2.00-1.80(m,1H),1.20-1.02(m,1H),0.92-0.80(m,6H); Calculate C- 22 H 21 ClF3N3O4S, 515.09; observed (M+H) + 516.7.
[1173] Example 26: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(N,N-dimethylsulfamoyl)acetamide:
[1174]
[1175] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that N,N-dimethylsulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 14.5 mg of the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 7.63-7.58 (m, 2H), 7.57-7.51 (m, 1H), 7.50-7.38 (m, 4H), 7.33-7.30 (m, 1H),4.63-4.55(m,1H),4.28-4.20(m,1H),3.26(d,J=9.9Hz,1H),2.89(s,6H),1.10-0.95(m,6H); Calculate C 23 H 27 ClN4O4S, 490.14; observed (M+H) + 491.7.
[1176] Example 27: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(tert-butylsulfonyl)acetamide
[1177]
[1178] The title compound was prepared according to the protocol of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that tert-butylsulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 10.5 mg of the title compound. Calculated C 25 H 30 ClN3O4S, 503.16; observed (M+H) + 504.7.
[1179] Example 28: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(cyclopropylsulfonyl)acetamide
[1180]
[1181] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that cyclopropanesulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 12.9 mg of the title compound. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.62-7.31 (m, 8H), 4.70-4.60 (m, 1H), 4.35-4.25 (m, 1H), 3.30-3.20 (m, 1H), 1.34-1.18 (m, 4H), 1.09-0.92 (m, 10H); calculated for C 24 H 26 ClN3O4S, 487.13; observed (M+H) + 488.7.
[1182] Example 28: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((difluoromethyl)sulfonyl)acetamide
[1183]
[1184] The title compound was prepared according to the protocol of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that difluoromethanesulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 23.4 mg of the title compound. Calculated C 22 H 22 ClF2N3O4S, 497.10; observed (M+H) + 498.7.
[1185] Example 29: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide
[1186]
[1187] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except using benzenesulfonamide instead of sulfonamide, and then purified by Combi-Flash to give 19.0 g of the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 7.90-7.82 (m, 2H), 7.52-7.43 (m, 4H), 7.43-7.32 (m, 6H), 7.23-7.21 (m, 1H), 4.50- 4.20(m,2H),3.20-3.10(m,1H),2.60-2.40(m,1H),2.05-1.85(m,1H),1.25-1.05(m,1H),0.97-0.84(m,6H); Calculate C 27 H 26 ClN3O4S; observed (M+H) + 524.7.
[1188] Example 30: Synthesis of N-(benzylsulfonyl)-2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetamide
[1189]
[1190] The title compound was prepared according to the protocol of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that α-toluenesulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 23.7 mg of the title compound. Calculated C 28 H 28 ClN3O4S, 537.15; observed (M+H) + 538.8.
[1191] Example 31: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)acetamide
[1192]
[1193] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that thiophene-2-sulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 25.4 mg of the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 7.68-7.58 (m, 1H), 7.55-7.44 (m, 5H), 7.44-7.34 (m, 3H), 7.25-7.22 (m, 1H), 6.98-6.90 (m, 1H) ,4.50-4.32(m,2H),3.20(d,J=9.9Hz,1H),2.62-2.48(m,1H),2.10-1.90(m,1H),1.25-1.05(m,1H),0.99-0.90(m,6H); Calculate C 25 H 24 ClN3O4S2, 529.09; observed (M+H) + 530.7.
[1194] Example 32: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((5-chlorothiophen-2-yl)sulfonyl)acetamide
[1195]
[1196] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that 5-chlorothiophene-2-sulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 24.9 mg of the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.52-7.44 (m, 4H), 7.44-7.32 (m, 4H), 7.25-7.20 (m, 1H), 6.72-6.64 (m, 1H), 4.54-4.20 (m ,2H),(m,1H),3.20(d,J=10.5Hz,1H),2.55-2.45(m,1H),2.00-1.85(m,1H),1.25-1.05(m,1H),0.97-0.86(m,6H); Calculate C 25 H 23 Cl2N3O4S2, 563.05; observed (M+H) + 564.7.
[1197] Example 33: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((1-methyl-1H-imidazol-4-yl)sulfonyl)acetamide:
[1198]
[1199] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that 1-methylimidazole-2-sulfonamide was used instead of sulfonamide, and then purified by Combi-Flash to give 4.3 mg of the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.61 (s, 1H), 7.57-7.51 (m, 2H), 7.50-7.34 (m, 5H), 7.26-7.23 (m, 1H), 7.23-7.20 (m, 1H), 4.62-6.52 (m, 1 H),4.43-4.32(m,1H),3.66(s,3H),3.18-3.12(m,1H),2.60-2.40(m,1H),2.00-1.85(m,1H),1.20-1.00(m,1H),0.93-0.82(m,6H); Calculate C 25 H 26 ClN5O4S, 527.14; observed (M+H) + 528.7.
[1200] Example 34: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((tetrahydro-2H-pyran-4-yl)sulfonyl)acetamide:
[1201]
[1202] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that oxane-4-sulfonamide was used instead of sulfonamide, and then purified by HPLC to give 23.0 mg of the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 7.59-7.53 (m, 2H), 7.53-7.34 (m, 5H), 7.28-7.24 (m, 1H), 4.55-4.46 (m, 1H), 4.29-4.19 (m, 1H), 4.10-4. C 26 H 30 ClN3O5S, 531.16; observed (M+H) + 532.8.
[1203] Example 35: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(pyridin-2-ylsulfonyl)acetamide:
[1204]
[1205] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that pyridine-2-sulfonamide was used instead of sulfonamide, and then purified by HPLC to give 27.0 mg of the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 8.65-8.58 (m, 1H), 8.13-8.06 (m, 1H), 7.92-7.83 (m, 1H), 7.54-7.32 (m, 8H), 7.20-7.16 (m, 1H), 4.66-4.55 (m, 1H), 4.44-4.34(m,1H),3.20-3.00(m,1H),2.50-2.32(m,1H),1.98-1.80(m, 1H),1.22-1.02(m,1H),0.85(t,J=7.7Hz,3H),0.77(d,J=6.3Hz,3H); Calculate C 26 H 25 ClN4O4S, 524.13; observed (M+H) + 525.8.
[1206] Example 36: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(pyridin-3-ylsulfonyl)acetamide:
[1207]
[1208] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except using pyridine-3-sulfonamide instead of sulfonamide, and then purified by HPLC to give 25.3 mg of the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 8.34-8.28 (m, 1H), 7.54-7.23 (m, 10H), 7.21-7.19 (m, 1H), 4.48-4.38 (m, 1H), 4.28-4.18 (m, 1H), 3. 09(d,J=10.5Hz,1H),2.44-2.26(m,1H),1.98-1.80(m,1H),1.22-1.00(m,1H),0.85(t,J=7.4Hz,3H),0.72(d,J=6.3Hz,3H); Calculate C 26 H 25 ClN4O4S, 524.13; observed (M+H) + 525.8.
[1209] Example 37: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(pyridin-4-ylsulfonyl)acetamide:
[1210]
[1211] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except using pyridine-4-sulfonamide instead of sulfonamide, and purified by HPLC to give 26.3 g of the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 8.78-8.70 (m, 1H), 7.87-7.80 (m, 2H), 7.54-7.28 (m, 8H), 7.22-7.18 (m, 1H), 4.48-4.39 (m, 1H), 4.27-4.18 ( m,1H),3.10(d,J=9.9Hz,1H),2.44-2.28(m,1H),1.98-1.80(m,1H),1.16-0.98(m,1H),0.86(t,J=7.4Hz,3H),0.74(d,J=6.3Hz,3H); Calculate C 26 H 25 ClN4O4S, 524.13; observed (M+H) + 525.8.
[1212] Example 38: Synthesis of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((2-fluorophenyl)sulfonyl)acetamide:
[1213]
[1214] The title compound was prepared according to the procedure of 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoyl acetamide, except that 2-fluorobenzenesulfonamide was used instead of sulfonamide, and then purified by HPLC followed by preparative TLC to give 14.0 mg of the title compound. Calculated C 27 H 25 ClFN3O4S, 541.12; observed (M+H) + 542.8.
[1215] Example 39: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide:
[1216]
[1217] 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid (20 mg, 0.05 mmol, 1 eq), sulfonamide (5 mg, 1.1 eq), 1.5 eq of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (14 mg, 0.08 mmol), hydroxybenzotriazole (12 mg, 0.08 eq) and excess N,N-diisopropylethylamine (35 mL, 0.2 mmol) were added to the intermediate in CHCl and stirred for 18 hours. The reaction product was then purified by HPLC to give the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.60-7.34 (m, 7H), 7.25-7.22 (m, 1H), 4.50-4.38 (m, 1H), 3.94-3.82 (m, 1H), 3.14-3.07 (m, 1 H),2.68-2.54(m,1H),2.54-2.42(m,1H),2.42-2.30(m,1H),1.98-1.85(m,1H),1.64-1.50(m,1H),1.12-0.86(m,6H); Calculate C 22 H 25 ClN4O4S, 476.13; observed (M+H) + 477.7.
[1218] Example 40: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(N,N-dimethylsulfamoyl)propionamide:
[1219]
[1220] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except using N,N-dimethylsulfonamide instead of sulfonamide, and then purified by HPLC to give the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 7.56-7.48 (m, 3H), 7.45-7.34 (m, 4H), 7.24-7.22 (m, 1H), 4.40-4.30 (m, 1H), 4.00-3.85 (m ,1H),3.12-3.05(m,1H),2.75(s,6H),2.55-2.30(m,3H),2.00-1.80(m,1H),1.65-1.50(m,1H),1.10-0.86(m,6H); Calculate C 24 H 26 ClN4O4S, 504.16; observed (M+H) + 505.7.
[1221] Example 41: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(tert-butylsulfonyl)propionamide:
[1222]
[1223] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except that tert-butylsulfonamide was used instead of sulfonamide, and then purified by HPLC to give the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.60-7.34 (m, 7H), 7.24-7.18 (m, 1H), 4.40-4.30 (m, 1H), 4.00-3.90 (m, 1H), 3.1 8-3.08(m,1H),2.60-2.40(m,3H),2.00-1.80(m,1H),1.65-1.50(m,1H),1.30(s,9H),1.12-0.86(m,6H); Calculate C 26 H 32 ClN3O4S, 517.18; observed (M+H) + 518.7.
[1224] Example 42: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(cyclopropylsulfonyl)propionamide:
[1225]
[1226] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except that cyclopropanesulfonamide was used instead of sulfonamide, and then purified by HPLC with a gradient of acetonitrile in water from 10% to 90% to give the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.62-7.34 (m, 7H), 7.25-7.10 (m, 1H), 4.44-4.30 (m, 1H), 4.00-3.88 (m, 1H),3.15-3.08(m,1H),2.66-2.40(m,4H),2.00-1.80(m,1H),1.65-1.50(m,1H),1.24-0.74(m,10H). Calculate C 25 H 28 ClN3O4S, 501.15; observed (M+H) + 502.7.
[1227] Example 43: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)propionamide:
[1228]
[1229] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except using benzenesulfonamide instead of sulfonamide, and then purified by HPLC to give the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.94-7.88 (m, 2H), 7.58-7.28 (m, 10H), 7.21-7.17 (m, 1H), 4.30-4.18 (m, 1H), 3.90-3.76 (m, 1 H),3.10-3.02(m,1H),2.54-2.36(m,2H),2.31-2.18(m,1H),2.00-1.80(m,1H),1.60-1.45(m,1H),1.08-0.86(m,6H); Calculate C 28 H 28 ClN3O4S, 537.15; observed (M+H) + 538.7.
[1230] Example 44: Synthesis of N-(benzylsulfonyl)-3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanamide:
[1231]
[1232] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except using α-toluenesulfonamide instead of sulfonamide, and then purified by HPLC to give the title compound. 1 H NMR (300 MHz, CDCl3): δ (ppm) 7.61-7.49 (m, 3H), 7.42-7.30 (m, 5H), 7.30-7.20 (m, 3H), 7.17-7.15 (m, 2H), 4.40-4.18 (m, 3H), 3.96-3.84 (m, 1H), 3.14-3.07 (m, 1H), 2.54-2.36 (m, 3H), 2.00-1.80 (m, 1H), 1.64-1.45 (m, 1H), 1.12-0.88 (m, 6H); calculated for C 29 H 30 ClN3O4S, 551.16; observed (M+H) + 552.8.
[1233] Example 45: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)propionamide (62059I):
[1234]
[1235] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except that thiophene-2-sulfonamide was used instead of sulfonamide, and then purified by HPLC with a gradient of acetonitrile in water from 65% to 75% to give the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 7.78-7.73 (m, 1H), 7.62-7.57 (m, 1H), 7.55-7.32 (m, 7H), 7.24-7.20 (m, 1H), 7.05-7.00 (m, 1H), 4.36- 4.20(m,1H),3.95-3.82(m,1H),3.12-3.04(m,1H),2.60-2.00(m,3H),2.00-1.80(m,1H),1.64-1.45(m,1H),1.12-0.87(m,6H); Calculate C 26 H 26 ClN3O4S2, 543.11; observed (M+H) + 544.7.
[1236] Example 46: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((5-chlorothiophen-2-yl)sulfonyl)propionamide:
[1237]
[1238] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except using 5-chlorothiophene-2-sulfonamide instead of sulfonamide, and then purified by HPLC with a gradient of 70% to 82% over 11 minutes to give the title compound. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.56-7.34 (m, 8H), 7.24-7.21 (m, 1H), 6.86-6.83 (m, 1H), 4.40-4.26 (m, 1H), 3.95- 3.83(m,1H),3.13-3.06(m,1H),2.60-2.20(m,3H),2.00-1.80(m,1H),1.64-1.45(m,1H),1.12-0.88(m,6H); Calculate C 26 H 25 Cl2N3O4S2, 577.07; observed (M+H) + 578.7.
[1239] Example 47: Synthesis of 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-((1-methyl-1H-imidazol-4-yl)sulfonyl)propionamide:
[1240]
[1241] The title compound was prepared according to the procedure for preparing 3-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide, except using 1-methylimidazole-2-sulfonamide instead of sulfonamide, and then purified by HPLC with a gradient of 60% to 67% over 8 minutes to give the title compound. 1 HNMR (300MHz, CDCl3): δ (ppm) 7.54-7.29 (m, 9H), 7.21-7.18 (m, 1H), 4.40-4.26 (m, 1H), 3.90-3.79 (m, 1H), 3. 66(s,3H),3.10-3.03(m,1H),2.60-2.30(m,3H),2.00-1.80(m,1H),1.60-1.50(m,1H),1.10-0.86(m,6H); Calculate C 26 H 28 ClN5O4S, 541.16; observed (M+H) + 542.8.
[1242] Example 48: Synthesis of 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide ()
[1243]
[1244] At 0 ° C, 3 equivalents of sodium triacetoxyborohydride (24 mg, 0.12 mmol) were added to 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide (20 mg, 0.04 mmol) in 1,2-dichloroethane. The reaction was allowed to reach 23 ° C and stirred for 4 days. Sodium cyanoborohydride (2 equivalents) was added to slow the reaction further. After the reaction was complete, the reaction was quenched with saturated NaHCO3 and then purified by HPLC with a gradient of 55% to 61% over 6 minutes to give the title compound. 1H NMR (300MHz, CDCl3): δ (ppm) 8.03-7.97 (m, 2H), 7.61-7.53 (m, 1H), 7.51-7.31 (m, 7H), 7.24-7.18 (m, 1H), 7.11-7.06 (m, 1H), 6.54 (d, J = 2. 4Hz,1H),5.47(s,1H),4.45(s,2H),3.12(d,J=9.3Hz,1H),1.90-1.75(m,1H),1.72-1.58(m,1H),1.24-1.06(m,1H),0.86-0.72(m,6H); Calculate C 27 H 28 ClN3O4S, 525.15; observed (M+H) + 526.8.
[1245] Example 49: Synthesis of 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)acetamide ():
[1246]
[1247] The title compound was prepared according to the procedure of 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide using 2-((S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide to provide the title compound. 1 HNMR (300MHz, CDCl3): δ (ppm) 7.82-7.79 (m, 1H), 7.62-7.58 (m, 1H), 7.50-7.4 4(m,2H),7.42-7.32(m,3H),7.25-7.18(m,1H),7.12-7.06(m,1H),7.05-7.00( m,1H),6.57-6.3(m,1H),5.55(s,1H),4.56-4.40(m,2H),3.17-3.10(m,1H),1 .92-1.78(m,1H),1.74-1.58(m,1H),1.22-1.06(m,1H),0.86-0.74(m,6H); Calculate C 25 H 26 ClN3O4S2, 531.11; observed (M+H) + 532.7.
[1248] Example 50: 3-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)propionamide (Isomer 1) and 3-((3R)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4-5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)propionamide (Isomer 2):
[1249]
[1250] 3-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)propionamide (Isomer 1) and 3-((3R)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4-5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)propionamide (Isomer 2): The title compound was prepared according to the procedure for 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4-5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide using 3-((S)-3-(S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)propionamide to provide two isomers. Isomer 1: 1 H NMR (300MHz, CDCl3): δ (ppm) 8.00-7.94 (m, 2H), 7.56-7.49 (m, 1H), 7.46-7.34 (m,7H),7.25-7.18(m,1H),7.16-7.10(m,1H),6.54-6.50(m,1H),5.10(s,1H) ,4.36-4.24(m,1H),3.90-3.76(m,1H),2.98-2.93(m,1H),2.80-2.40(m,3H)1 .98-1.84(m,1H),1.40-1.30(m,1H),1.00-0.94(m,3H),0.87-0.76(m,3H); Calculate C 28 H 30 ClN3O4S, 539.16; observed (M+H) + 540.8. Isomer-2. 1H NMR (300MHz, CDCl3): δ (ppm) 8.00-7.95 (m, 2H), 7.56-7.49 (m, 1H), 7.45-7.32 (m, 7H) ,7.25-7.18(m,1H),7.16-7.10(m,1H),6.52(d,J=2.1Hz,1H),5.10(s,1H),4.36-4.2 4 (m, 1H), 3.88-3.76 (m, 1H), 2.96 (d, J = 9.3 Hz, 1H), 2.80-2.76 (m, 1H), 2.74-2.40 (m, 1H), 1.96-1.84 (m, 1H), 1.74-1.60 (m, 1H), 1.20-1.06 (m, 1H), 0.88-0.80 (m, 6H); calculated for C 28 H 30 ClN3O4S, 539.16; observed (M+H) + 540.8.
[1251] Example 51: 3-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)propanamide (Isomer 1) and 3-((3R)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4-5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)propanamide (Isomer 2).
[1252]
[1253] The title compound was prepared according to the procedure of 2-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide using 3-((S)-3-(S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)propanamide to provide two isomers. 3-((3S)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4-5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)propionamide (Isomer 1): 1H NMR (300MHz, CDCl3): δ (ppm) 7.80-7.76 (m, 1H), 7.58-7.54 (m, 1H), 7.44-7.30 (m, 6H) ,7.21-7.13(m,1H),7.01-6.96(m,1H),6.54-6.50(m,1H),5.04(s,1H),4.37-4.24(m, 1H), 3.94-3.80 (m, 1H), 2.95 (d, J = 9.3 Hz, 1H), 2.86-2.72 (m, 1H), 2.70-2.40 (m, 1H), 2.00-1.82 (m, 2H), 1.42-1.28 (m, 1H), 0.96 (d, J = 6.3 Hz, 3H), 0.80 (t, J = 7.2 Hz, 3H); calculated for C 26 H 28 ClN3O4S2, 545.12; observed (M+H) + 546.8. 3-((3R)-3-((S)-sec-butyl)-7-chloro-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(thiophen-2-ylsulfonyl)propionamide (Isomer 2): 1 H NMR (300MHz, CDCl3): δ (ppm) 7.82-7.76 (m, 1H), 7.59-7.54 (m, 1H), 7.44-7.28 (m, 6H ),7.22-7.15(m,1H),7.03-6.96(m,1H),6.58-6.52(m,1H),5.09(s,1H),4.40-4.26 (m, 1H), 3.94-3.82 (m, 1H), 3.00 (d, J = 9.3 Hz, 1H), 2.84-2.72 (m, 1H), 2.70-2.40 (m, 1H), 1.98-1.85 (m, 1H), 1.76-1.60 (m, 1H), 1.22-1.06 (m, 1H), 0.90-0.80 (m, 6H); calculated for C 26 H 28 ClN3O4S2, 545.12; observed (M+H) + 546.8.
[1254] Example 52: Synthesis of 3-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid:
[1255]
[1256] One equivalent of 2-((tert-Butyloxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid (112 mg, 0.43 mmol, 1 equivalent) and 1.2 equivalents of N,N-dicyclohexylcarbodiimide (107 mg) were added to (2-amino-5-chlorophenyl)(phenyl)methanone (100 mg, 1.43 mmol) in toluene. After completion of the reaction, the reaction was filtered and the filtrate was redissolved in formic acid to remove the Boc group. The formic acid was evaporated and the reaction was redissolved in methanol and stirred for 18 hours. After completion, the cyclization reaction was purified by HPLC to give the intermediate 7-chloro-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one (42.5 mg) as a yellow sticky solid. To the intermediate (20 mg, 0.06 mmol) in acetonitrile were added 2 equivalents of potassium carbonate (16 mg), 1.6 equivalents of ethyl 3-bromopropionate (10 mL), and 0.5 equivalents of benzyltributylammonium bromide (9 mg). The reaction was heated to 90°C for 3 days. Upon completion, purification by Combi-Flash (30% ethyl acetate in hexanes) afforded ethyl 3-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate (16.1 mg) as a clear oil. The intermediate was treated with 3 equivalents of 1M LiOH in tetrahydrofuran and stirred for 18 hours. The reaction was purified by HPLC with a gradient of 50% to 54% over 10 minutes to give 3-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.58-7.53 (m, 2H), 7.53-7.34 (m, 5H), 7.30-7.25 (m, 1H), 4.52-4.47 (m, 2H), 4.08-3.99 (m, 1H) ,3.97-3.88(m,1H),3.62-3.48(m,2H),3.27(d,J=9.6Hz,1H),2.30-2.40(m,1H),1.99-1.72(m,2H),1.36-1.14(m,2H); Calculate C 23 H 23 ClN2O4, 426.13; observed (M+H) + 427.6.
[1257] Example 53: Synthesis of 2-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid
[1258]
[1259] According to the preparation procedure of compound 3-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid, the intermediate 7-chloro-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one (16 mg, 0.046 mmol) was treated with 2 equivalents of potassium carbonate (31 mg, 0.24 mmol), 1.6 equivalents of methyl 2-bromoacetate (6 μl, 0.068 mmol) and 0.5 equivalents of benzyltributylammonium bromide (8 mg, 0.023 mmol) in acetonitrile. After Combi-Flash purification using a 30% ethyl acetate in hexanes gradient, the resulting intermediate, methyl 2-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate, was dissolved in tetrahydrofuran and treated with 3 equivalents of 1M LiOH. Upon completion, the reaction was purified by HPLC to yield 2-(7-chloro-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.58-7.53 (m, 2H), 7.53-7.34 (m, 5H), 7.30-7.25 (m, 1H), 4.52-4.47 (m, 2H), 4.08-3.99 (m, 1H) ,3.97-3.88(m,1H),3.62-3.48(m,2H),3.27(d,J=9.6Hz,1H),2.30-2.40(m,1H),1.99-1.72(m,2H),1.36-1.14(m,2H); Calculate C 22 H 21 ClN2O4, 412.12; observed (M+H) + 413.6.
[1260] Example 54: Synthesis of (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)propionamide
[1261]
[1262] 1.1 equivalents of methanesulfonamide (3 mg), 1.1 equivalents of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (5 mg), 1.1 equivalents of hydroxybenzotriazole (4 mg) and excess N,N-diisopropylethylamine (2 equivalents) were added to (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid in CHCl. Upon completion, the reaction was purified by HPLC using a gradient from 70% to 80% over 10 minutes to give the product (5.4 mg). 1 H NMR (300MHz, CDCl3): δ (ppm) 7.60-7.50 (m, 3H), 7.50-7.35 (m, 4H), 7.25-7.22 (m, 1H), 4.42-4.30 (m, 1H), 3.98-3.86 (m, 1H), 3.25 (d, J=9.9Hz,1H),2.52-2.36(m,3H),1.84-1.70(m,1H),1.66-1.52(m,1H),1.52-1.37(m,1H),1.34-1.16(m,1H),0.88-0.74(m,6H); Calculate C- 24 H 28 ClN3O4S, 489.15; observed (M+H) + 490.8.
[1263] Example 55: Synthesis of (S)-N-(benzylsulfonyl)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanamide:
[1264]
[1265] According to the preparation process of compound (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)propionamide, the intermediate (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propionic acid Treatment with 1.1 equivalents of α-toluenesulfonamide, 1.1 equivalents of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and 1.1 equivalents of hydroxybenzotriazole, followed by purification by HPLC, gave (S)-N-(phenylsulfonyl)-3-(7-chloro-2-oxy-3-(pentan-3-yl)-5-benzo-2,3-dihydroxy-1H-benzoic acid [e][1.4]diazetidin-1-yl)propanamide. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.60-7.50 (m, 3H), 7.45-7.32 (m, 4H), 7.32-7.23 (m, 4H), 7.20-7.20 (m, 1H), 4.36-4.16 (m, 3H), 3.97-3.82 (m, 1H) ,3.26(d,J=9.9Hz,1H),2.50-2.30(m,3H),1.85-1.70(m,1H),1.67-1. 53(m,1H),1.53-1.36(m,1H),1.36-1.16(m,1H),0.90-0.72(m,6H); Calculate C 30 H 32 ClN3O4S, 565.18; observed (M+H) + 566.9.
[1266] Example 56: Synthesis of (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide:
[1267]
[1268] According to the preparation process of compound (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine-1-yl)-N-(methylsulfonyl)propionamide, the intermediate (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine-1 -yl)propanoic acid was treated with 1.1 equivalents of sulfonamide, 1.1 equivalents of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and 1.1 equivalents of hydroxybenzotriazole, followed by purification by HPLC to give (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-sulfamoylpropionamide. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.62-7.50 (m, 3H), 7.50-7.35 (m, 4H), 7.25-7.20 (m, 1H), 4.50-4.34 (m, 1H), 3.95-3.80 (m, 1H), 3.25 (d, J = 9.9Hz, 1H),2.68-2.54(m,1H),2.48-2.30(m,2H),1.84-1.69(m,1H),1.65-1. 51(m,1H),1.51-1.37(m,1H),1.30-1.16(m,1H),0.90-0.72(m,6H); Calculate C 23 H 27 ClN4O4S, 490.14; observed (M+H) + 491.8.
[1269] Example 57: Synthesis of (S)-2-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)acetamide:
[1270]
[1271] 1.1 equivalents of methanesulfonamide, 1.1 equivalents of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, 1.1 equivalents of hydroxybenzotriazole, and excess N,N-diisopropylethylamine were added to (S)-2-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid in CHCl. Upon completion, the reaction was purified by HPLC to give (S)-2-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)acetamide. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.62-7.55 (m, 2H), 7.55-7.30 (m, 6H), 4.56-4.46 (m, 1H), 4.32-4.24 (m, 1H), 3.43-3.37 (m, 1H), 3.24- 3.20(m,3H),2.50-2.36(m,1H),1.90-1.70(m,1H),1.70-1.52(m,1H),1.52-1.37(m,1H),1.37-1.20(m,1H),0.89-0.78(m,6H); Calculate C 23 H 26 ClN3O4S, 475.13; observed (M+H) + 476.7.
[1272] Example 58: Synthesis of (S)-2-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide:
[1273]
[1274] According to the preparation process of compound (S)-2-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)acetamide, the intermediate (S)-3-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(methylsulfonyl)acetamide was prepared. )propionic acid was treated with 1.1 equivalents of benzenesulfonamide, 1.1 equivalents of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and 1.1 equivalents of hydroxybenzotriazole, followed by purification by HPLC to give (S)-2-(7-chloro-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)-N-(phenylsulfonyl)acetamide.1 H NMR (300MHz, CDCl3): δ (ppm) 8.01-7.95 (m, 2H), 7.60-7.29 (m, 10H), 7.22-7.19 (m, 1H), 4.52-4.44 (m, 1H), 4.24-4.12 (m, 1H) ,3.25(d,J=10.5Hz,1H),2.38-2.25(m,1H),1.80-1.66(m,1H),1.63-1.46(m,1H),1.30-1.06(m,2H),0.82-0.66(m,6H); Calculate C- 28 H 28 ClN3O4S, 537.15; observed (M+H) + 538.8.
[1275] Example 59: Synthesis of 2-((S)-3-((R)-1-(tert-butoxy)ethyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid:
[1276]
[1277] Step 1: (S)-4-((R)-1-(tert-Butoxy)ethyl)oxazolidine-2,5-dione: A round-bottom flask equipped with a magnetic stir bar, condenser, and N2 inlet was charged with (2S,3R)-2-amino-3-(tert-butoxy)butanoic acid (265 mg, 1.515 mmol) in anhydrous tetrahydrofuran (3 mL) and heated at 50°C. A solution of triphosgene (150 mg, 0.505 mmol) in anhydrous tetrahydrofuran (5 mL) was added to the reaction via a dropping funnel, and the reaction mixture was heated at reflux for 3 hours. The reaction mixture was cooled to 23°C and evaporated to dryness (bath temperature off) to give (S)-4-((R)-1-(tert-butoxy)ethyl)oxazolidine-2,5-dione (2) as a white solid (304 mg, 100% yield), which was used in the next step without further purification.
[1278]
[1279] Step 2: (S)-3-((R)-1-(tert-Butoxy)ethyl)-7-chloro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one and (S)-7-chloro-3-((R)-1-hydroxyethyl)-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one: In a round-bottom flask equipped with a magnetic stir bar, condenser, and N2 inlet, (S)-4-((R)-1-(tert-Butoxy)ethyl)oxazolidine-2,5-dione (304 mg, 1.5123 mmol) and 2-amino-5-chlorobenzophenone (292 mg, 1.2603 mmol) in anhydrous toluene (8 mL) were added. Trifluoroacetic acid (TFA) (0.194 mL, 2.5206 mmol) was added to the reaction mixture and stirred at 65°C for 18 hours. To the reaction mixture was then added triethylamine (Et3N) (0.35 mL, 2.5206 mmol) and stirred at 80°C for 3 hours. The reaction mixture was cooled to 23°C, evaporated, quenched with 1N HCl and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO3 solution and brine solution, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by Combi-Flash (0-30% ethyl acetate in dichloromethane) to give (S)-3-((R)-1-(tert-butoxy)ethyl)-7-chloro-5-phenyl-1H-benzo[e][1,4]diazepine-2(3H)-one (4,66-04-OtBu, 35 mg, 7.5% yield) as an off-white solid; calculated C 21 H 23 ClN2O2, 370.14; observed (M+H) + 371.6 and (S)-7-chloro-3-((R)-1-hydroxyethyl)-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (5,66-04-OH, 60 mg, 15.2% yield), as a colorless liquid; calculated C 17 H 15 ClN2O2, 314.08; observed (M+H) + 315.5.
[1280]
[1281] Step 3: To a round-bottom flask equipped with a magnetic stir bar and N2 inlet was added (S)-3-((R)-1-(tert-butoxy)ethyl)-7-chloro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (4, 35 mg, 0.0943 mmol) in anhydrous acetonitrile (2 mL). Benzyltributylammonium bromide (16.8 mg, 0.0471 mmol), potassium carbonate (65.1 mg, 0.4715 mmol) and methyl 2-bromoacetate (0.014 mL, 0.1414 mmol) were added to the reaction mixture and stirred at 23°C for 18 hours. The reaction mixture was filtered and evaporated on a rotary evaporator. The resulting material was purified by Combi-Flash (0-30% ethyl acetate in hexanes) to afford methyl 2-((S)-3-((R)-1-(tert-butoxy)ethyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (30 mg) as a colorless liquid. 24 H 27 ClN2O4, 442.17; observed (M+H) + 443.7.
[1282]
[1283] Step 4: To a round-bottom flask equipped with a magnetic stir bar was added methyl 2-((S)-3-((R)-1-(tert-butoxy)ethyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (6, 30 mg, 0.0677 mmol) in tetrahydrofuran (2 mL). Aqueous LiOH·H2O (1 M) solution (0.20 mL, 0.203 mmol) was added to the reaction mixture and stirred at 23°C for 18 hours. LC-MS showed the desired product. The reaction mixture was concentrated on a rotary evaporator. The crude product was purified by preparative HPLC to give the desired product, 2-((S)-3-((R)-1-(tert-butoxy)ethyl)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (20 mg) as an off-white solid. 1 H NMR (300 MHz, CDCl3): δ (ppm) 7.56-7.61 (m, 3H), 7.45-7.50 (m, 2H), 7.28-7.33 (m, 3H), 4.74-4.81 (m, 1H), 4.59-4.68 (m, 1H), 4.43-4.52 (m, 1H), 3.69 (d, J = 9.37 Hz, 1H), 1.39 (s, 9H), 1.33 (d, J = 5.86 Hz, 3H); observed (M+H)+ 429.7.
[1284] Example 60: Synthesis of 2-((S)-7-chloro-3-((R)-1-hydroxyethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid
[1285]
[1286] Step 1: 2-((S)-7-chloro-3-((R)-1-hydroxyethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (7): In a round-bottom flask equipped with a magnetic stir bar and N2 inlet was added (S)-7-chloro-3-((R)-1-hydroxyethyl)-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (5, 30 mg, 0.0953 mmol) in dry N,N-dimethylformamide (1.5 mL). The resulting solution was cooled to 0°C, K2CO3 (26.3 mg, 0.1906 mmol) and ethyl 2-bromoacetate (0.012 mL, 0.1143 mmol) were added to the reaction mixture and stirred at 0°C for 2 hours. The reaction mixture was quenched with ice water and extracted with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated on a rotary evaporator. The crude product was purified by Combi-Flash (0-30% ethyl acetate in hexanes) to give ethyl 2-((S)-7-chloro-3-((R)-1-hydroxyethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (27 mg) as a colorless liquid. Calculated C 21 H 21 ClN2O4, 400.12; observed (M+H) + 401.6.
[1287]
[1288] Step 2: 2-((S)-7-Chloro-3-((R)-1-hydroxyethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid: The title compound was prepared using 2-((S)-7-chloro-3-((R)-1-hydroxyethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate according to the procedure for 2-((S)-3-(S)-sec-butyl)-5-(4-fluorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate to give the title compound as an off-white solid in 48% yield. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.63 (dd, J = 13.47, 8.20Hz, 2H), 7.57 (d, J = 7.62Hz, 2H), 7.44-7.50 (m, 2H), 7.35 (d, J = 8.79Hz, 1H), 7 .30(d,J=1.76Hz,1H),4.61–4.76(m,2H),4.58(br.s,1H),4.37-4.45(m,1H),3.68(d,J=6.44Hz,1H),1.30(d,J=5.86Hz,3H); Calculate C 19 H 17 ClN2O4, 372.09; observed (M+H) + 373.5.
[1289] Example 61: Synthesis of (S)-2-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid
[1290]
[1291] Step 1: (S)-2-amino-2-cyclopropylacetic acid (174 mg, 1.515 mmol) in anhydrous tetrahydrofuran (3 mL) was added to a round-bottom flask equipped with a magnetic stir bar, a condenser, and an N2 inlet and heated at 50°C. Triphosgene (150 mg, 0.505 mmol) in anhydrous tetrahydrofuran (5 mL) was added to the reaction via a dropping funnel, and the reaction mixture was heated under reflux for 3 hours. The reaction mixture was cooled to 23°C and evaporated to dryness to afford (S)-4-cyclopropyloxazolidine-2,5-dione (213 mg) as a white solid, which was used directly in the next step without further purification.
[1292]
[1293] Step 2: To a round-bottom flask equipped with a magnetic stir bar, condenser, and N2 inlet was added (S)-4-cyclopropyloxazolidine-2,5-dione (212 mg, 1.502 mmol) and 2-amino-5-chlorobenzophenone (290 mg, 1.2517 mmol) in anhydrous toluene (8 mL). Trifluoroacetic acid (TFA) (0.192 mL, 2.5034 mmol) was added to the reaction mixture and stirred at 65°C for 18 hours. Triethylamine (Et3N) (0.35 mL, 2.5034 mmol) was then added to the reaction mixture and stirred at 80°C for 3 hours. The reaction mixture was cooled to 23°C, evaporated, quenched with 1N HCl, and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO3 solution and brine solution, dried over anhydrous Na2SO4, and concentrated on a rotary evaporator. The crude product was purified by Combi-Flash (0-30% ethyl acetate in hexanes) to give (S)-7-chloro-3-cyclopropyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (210 mg) as an off-white solid; calculated C 18 H 15 ClN2O, 310.09; observed (M+H) + 311.5.
[1294]
[1295] Step 3: To a round-bottom flask equipped with a magnetic stir bar and N2 inlet was added (S)-7-chloro-3-cyclopropyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (30 mg, 0.0965 mmol) in anhydrous acetonitrile (2 mL). Benzyltributylammonium bromide (17 mg, 0.0482 mmol), potassium carbonate (66 mg, 0.4825 mmol) and methyl 2-bromoacetate (0.014 mL, 0.1447 mmol) were added to the reaction mixture and stirred at 23°C for 18 hours. The reaction mixture was filtered and evaporated on a rotary evaporator. The crude product was purified by Combi-Flash (0-30% ethyl acetate in hexanes) to give (S)-methyl 2-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (32 mg) as a white solid. 21 H 19 ClN2O3, 382.11; observed (M+H) + 383.6.
[1296]
[1297] Step 4: To a round-bottom flask equipped with a magnetic stir bar was added (S)-methyl 2-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (32 mg, 0.0835 mmol) in tetrahydrofuran (2 mL). Aqueous LiOH·H2O (1 M) solution (0.25 mL, 0.2507 mmol) was added to the reaction mixture and stirred at 23°C for 18 hours. The reaction mixture was concentrated on a rotary evaporator. The crude product was purified by preparative HPLC to give (S)-2-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (13 mg) as an off-white solid. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.62 (d, J = 7.62Hz, 4H), 7.45-7.50 (m, 3H), 7.37 (d, J = 8.79Hz, 1H), 4.66-4.74 (m, 1H), 4.4 4-4.51(m,1H),3.12(d,J=8.79Hz,1H),1.82-1.89(m,1H),0.76-0.85(m,2H),0.37-0.43(m,1H),0.19-0.27(m,1H); Calculate C 20 H 17 ClN2O3, 368.09; observed (M+H) + 369.5.
[1298] Example 62: Synthesis of ethyl (S)-3-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate
[1299]
[1300] Step 1: To a round-bottom flask equipped with a magnetic stir bar, condenser, and N2 inlet was added (S)-7-chloro-3-cyclopropyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (30 mg, 0.0965 mmol) in anhydrous acetonitrile (2 mL). Benzyltributylammonium bromide (17 mg, 0.0482 mmol), potassium carbonate (66 mg, 0.4825 mmol), and ethyl 3-bromopropionate (0.018 mL, 0.1447 mmol) were added to the reaction mixture and stirred at 90°C for 18 hours. The reaction mixture was filtered and evaporated on a rotary evaporator. The crude product was purified by Combi-Flash (0-30% ethyl acetate in hexanes) to give (S)-ethyl 3-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate (37 mg) as a colorless gum. 23 H 23 ClN2O3, 410.14; observed (M+H) + 411.7.
[1301]
[1302] Step 2: (S)-3-(7-Chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid: The title compound was prepared using 3-(7-chloro-3-cyclopropyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate according to the procedure of 2-((S)-3-(S)-sec-butyl)-8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid to give the title compound as a light yellow solid in 75% yield. 1 H NMR (300MHz, CDCl3): δ (ppm) 7.74 (d, J = 9.37Hz, 1H), 7.65 (d, J = 7.03Hz, 2H), 7.44-7.55 (m, 4H), 7.27-7.31 (m, 1H), 4.82-4.93 (m, 1H), 3.83-3.95 (m ,1H),3.02(d,J=9.96Hz,1H),2.65-2.74(m,1H),2.33-2.43(m,1H),1.91- 2.00(m,1H),0.83-0.96(m,2H),0.34-0.43(m,1H),0.17-0.27(m,1H); Calculate C 21 H 19 ClN2O3, 382.11; observed (M+H)+ 383.6.
[1303] Example 63: Synthesis of 2-(7-chloro-2-oxo-5-phenyl-3-(trifluoromethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid:
[1304]
[1305] Step 1: 4-(Trifluoromethyl)oxazolidine-2,5-dione: The title compound was prepared according to the procedure for (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione using 2-amino-3,3,3-trifluoropropionic acid.
[1306]
[1307] The title compound was prepared according to the method of (S)-3-((S)-sec-butyl)-9-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one using 4-(trifluoromethyl)oxazolidine-2,5-dione and (2-amino-5-chlorophenyl)(phenyl)methanone to afford the title compound as an off-white solid in 13% yield. Calculated C 16 H 10 ClF3N2O, 338.04; observed (M+H) + 339.5.
[1308]
[1309] Step 3: To a round-bottom flask equipped with a magnetic stir bar and N2 inlet was added 7-chloro-5-phenyl-3-(trifluoromethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one (15, 38 mg, 0.112 mmol) in anhydrous acetonitrile (2 mL). Benzyltributylammonium bromide (8 mg, 0.022 mmol), potassium carbonate (23 mg, 0.168 mmol) and tert-butyl 2-chloroacetate (0.017 mL, 0.123 mmol) were added to the reaction mixture and stirred at 23°C for 5 hours. The reaction mixture was filtered and evaporated on a rotary evaporator. The crude product was purified by Combi-Flash (0-30% ethyl acetate in hexanes) to give tert-butyl 2-(7-chloro-2-oxo-5-phenyl-3-(trifluoromethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (23 mg) as a colorless liquid. 22 H 20 ClF3N2O3, 452.11; observed (M+H) + 453.7.
[1310]
[1311] Step 4: To a round-bottom flask equipped with a magnetic stir bar was added 2-(7-chloro-2-oxo-5-phenyl-3-(trifluoromethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate (16, 23 mg, 0.050 mmol) in CHCl (4 mL). Trifluoroacetic acid (TFA) (1 mL) was added to the reaction mixture and stirred at 23 °C for 3 hours. The reaction mixture was concentrated on a rotary evaporator. The crude product was purified by preparative HPLC to give the desired product, 2-(7-chloro-2-oxo-5-phenyl-3-(trifluoromethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (12 mg), as an off-white solid. 1 H NMR (300 MHz, MeOD): δ (ppm) 7.60-7.72 (m, 3H), 7.52-7.59 (m, 2H), 7.43-7.50 (m, 2H), 7.29 (d, J = 2.34 Hz, 1H), 4.73-4.81 (m, 1H), 4.58-4.61 (m, 1H), 4.53-4.57 (m, 1H); calculated for C 18 H 12 ClF3N2O3, 396.05; observed (M+H) + 397.6.
[1312] Example 64: Synthesis of (S)-3-(2-oxo-3-(pentan-3-yl)-5,7-diphenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoic acid
[1313]
[1314] Step 1: (S)-4-(Pentan-3-yl)oxazolidine-2,5-dione: Prepare the title compound according to the procedure for (S)-3-((S)-sec-butyl)-9-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one using (S)-2-amino-3-ethylpentanoic acid to give the title compound as a colorless liquid. Calculation of C 25 H 29 BrN2O3, 484.14; observed (M+H) + 485.8.
[1315]
[1316] Step 2: (S)-7-Bromo-3-(pentan-3-yl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one: Prepare the title compound according to the procedure for (S)-3-((S)-sec-butyl)-9-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one using (S)-4-(pentan-3-yl)oxazolidine-2,5-dione and (2-amino-5-bromophenyl)(phenyl)methanone to give the title compound as a colorless liquid. Calculation of C 25 H 29 BrN2O3, 484.14; observed (M+H) + 485.8.
[1317]
[1318] Step 3: Ethyl (S)-3-(7-bromo-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate (21,67-82): The title compound was prepared according to the procedure for ethyl 2-((S)-3-((S)-sec-butyl)-9-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetate using (S)-7-bromo-3-(pentan-3-yl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one and ethyl 3-bromopropanoate to give the title compound as a colorless liquid. Calculation of C 25 H 29 BrN2O3, 484.14; observed (M+H) + 485.8.
[1319]
[1320] Step 4: To a sealable tube was added ethyl (S)-3-(7-bromo-2-oxo-3-(pentan-3-yl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)propanoate (40 mg, 0.0826 mmol), phenylboronic acid (15 mg, 0.1239 mmol) and potassium carbonate (KCO) (17 mg, 0.1239 mmol) in 1,4-dioxane:HO (1.6:0.4 mL). The mixture was then degassed with argon for 5 minutes, after which bis(triphenylphosphi...
Claims
1. A compound having formula (I): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, isotope analogs, prodrugs and complexes thereof, in: A Choose freedom as well as The group composed of; When A is When , m is 0; When A is When , n is selected from 0 and 1; R 1 Selected from the group consisting of C3-7 cycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl; When A is When , m is selected from 0 and 1; When A is When n, n is selected from 0 and 1; R 2 Selected from the group consisting of C3-C8 cycloalkyl, C4-C10 bicycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl; When A is When , m is selected from 0 and 1; When A is When , n is selected from 0 and 1; R 3 Selected from the group consisting of C3-C8 cycloalkyl, C3-C7 branched alkyl; C1-C6 haloalkyl, C3-C7 branched haloalkyl, optionally substituted aryl and optionally substituted heteroaryl; R 4 Freedom to choose as well as The group composed of; p is 1, 2, 3, 4 or 5; When R 4 for When , p is not 1; When R 4 for When , p is not 1; X 1 is 0, 1, 2, or 3; Y is 0, 1, 2, 3, or 4; XChoose Freedom The group composed of; R a Selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and halide; R b Selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, and halide; R c Selected from C1-C12 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH 2 F. CHF 2 CF 3 , C2-C9 haloalkyl, C3-C9 branched haloalkyl, NR d R e , optionally substituted benzyl, optionally substituted CH 2 The group consisting of heteroaryl, optionally substituted aryl and optionally substituted heteroaryl, and a C3-C6 cycloalkyl ring optionally containing oxygen; R a and R b Together they may form a C3-C6 cycloalkyl ring optionally containing oxygen; R d is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, an optional aromatic ring, and an optionally substituted heteroaromatic ring; R e is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, an optional aromatic ring, and an optionally substituted heteroaromatic ring; R f Selected from hydrogen, C1-C12 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH 2 F. CHF 2 CF 3 , C2-C9 haloalkyl, C3-C9 branched haloalkyl, optionally substituted benzyl, optionally substituted CH 2 The group consisting of heteroaryl, optionally substituted aryl, optionally substituted heteroaryl and a C3-C6 cycloalkyl ring optionally containing oxygen; R 5 Selected from C2-C8 alkyl, C3-C11 branched alkyl, C3-C8 cycloalkyl, C5-C15 bicycloalkyl, CH 2 F. CHF 2 CF 3 , C2-C9 haloalkyl, C3-C9 branched haloalkyl, optionally substituted benzyl, optionally substituted CH 2 Heteroaryl, CH 2 OR 5a 、CH(CH 3 )OR 5a , C(R 5e ) 2 OR 5a , C(R 5e ) 2 OR 5a , CH 2 SR 5a , CH 2 CH 2 SCH 3 , CH 2 CH 2 SO 2 CH 3 , CH 2 CH 2 CH 2 NR 5c R 5d , CH 2 COR 5b , CH 2 CH 2 COR 5b , (CH 2 ) z The group consisting of (C3-C7 cycloalkyl) and a C3-C6 cycloalkyl ring optionally containing oxygen; z is 1, 2, 3, 4, 5, or 6; R 5a is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C7 branched alkyl, optionally substituted phenyl, optionally substituted benzyl and optionally substituted CH 2 CH 2 The group consisting of Ar; R 5b Selected from OH, C1-C6 alkoxy and NH 2 The group composed of; R 5c and R 5d are each independently selected from hydrogen and optionally substituted C1-C6 alkyl; R 5e is a C1-C4 alkyl group; R 6 and R 7 It is hydrogen; or R 6 and R 7 Together with the atoms to which they are attached, they form a 6-membered aromatic ring selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted; or R 6 and R 7 Together with the atoms to which they are attached, they form a substituted 5-6 membered heteroaromatic ring containing 1-2 nitrogen atoms, the heteroaromatic ring being selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkoxy, At least one part of the group consisting of C3-C8 cycloalkyl, C3-C8 heterocycle, aryl and heteroaryl is substituted; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; The following compounds are expressly excluded from the scope of the present invention: as well as 2. The compound according to claim 1, having formula (II): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
3. The compound according to claim 1, having formula (III): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
4. The compound according to claim 1, having formula (IV): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 8a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 8b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 8c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 8d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 8a , R 8b and R 8d At least two of them are hydrogen.
5. The compound according to claim 1, having formula (V): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
6. The compound according to claim 1, having formula (VI): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 9a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 9b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 9c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 9d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 9a , R 9b and R 9d At least two of them are hydrogen.
7. The compound according to claim 1, having formula (VII): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
8. The compound according to claim 1, having formula (VIII): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
9. The compound according to claim 1, having the formula (IX): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 10a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 10b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 10c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 10d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 10a , R 10b and R 10d At least two of them are hydrogen.
10. The compound according to claim 1, having formula (X): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
11. The compound according to claim 1, having the formula (XI): Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof in: R 11a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic ring, aryl, and heteroaromatic ring; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 11b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic ring, aryl, and heteroaromatic ring; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 11c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic ring, aryl, and heteroaromatic ring; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 11d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic ring, aryl, and heteroaromatic ring; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 11a , R 11b and R 11d At least two of them are hydrogen.
12. The compound according to claim 1, having the formula (XII): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
13. The compound according to claim 1, having the formula (XIII): Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof in: R 12a Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 12b Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 12c Selected from halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 12d Selected from hydrogen, halogen, C1-C6 haloalkyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, The group consisting of C3-C8 cycloalkyl, C3-C8 heterocyclic, aryl and heteroaryl; R 13 Selected from the group consisting of hydrogen and C1-C6 alkyl; R 14 Selected from the group consisting of hydrogen and C1-C6 alkyl; q is 0, 1, 2, 3, 4, 5, or 6; R 12a , R 12b and R 12d At least two of them are hydrogen.
14. The compound according to claim 1, having the formula (XIV): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
15. The compound according to claim 1, having formula (XV): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
16. The compound according to claim 1, having the formula (XVI): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
17. The compound according to claim 1, having the formula (XVII): Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
18. The compound according to claim 1, which has the formula (XVIII): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 15 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl; R 16 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl.
19. The compound according to claim 1, which has the formula (XIX): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 17 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl.
20. The compound according to claim 1, which has the formula (XX): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 18 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl.
21. The compound according to claim 1, which has the formula (XXI): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, in: R 19 Selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 haloalkyl.
22. A composition comprising an effective amount of at least one compound according to any one of claims 1 to 21.
23. The composition of claim 22, further comprising at least one excipient.
24. A method for treating or preventing yellow fever virus infection, the method comprising administering to a subject an effective amount of at least one compound according to claim 1 to treat or prevent yellow fever virus infection.
25. The method according to claim 24, in, The at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
